Diimide degrader and use thereof

By designing the diimide compound SBM-L-DIM and utilizing the E3 ligase-mediated pathway, selective degradation of STAT6 protein was achieved, solving the problem of the difficulty in effectively degrading STAT6 in existing technologies and showing potential for treating related diseases.

WO2026238103A1PCT designated stage Publication Date: 2026-11-19SHANGHAI FOSUN PHARMA DEV CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2026/097260
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2026-03-18
Filing Date
2026-05-15
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Existing technologies are unable to effectively degrade the signal transduction and transcription activator 6 (STAT6) protein, affecting the treatment efficacy of related diseases.

Method used

A novel diimide compound, SBM-L-DIM, was developed to selectively degrade STAT6 by binding to the STAT6 protein and utilizing an E3 ligase-mediated protein degradation pathway.

Benefits of technology

It achieves efficient degradation of STAT6 and has potential therapeutic effects on IL-4-induced EMT and invasive and inflammatory diseases of colorectal cancer cells.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PCTCN2026097260-FTAPPB-I100001
    Figure PCTCN2026097260-FTAPPB-I100001
  • Figure PCTCN2026097260-FTAPPB-I100002
    Figure PCTCN2026097260-FTAPPB-I100002
  • Figure PCTCN2026097260-FTAPPB-I100003
    Figure PCTCN2026097260-FTAPPB-I100003
Patent Text Reader

Abstract

Provided in the present invention are a diimide degrader and the use thereof. Specifically provided are a compound of formula (I) and the use thereof in the preparation of a STAT6 protein degrader or in the prevention or treatment of diseases mediated by STAT6 proteins. SBM-L-DIM(I)
Need to check novelty before this filing date? Find Prior Art

Description

A diimide degrading agent and its application Technical Field

[0001] This invention relates to a class of diimide compounds that can be used for ubiquitination and / or degradation of STAT6 (signal transducers and activators of transcription 6) proteins and their applications. Background Technology

[0002] Proteolysis-targeting chimeras (PROTACs) are compounds with two heterofunctional ligands linked by a linker: one ligand targets the target protein (POI), while the other specifically recruits an E3 ligase. When a PROTAC binds to the E3 ligase and the target protein, a ternary complex is formed. By hijacking the E3 ligase, the PROTAC positions the POI in a favorable spatial location to promote its ubiquitination, thereby selectively reducing the level of the target protein. The advantage of this approach is that PROTACs can catalyze multiple rounds of target protein degradation, which is the biggest difference between PROTAC molecules and small molecule inhibitors.

[0003] Signal transducer and activator of transcription 6 (STAT6 or interleukin-4-Stat / IL4-Stat) is a transcription factor belonging to the structurally conserved family of signal transducer and activator of transcription (STAT) proteins (STAT1 to STAT6). Like other STAT proteins, STAT6 activation is triggered when hormones, immunomodulatory cytokines, or growth factors bind to specific receptors on the cell surface. Once activated, phosphorylation of the C-terminal tyrosine residue occurs, leading to signal transduction from the cytoplasm to the nucleus, thereby activating gene expression. Recent studies have shown that STAT6 signaling is crucial for IL-4-induced and IL-13-induced epithelial-mesenchymal transition (EMT) and the invasiveness of colorectal cancer cells (CRC). Furthermore, STAT6 is involved in inflammatory diseases and other related conditions. Therefore, small molecule compounds targeting disease-related proteins such as STAT6 using E3 ligase-mediated protein degradation hold promise as therapeutic agents. Summary of the Invention

[0004] The purpose of this invention is to provide a novel diimide-based STAT6 protein degrader with excellent activity.

[0005] In a first aspect, the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof.

[0006] SBM-L-DIM(I)

[0007] in,

[0008] DIM (DIM is the degradation-inducible moiety) is selected from the following group:

[0009] Wherein, W1 is a bond or NH;

[0010] Ring G is selected from C6-C10 aromatic rings, 5-10 membered heteroaromatic rings containing 1-3 heteroatoms selected from N, O, S, and Se, 5-6 membered heterocycles containing 1-3 heteroatoms selected from N, O, and S, 5-6 membered heteroaromatic rings containing 1-3 heteroatoms selected from N, O, S, and Se, saturated or partially saturated C5-C6 carbon rings, and saturated or partially saturated 5-10 membered heterocycles containing 1-3 heteroatoms selected from N, O, and S;

[0011] n1 is 0, 1, 2 or 3;

[0012] Each R A Independently selected from the group consisting of: H, O=, S=, C1-C6 alkoxy, C1-C6 alkyl, C1-C6 haloalkyl, halogen, C1-C6 alkyl=, C3-C6 cycloalkyl=, C2-C6 alkenyl, C2-C6 alkynyl, haloC1-C6 alkyl=, haloC3-C6 cycloalkyl=, haloC2-C6 alkenyl, haloC2-C6 alkynyl;

[0013] L (where L is a divalent linker) is:

[0014] Y1 is selected from the following group: -L1-, =NO-L1-, =N-NH-L1-, =N-L1-; wherein L1 is independently selected from the following group: bond, C1-C6 alkylene, C1-C6 alkylene=, C2-C6 alkenylene, C1-C6 haloalkylene, C2-C6 alkyneylene, C1-C3 alkylene-O-C1-C3 alkylene-O-C1-C3 alkylene-O-, C1-C3 alkylene-O-;

[0015] Y2 is selected from the following group: bond, C1-C6 alkylene, C1-C6 alkylene=, C2-C6 alkenylene, C1-C6 haloalkylene, C2-C6 alkynylene, C1-C3 alkylene-O-C1-C3 alkylalkylene, C1-C3 alkylene-O-C1-C3 alkylene-O-, C1-C3 alkylene-O-;

[0016] Ring F is selected from saturated or partially saturated C4 to C12 carbon rings and saturated or partially saturated 4 to 12-membered heterocycles containing 1 to 3 heteroatoms selected from N, O, S, P and Se; the carbon ring and heterocycle are independently monocyclic or bicyclic fused rings, spirocyclic or bridged rings;

[0017] The ring H is selected from non-existent, C6-C10 aromatic rings, 5-10 membered aromatic heterocycles containing 1-3 heteroatoms selected from N, O, S, P and Se, saturated or partially saturated C3-C10 membered carbon rings, and saturated or partially saturated 3-10 membered heterocycles containing 1-3 heteroatoms selected from N, O, S, P and Se; the carbon ring and heterocycle are independently monocyclic or bicyclic fused rings, spirocyclic rings, or bridged rings;

[0018] Each R 11 and R 12 Independently selected from hydrogen, deuterium, cyano, carbonyl, C1-C6 haloalkoxy, C1-C6 alkoxy, C1-C6 alkyl, C1-C6 haloalkyl, halogen, C3-C6 cycloalkyl, C1-C6 alkyl, C2-C6 ynyl, C2-C6 alkenyl, haloC1-C6 alkyl, haloC3-C6 cycloalkyl, haloC2-C6 alkenyl, haloC2-C6 ynyl; or two R atoms on the same or different carbon atoms. 11 They connect together to form C1-C2 alkylene groups;

[0019] SBM (SBM is the STAT6-binding moiety that can bind to the STAT6 protein) is selected from formula IA or formula IB:

[0020] L3 is selected from vinylene, ethynylene, -COC1-C6 alkylene, -COC3-C6 cycloalkyl, -CO- 3-6 membered heterocyclic group containing 1-3 heteroatoms selected from O, N and S, -CH2COC1-C6 alkylene, C1-C6 alkylene, C1-C6 haloalkylene, 5-10 membered heteroaryl group containing 1-3 heteroatoms selected from O, N and S, -C(O)NR8-, -NR8CO, -NR8-, -O-, -S-, -S(O)-, -S(O)2-;

[0021] L4 is selected from single bond, O, NR8, carbonyl, -NR8CO-, -SO2-, vinylidene, ethynylidene, halovinylidene, C1-C6 alkylidene, -COC1-C6 alkylidene;

[0022] Ring A1 is selected from: C6-C10 aromatic rings, 5-6 membered aromatic heterocycles containing 1-3 heteroatoms selected from N, O, S, P and Se, benzo[a] 5-6 membered aromatic heterocycles containing 1-3 heteroatoms selected from N, O, S, P and Se, 5-6 membered aromatic heterocycles containing 1-3 heteroatoms selected from N, O, S, P and Se, and 5-6 membered aromatic heterocycles containing 1-3 heteroatoms selected from N, O, S, P and Se;

[0023] Ring B is selected from C3-C20 membered carbon rings that are absent, saturated, or partially saturated; 3-20 membered heterocycles that are saturated or partially saturated and contain 1-3 heteroatoms selected from N, O, S, P, and Se; C6-C20 membered aromatic rings; or 5-20 membered aromatic heterocycles that contain 1-3 heteroatoms selected from N, O, S, P, and Se; wherein the carbon ring and heterocycle are independently monocyclic, bicyclic, or tricyclic fused rings, spirocyclic, or bridged rings.

[0024] The ring C is selected from non-existent, C6-C10 aromatic rings, 5-10 membered aromatic heterocycles containing 1-3 heteroatoms selected from N, O, S, P and Se, saturated or partially saturated C3-C10 membered carbon rings, and saturated or partially saturated 3-10 membered heterocycles containing 1-3 heteroatoms selected from N, O, S, P and Se.

[0025] X2, X3, and X4 are independently selected from C, N(H), O, S, and Se; and X2, X3, and X4 together with the two C atoms on the benzene ring they are attached to form a 5-membered heteroaromatic ring with 1 or 2 heteroatoms;

[0026] Each m can be 0, 1, 2, 3 or 4 independently;

[0027] Each n is independently 0, 1, or 2;

[0028] Each of R3, R4, R5, R6, R7 and R 10 Independently selected from the group consisting of: hydrogen, deuterium, halogen, cyano, carbonyl, C1-C6 alkyl, C1-C6 haloalkyl, =C1-C6 alkyl, =C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C3-C6 cycloalkyl, -CONR8R9, -NR8COR9, -NR8R9, -OR8, -SR8, -S(O)R8, -P(O)(OH)2, -S(O)2NR8R9, -S(O)2R8;

[0029] Each R8 and R9 is independently selected from the group consisting of: hydrogen, deuterium, halogen, cyano, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C3-C6 cycloalkyl; or the N atom to which R8 and R9 are attached may form a substituted or unsubstituted 5- to 10-membered aromatic heterocycle containing 1-3 heteroatoms selected from N, O and S, or a substituted or unsubstituted 5- to 10-membered heterocycle containing 1-3 heteroatoms selected from N, O and S, wherein any substituent on the aromatic heterocycle or heterocycle may be attached to any R3 to form a C1-C6 alkylene, C2-C6 alkenylene, C2-C6 alkyneylene, C1-C3 alkylene-O-C1-C3 alkylene-O-C1-C3 alkylene-O-, C1-C6 alkylene-O-;

[0030] Any two adjacent R4 and X2, X3, X4 can be connected to form a saturated or partially saturated C3 to C20 membered carbon ring, or a saturated or partially saturated 3 to 20 membered heterocycle containing 1 to 3 heteroatoms selected from N, O, S, P and Se. The carbon ring and heterocycle are independently monocyclic, bicyclic or tricyclic fused rings, spirocyclic or bridged rings.

[0031] R7 and L4 and / or R5 can be connected to form saturated or partially saturated C3 to C20 membered carbon rings, or saturated or partially saturated 3 to 20 membered heterocycles containing 1 to 3 heteroatoms selected from N, O, S, P and Se, wherein the carbon ring and heterocycle are independently monocyclic, bicyclic or tricyclic fused rings, spirocyclic or bridged rings.

[0032] Each of R3 and R4, R7, R 11 Any one of them can be connected to form a saturated or partially saturated C3 to C20 membered carbon ring, or a saturated or partially saturated 3 to 20 membered heterocycle containing 1 to 4 heteroatoms selected from N, O, S, P and Se, wherein the carbon ring and heterocycle are independently fused rings, spiro rings or bridged rings of monocyclic, bicyclic or tricyclic nature.

[0033] R 10 It can be connected with any one of X2, R8, and R5 to form a saturated or partially saturated C3-C7 membered carbon ring, or a saturated or partially saturated 3-7 membered heterocycle containing 1-3 heteroatoms selected from N, O, S, P, and Se; ring E is a saturated or partially saturated C3-C6 membered carbon ring, or a saturated or partially saturated 3-6 membered heterocycle containing 1-3 heteroatoms selected from N, O, S, P, and Se, or a phenyl or a 5-6 membered aromatic heterocycle containing 1-3 heteroatoms selected from N, O, S, P, and Se;

[0034] Among them, ring D is a saturated or partially saturated C3-C6 membered carbon ring, a saturated or partially saturated 3-6 membered heterocycle containing 1-3 heteroatoms selected from N, O, S, P and Se, a phenyl ring, a 5-6 membered aromatic heterocycle containing 1-3 heteroatoms selected from N, O, S, P and Se, or a 5-6 membered aromatic heterocycle containing 1-3 heteroatoms selected from N, O, S, P and Se and a benzo[a]benzene ring;

[0035] Furthermore, rings E and D together form a spiral ring or a parallel ring structure;

[0036] n, m, X2, L3, L4, R4, R5, R6, B, and C are defined as above;

[0037] Each of the above groups may optionally be further substituted by one or more groups selected from the group consisting of: D, oxo, halogen, -CO-, thio, -NO2, -CN, -N3, OH, COOH, SF5, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkyl-ON=, substituted or unsubstituted C3-C6 cycloalkyl=, substituted or unsubstituted C1-C6 alkyl=, substituted or unsubstituted C1-C6 alkyl-S-, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C2-C6 alkynyl, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted C1-C6 alkoxy, amino, substituted or unsubstituted C1-C6 alkyl NH-, substituted or unsubstituted (C1-C6 alkyl)2N-, substituted or unsubstituted C1-C6 alkyl CO-, substituted or unsubstituted C1-C6 alkyl COO-, substituted or unsubstituted C1-C6 alkyl OCO-, substituted or unsubstituted C1-C6 alkylCONH-, substituted or unsubstituted C1-C6 alkylNHCO-, substituted or unsubstituted substituted or unsubstituted C6-C10 aryl, substituted or unsubstituted 5-10-membered heteroaryl containing 1-3 heteroatoms selected from N, O, S, substituted or unsubstituted 3-8-membered heterocyclic group containing 1-3 heteroatoms selected from N, O, S, or two adjacent substituents on the cycloalkyl, heterocyclic, aryl, or heteroaryl group optionally form a substituted or unsubstituted C3-8 cycloalkyl or a substituted or unsubstituted 3-8-membered heterocyclic group containing 1-3 heteroatoms selected from N, O, S together with the atoms attached thereto; wherein “substitution” means that one or more H on the group are independently substituted by a group selected from the group consisting of: D, halogen, -CN, OH, amino, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy.

[0038] In another preferred embodiment, in DIM, ring G is selected from C6-C10 aromatic rings, 5-10 membered heteroaromatic rings containing 1-3 heteroatoms selected from N, O, and S, 5-6 membered heterocyclic rings containing 1-3 heteroatoms selected from N, O, and S, 5-6 membered heteroaromatic rings containing 1-3 heteroatoms selected from N, O, and S, saturated or partially saturated C5-C6 carbon rings, and saturated or partially saturated 5-10 membered heterocyclic rings containing 1-3 heteroatoms selected from N, O, and S.

[0039] In another preferred embodiment, in DIM, ring G is selected from C6-C10 aromatic rings, benzo[a] 5-6 membered heterocycles containing 1-3 heteroatoms selected from N, O, and S, benzo[a] 5-6 membered heteroaromatic rings containing 1-3 heteroatoms selected from N, O, and S, benzo[a] 5-6 membered heteroaromatic rings containing 1 Se heteroatom, benzo[a] saturated or partially saturated C5-C6 carbon rings, and benzo[a] saturated or partially saturated 5-10 membered heterocycles containing 1-3 heteroatoms selected from N, O, and S.

[0040] In another preferred embodiment, in DIM, ring G is selected from C6-C10 aromatic rings, benzo[a] 5-6 membered heterocycles containing 1-3 heteroatoms selected from N, O, and S, benzo[a] 5-6 membered heteroaromatic rings containing 1-3 heteroatoms selected from N, O, and S, benzo[a] saturated or partially saturated C5-C6 carbon rings, and benzo[a] saturated or partially saturated 5-10 membered heterocycles containing 1-3 heteroatoms selected from N, O, and S.

[0041] In another preferred embodiment, in DIM, ring G is selected from benzene ring, a 6-membered heteroaromatic ring containing 1-2 heteroatoms selected from N, a 5-6 membered heterocyclic ring containing 1-3 heteroatoms selected from N, O, and S, a 5-6 membered heteroaromatic ring containing 1-3 heteroatoms selected from N, O, and S, or a 5-6 membered heterocyclic ring containing 1-3 heteroatoms selected from N, O, and S.

[0042] In another preferred embodiment, in DIM, ring G is a 5-6 membered heteroaromatic ring of benzene containing one Se heteroatom or a 5-6 membered heteroaromatic ring containing one N and one Se heteroatom.

[0043] In another preferred embodiment, in DIM, ring G is selected from benzene ring, benzo[a] 5-membered heterocycle containing 1-2 N heteroatoms, benzo[a] 5-membered heteroaromatic ring containing 1 N and 1 O heteroatoms, benzo[a] 5-membered heteroaromatic ring containing 1-2 N heteroatoms, benzo[a] 5-membered heteroaromatic ring containing 1 Se heteroatomum, saturated 5- to 6-membered heterocycles containing 1-2 N heteroatoms, or 5-membered heteroaromatic ring containing 1 N and 1 Se heteroatoms.

[0044] In another preferred embodiment, in DIM, ring G is selected from benzene rings, benzo[a] 5-membered heterocycles containing 1-2 N heteroatoms, benzo[a] 5-membered heteroaromatic rings containing 1-2 N heteroatoms, and saturated 5- to 6-membered heterocycles containing 1-2 N heteroatoms.

[0045] In another preferred embodiment, each R A Independently selected from the group consisting of: H, oxo, C1-C6 alkoxy, C1-C6 alkyl, C1-C6 haloalkyl, halogen, C1-C6 alkyl=, C3-C6 cycloalkyl=, C2-C6 alkenyl, C2-C6 alkynyl, haloC1-C6 alkyl=, haloC3-C6 cycloalkyl=, haloC2-C6 alkenyl, haloC2-C6 alkynyl.

[0046] In another preferred embodiment, each R A Independently selected from the group consisting of: H, oxo, C1-C6 alkoxy, C1-C6 alkyl, C1-C6 haloalkyl, halogen, C1-C6 alkyl=, haloC1-C6 alkyl=, preferably each R A Independently selected from the group consisting of C1-C6 alkyl groups, more preferably methyl groups.

[0047] In another preferred embodiment, in DIM, ring G is selected from benzene rings, and each R... A Independently selected from the group consisting of: C1-C6 alkoxy, C1-C6 alkyl, C1-C6 haloalkyl, and halogen; preferably each R A Selected independently from the group: halogens.

[0048] In another preferred embodiment, n1 is 0. In another preferred embodiment, n1 is 1 or 2. In another preferred embodiment, n1 is 1.

[0049] In another preferred embodiment, in DIM, ring G is selected from a 5-membered heteroaromatic ring of benzene containing 1-2 N heteroatoms; wherein each R A Independently selected from the group consisting of: C1-C6 alkoxy, C1-C6 alkyl, C1-C6 haloalkyl, and halogen; preferably each R A Independently selected from the group consisting of C1-C6 alkyl groups, more preferably methyl groups.

[0050] In another preferred embodiment, in DIM, ring G is selected from a 5-membered heterocycle of benzene and containing 1-2 N heteroatoms; wherein the 5-membered heterocycle is optionally oxidized, and each R A Independently selected from the group consisting of: C1-C6 alkoxy, C1-C6 alkyl, C1-C6 haloalkyl, and halogen; preferably each R A Independently selected from the group consisting of C1-C6 alkyl groups, more preferably methyl groups.

[0051] In another preferred embodiment, in DIM, ring G is selected from saturated 5- to 6-membered heterocycles containing one N heteroatom, and each R... A Independently selected from the group consisting of: halogenated C1-C6 alkyl (preferably CF2).

[0052] In another preferred embodiment, W1 is a bond. In another preferred embodiment, W1 is NH.

[0053] In another preferred embodiment, W1 is a bond or NH only when ring G is a benzene ring.

[0054] In another preferred embodiment, in DIM, when ring G is a benzene ring, contains 1-2 six-membered heteroaromatic rings selected from N heteroatoms, or contains 1-2 saturated five- to six-membered heterocycles with N heteroatoms, Y1 is a bond.

[0055] In another preferred embodiment, when ring G in DIM is a 5-6 membered heterocycle containing 1-3 heteroatoms selected from N, O, and S, or a 5-6 membered heteroaromatic ring containing 1-3 heteroatoms selected from N, O, and S, Y1 is a bond or a C1-C3 alkylene ring.

[0056] A compound of formula (I), or a pharmaceutically acceptable salt thereof, SBM-L-DIM (I)

[0057] in,

[0058] DIM (DIM is the degradation-inducible moiety) is selected from the following group:

[0059] Wherein, R1 is a C1-C4 alkyl group;

[0060] X is selected from O, NH, and S;

[0061] Each R2 is independently selected from H, C1-C6 alkoxy, C1-C6 alkyl, C1-C6 haloalkyl, and halogen;

[0062] L (where L is a divalent linker) is:

[0063] Y1 is selected from the following group: -L1-, =NO-L1-, =N-NH-L1-, =N-L1-; wherein L1 is independently selected from the following group: bond, C1-C6 alkylene, C1-C6 alkylene=, C2-C6 alkenylene, C1-C6 haloalkylene, C2-C6 alkyneylene, C1-C3 alkylene-O-C1-C3 alkylene, C1-C3 alkylene-O-C1-C3 alkylene-O-, C1-C3 alkylene-O-;

[0064] Y2 is selected from the following group: bond, C1-C6 alkylene, C1-C6 alkylene=, C2-C6 alkenylene, C1-C6 haloalkylene, C2-C6 alkynylene, C1-C3 alkylene-O-C1-C3 alkylene, C1-C3 alkylene-O-C1-C3 alkylene-O-, C1-C3 alkylene-O-;

[0065] Ring F is selected from saturated or partially saturated C4 to C12 carbon rings and saturated or partially saturated 4 to 12-membered heterocycles containing 1 to 3 heteroatoms selected from N, O, S, P and Se; the carbon ring and heterocycle are independently monocyclic or bicyclic fused rings, spirocyclic or bridged rings;

[0066] The ring H is selected from non-existent, C6-C10 aromatic rings, 5-10 membered aromatic heterocycles containing 1-3 heteroatoms selected from N, O, S, P and Se, saturated or partially saturated C3-C10 membered carbon rings, and saturated or partially saturated 3-10 membered heterocycles containing 1-3 heteroatoms selected from N, O, S, P and Se; the carbon ring and heterocycle are independently monocyclic or bicyclic fused rings, spirocyclic rings, or bridged rings;

[0067] Each R 11 and R 12Independently selected from H, hydrogen, deuterium, cyano, carbonyl, C1-C6 haloalkoxy, C1-C6 alkoxy, C1-C6 alkyl, C1-C6 haloalkyl, halogen, C3-C6 cycloalkyl, C1-C6 alkyl, C2-C6 ynyl, C2-C6 alkenyl, haloC1-C6 alkyl, haloC3-C6 cycloalkyl, haloC2-C6 alkenyl, haloC2-C6 ynyl; or two R atoms on the same or different carbon atoms. 11 They connect together to form C1-C2 alkylene groups;

[0068] SBM (SBM is the STAT6-binding moiety that can bind to the STAT6 protein) is selected from formula IA or formula IB:

[0069] L3 is selected from vinylene, ethynylene, -COC1-C6 alkylene, -COC3-C6 cycloalkyl, -CO- 3-6 membered heterocyclic group containing 1-3 heteroatoms selected from O, N and S, -CH2COC1-C6 alkylene, C1-C6 alkylene, C1-C6 haloalkylene, 5-10 membered heteroaryl group containing 1-3 heteroatoms selected from O, N and S, -C(O)NR8-, -NR8CO, -NR8-, -O-, -S-, -S(O)-, -S(O)2-;

[0070] L4 is selected from single bond, O, -NHCO-, NR8, carbonyl, -SO2-, vinylidene, ethynylidene, C1-C6 alkylidene, -COC1-C6 alkylidene;

[0071] Ring A1 is selected from: C6-C10 aromatic rings, 5-6 membered aromatic heterocycles containing 1-3 heteroatoms selected from N, O, S, P and Se, benzo[a] 5-6 membered aromatic heterocycles containing 1-3 heteroatoms selected from N, O, S, P and Se, 5-6 membered aromatic heterocycles containing 1-3 heteroatoms selected from N, O, S, P and Se, and 5-6 membered aromatic heterocycles containing 1-3 heteroatoms selected from N, O, S, P and Se;

[0072] Ring B is selected from C3-C20 membered carbon rings that are absent, saturated, or partially saturated; 3-20 membered heterocycles that are saturated or partially saturated and contain 1-3 heteroatoms selected from N, O, S, P, and Se; C6-C20 membered aromatic rings; or 5-20 membered aromatic heterocycles that contain 1-3 heteroatoms selected from N, O, S, P, and Se; wherein the carbon ring and heterocycle are independently monocyclic, bicyclic, or tricyclic fused rings, spirocyclic, or bridged rings.

[0073] The ring C is independently selected from non-existent, C6-C10 aromatic rings, 5-10 membered aromatic heterocycles containing 1-3 heteroatoms selected from N, O, S, P and Se, saturated or partially saturated C3-C10 membered carbon rings, and saturated or partially saturated 3-10 membered heterocycles containing 1-3 heteroatoms selected from N, O, S, P and Se.

[0074] X2, X3, and X4 are independently selected from C, N(H), O, S, and Se; and X2, X3, and X4 together with the two C atoms on the benzene ring they are attached to form a 5-membered heteroaromatic ring with 1 or 2 heteroatoms;

[0075] Each m is independently 0, 1, or 2;

[0076] Each n is independently 0, 1, or 2;

[0077] Each of R3, R4, R5, R6, R7 and R 10 Independently selected from the group consisting of: hydrogen, deuterium, halogen, cyano, carbonyl, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C3-C6 cycloalkyl, -CONR8R9, -NR8COR9, -NR8R9, -OR8, -SR8, -S(O)R8, -P(O)(OH)2, -S(O)2R8;

[0078] Each R8 and R9 is independently selected from the following group: hydrogen, deuterium, halogen, cyano, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C3-C6 cycloalkyl; or the N atom to which R8 and R9 are attached can form a substituted or unsubstituted 5- to 10-membered aromatic heterocycle containing 1 to 3 heteroatoms selected from N, O and S, or a 5- to 10-membered heterocycle containing 1 to 3 heteroatoms selected from N, O and S;

[0079] Any two adjacent R4 and X2, X3, X4 can be connected to form a saturated or partially saturated C3 to C20 membered carbon ring, or a saturated or partially saturated 3 to 20 membered heterocycle containing 1 to 3 heteroatoms selected from N, O, S, P and Se. The carbon ring and heterocycle are independently monocyclic, bicyclic or tricyclic fused rings, spirocyclic or bridged rings.

[0080] R7 and L4 and / or R5 can be connected to form saturated or partially saturated C3 to C20 membered carbon rings, or saturated or partially saturated 3 to 20 membered heterocycles containing 1 to 3 heteroatoms selected from N, O, S, P and Se, wherein the carbon ring and heterocycle are independently monocyclic, bicyclic or tricyclic fused rings, spirocyclic or bridged rings.

[0081] Each of R3 and R4, R7, R 11Any one of them can be connected to form a saturated or partially saturated C3 to C20 membered carbon ring, or a saturated or partially saturated 3 to 20 membered heterocycle containing 1 to 4 heteroatoms selected from N, O, S, P and Se, wherein the carbon ring and heterocycle are independently fused rings, spiro rings or bridged rings of monocyclic, bicyclic or tricyclic nature.

[0082] R 10 It can be connected with any one of X2, R8, and R5 to form a saturated or partially saturated C3-C7 membered carbon ring, or a saturated or partially saturated 3-7 membered heterocycle containing 1-3 heteroatoms selected from N, O, S, P, and Se; ring E is a saturated or partially saturated C3-C6 membered carbon ring, or a saturated or partially saturated 3-6 membered heterocycle containing 1-3 heteroatoms selected from N, O, S, P, and Se, or a phenyl or a 5-6 membered aromatic heterocycle containing 1-3 heteroatoms selected from N, O, S, P, and Se;

[0083] Among them, ring D is a saturated or partially saturated C3-C6 membered carbon ring, a saturated or partially saturated 3-6 membered heterocycle containing 1-3 heteroatoms selected from N, O, S, P and Se, a phenyl ring, a 5-6 membered aromatic heterocycle containing 1-3 heteroatoms selected from N, O, S, P and Se, or a 5-6 membered aromatic heterocycle containing 1-3 heteroatoms selected from N, O, S, P and Se and a benzo[a]benzene ring;

[0084] Furthermore, rings E and D together form a spiral ring or a parallel ring structure;

[0085] n, m, X2, L3, L4, R4, R5, R6, B, and C are defined as above;

[0086] Wherein, the alkylene, vinylene, ethynylene, alkyl, cycloalkyl, heterocyclic, fused ring, spirocyclic, bridged ring, aryl, or heteroaryl group may optionally be substituted by one or more groups selected from the group consisting of: D, oxo, halogen, -CO-, thio, -NO2, -CN, -N3, OH, COOH, SF5, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkyl-ON=, substituted or unsubstituted C3-C6 cycloalkyl=, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkyl-S-, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C2-C6 alkynyl, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted C1-C6 alkoxy, amino, substituted or unsubstituted C1-C6 alkyl NH-, substituted or unsubstituted (C1-C6 alkyl)2N-, substituted or unsubstituted C1-C6 alkyl CO-, substituted or unsubstituted C1-C6 alkyl CO O-, substituted or unsubstituted C1-C6 alkyl OCO-, substituted or unsubstituted C1-C6 alkyl CONH-, substituted or unsubstituted C1-C6 alkyl NHCO-, substituted or unsubstituted substituted or unsubstituted C6-C10 aryl, substituted or unsubstituted 5-10-membered heteroaryl containing 1-3 heteroatoms selected from N, O, S, substituted or unsubstituted 3-8-membered heterocyclic group containing 1-3 heteroatoms selected from N, O, S, or the cycloalkyl, heterocyclic group, Two adjacent substituents on an aryl or heteroaryl group may optionally form a substituted or unsubstituted C3-8 cycloalkyl group or a substituted or unsubstituted 3-8 membered heterocyclic group containing 1-3 heteroatoms selected from N, O, and S; wherein “substitution” means that one or more H atoms on the group are independently substituted by a group selected from the group consisting of: D, halogen, -CN, OH, amino, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, and C1-C6 haloalkoxy.

[0087] In another preferred embodiment, the compound of formula (I), or a pharmaceutically acceptable salt thereof, SBM-L-DIM (I)

[0088] in,

[0089] DIM (DIM is the degradation-inducible moiety) is selected from the following group:

[0090] Wherein, R1 is a C1-C4 alkyl group;

[0091] X is selected from O, NH, and S;

[0092] Each R2 is independently selected from H, C1-C6 alkoxy, C1-C6 alkyl, C1-C6 haloalkyl, and halogen;

[0093] L (where L is a divalent linker) is:

[0094] Wherein, X1 is independently selected from N or CH;

[0095] L1 is independently selected from the group consisting of: bond, C1-C6 alkylene, C1-C6 haloalkylene and ethynylene;

[0096] Each R 11 and R 12 Independently selected from H, C1-C6 alkoxy, C1-C6 alkyl, C1-C6 haloalkyl and halogen;

[0097] SBM (SBM is the STAT6-binding moiety that can bind to the STAT6 protein) is selected from formula IA or formula IB:

[0098] L3 is selected from vinylene, ethynylene, -COC1-C6 alkylene, -COC3-C6 cycloalkyl, -CO- 3-6 membered heterocyclic group containing 1-3 heteroatoms selected from O, N and S, -CH2COC1-C6 alkylene, C1-C6 alkylene, C1-C6 haloalkylene, 5-10 membered heteroaryl group containing 1-3 heteroatoms selected from O, N and S, -C(O)NR8-, -NR8CO-, -NR8-, -O-, -S-, -S(O)-, -S(O)2-;

[0099] L4 is selected from single bond, O, NR8, carbonyl, -SO2-, vinylidene, ethynylidene, C1-C6 alkylidene, and -COC1-C6 alkylidene.

[0100] Ring B is selected from C3-C20 membered carbon rings that are absent, saturated, or partially saturated; 3-20 membered heterocycles that are saturated or partially saturated and contain 1-3 heteroatoms selected from N, O, S, P, and Se; C6-C20 membered aromatic rings; or 5-20 membered aromatic heterocycles that contain 1-3 heteroatoms selected from N, O, S, P, and Se; wherein the carbon ring and heterocycle are independently monocyclic, bicyclic, or tricyclic fused rings, spirocyclic, or bridged rings.

[0101] The ring C is independently selected from C6-C10 aromatic rings, 5-10 membered aromatic heterocycles containing 1-3 heteroatoms selected from N, O, S, P and Se, saturated or partially saturated C3-C10 membered carbon rings, and saturated or partially saturated 3-10 membered heterocycles containing 1-3 heteroatoms selected from N, O, S, P and Se.

[0102] X2, X3, and X4 are independently selected from C, N(H), O, S, and Se;

[0103] Each m is independently 0, 1, or 2;

[0104] Each n is independently 0, 1, or 2;

[0105] Each of R3, R4, R5, R6, R7 and R 10 Independently selected from the group consisting of: hydrogen, deuterium, halogen, cyano, carbonyl, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C3-C6 cycloalkyl, -CONR8R9, -NR8COR9, -NR8R9, -OR8, -SR8, -S(O)R8, -S(O)2R8;

[0106] Each R8 and R9 is independently selected from the following group: hydrogen, deuterium, halogen, cyano, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C3-C6 cycloalkyl; or the N atom to which R8 and R9 are attached can form a substituted or unsubstituted 5- to 10-membered aromatic heterocycle containing 1 to 3 heteroatoms selected from N, O and S, or a 5- to 10-membered heterocycle containing 1 to 3 heteroatoms selected from N, O and S;

[0107] Any two adjacent R4 and X2, X3, X4 can be connected to form a saturated or partially saturated C3 to C20 membered carbon ring, or a saturated or partially saturated 3 to 20 membered heterocycle containing 1 to 3 heteroatoms selected from N, O, S, P and Se. The carbon ring and heterocycle are independently monocyclic, bicyclic or tricyclic fused rings, spirocyclic or bridged rings.

[0108] R7 and L4 and / or R5 can be connected to form saturated or partially saturated C3 to C20 membered carbon rings, or saturated or partially saturated 3 to 20 membered heterocycles containing 1 to 3 heteroatoms selected from N, O, S, P and Se, wherein the carbon ring and heterocycle are independently monocyclic, bicyclic or tricyclic fused rings, spirocyclic or bridged rings.

[0109] Each of R3 and R4, R7, R 11 Any one of them can be connected to form a saturated or partially saturated C3 to C20 membered carbon ring, or a saturated or partially saturated 3 to 20 membered heterocycle containing 1 to 3 heteroatoms selected from N, O, S, P and Se, wherein the carbon ring and heterocycle are independently fused rings, spiro rings or bridged rings of monocyclic, bicyclic or tricyclic nature.

[0110] R 10 It can be connected with any one of X2, R8, and R5 to form a saturated or partially saturated C3 to C7 membered carbon rings, or a saturated or partially saturated 3 to 7 membered heterocycle containing 1 to 3 heteroatoms selected from N, O, S, P, and Se.

[0111] Ring E is a saturated or partially saturated C3-C6 membered carbon ring, a saturated or partially saturated 3-6 membered heterocycle containing 1-3 heteroatoms selected from N, O, S, P and Se, a phenyl ring, a 5-6 membered aromatic heterocycle containing 1-3 heteroatoms selected from N, O, S, P and Se, or a 5-6 membered aromatic heterocycle containing 1-3 heteroatoms selected from N, O, S, P and Se and a benzo[a]benzene ring;

[0112] Among them, ring D is a saturated or partially saturated C3 to C6 membered carbon ring, a saturated or partially saturated 3 to 6 membered heterocycle containing 1 to 3 heteroatoms selected from N, O, S, P and Se, a phenyl ring, or a 5 to 6 membered aromatic heterocycle containing 1 to 3 heteroatoms selected from N, O, S, P and Se.

[0113] Furthermore, rings E and D together form a spiral ring or a parallel ring structure;

[0114] n, m, X2, L3, L4, R4, R5, R6, B, and C are as defined in this invention;

[0115] Wherein, the alkylene, vinylene, ethynylene, alkyl, cycloalkyl, heterocyclic, fused, spirocyclic, bridged, aryl, or heteroaryl group may optionally be substituted by one or more groups selected from the group consisting of: D, oxo, halogen, -CO-, thio, -NO2, -CN, -N3, OH, COOH, SF5, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkyl-ON=, substituted or unsubstituted C1-C6 alkyl- S-, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C2-C6 alkynyl, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted C1-C6 alkoxy, amino, substituted or unsubstituted C1-C6 alkyl NH-, substituted or unsubstituted (C1-C6 alkyl)2N-, substituted or unsubstituted C1-C6 alkyl CO-, substituted or unsubstituted C1-C6 alkyl COO-, substituted or unsubstituted C1-C6 alkyl The cycloalkyl group can be substituted or unsubstituted C1-C6 alkyl group CONH-, substituted or unsubstituted C1-C6 alkyl group NHCO-, substituted or unsubstituted substituted or unsubstituted C6-C10 aryl group, substituted or unsubstituted 5-10 heteroaryl group containing 1-3 heteroatoms selected from N, O, and S, or substituted or unsubstituted 3-8 heterocyclic group containing 1-3 heteroatoms selected from N, O, and S. Alternatively, two adjacent substituents on the cycloalkyl, heterocyclic, aryl, or heteroaryl group may optionally form a substituted or unsubstituted C3-8 cycloalkyl group or a substituted or unsubstituted 3-8 heterocyclic group containing 1-3 heteroatoms selected from N, O, and S together with the atoms attached to them. Wherein, "substituted" means that one or more H atoms on the group are independently substituted by a group selected from the group consisting of: D, halogen, -CN, OH, amino, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, and C1-C6 haloalkoxy.

[0116] In another preferred embodiment, DIM is selected from the following group:

[0117] Wherein, R1 is a C1-C4 alkyl or a C1-C4 haloalkyl;

[0118] X is selected from O, NH, and S;

[0119] Each R2 is independently selected from H, C1-C6 alkoxy, C1-C6 alkyl, C1-C6 haloalkyl, and halogen.

[0120] Each n is independently 0, 1, or 2.

[0121] In another preferred embodiment, Y1 is selected from: bond, C1-C3 alkylene, =NO-, =N-NH-, =N-; preferably, Y1 is selected from: bond, ethylene; more preferably, Y1 is a bond.

[0122] In another preferred embodiment, ring F is selected from the following group:

[0123] In another preferred embodiment, ring F is selected from the following group: Preferred More preferably

[0124] In another preferred embodiment, Y2 is the bond.

[0125] In another preferred embodiment, ring H does not exist.

[0126] In another preferred embodiment, L is selected from:

[0127] Wherein, X1 is independently selected from N or CH;

[0128] X1 ’ Selected from N, CH, O, S, or P=O;

[0129] L1 is independently selected from the group consisting of: bond, C1-C6 alkylene, C1-C6 alkylene, C2-C6 alkenyl, C1-C6 haloalkylene and ethynylene;

[0130] Each R 11 and R 12 Independently selected from H, C1-C6 alkoxy, C1-C6 alkyl, C1-C6 haloalkyl, and halogen; or two R atoms on the same or different carbon atoms. 11 They connect together to form C1-C2 alkylene groups;

[0131] Each n is independently 0, 1, or 2.

[0132] In another preferred embodiment, SBM is selected from formula Ia or formula Ib:

[0133] In Formulas Ia and Ib, ring A is independently selected from saturated or partially saturated C3 to C10 membered carbon rings and saturated or partially saturated 3 to 10 membered heterocycles containing 1 to 3 heteroatoms selected from N, O, S, P and Se. The carbon ring and heterocycle are independently fused rings, spiro rings or bridged rings of monocyclic or bicyclic structures.

[0134] Each of n, m, X2, L3, R3, R4, R5, R6, R 10 B and C are as defined in this invention.

[0135] In another preferred embodiment, in formulas Ia and Ib, ring A is independently selected from partially saturated 3- to 7-membered monocyclic heterocycles containing 1-3 heteroatoms selected from N, O, S, P, and Se.

[0136] In another preferred embodiment, in formulas Ia and Ib, ring A is a partially saturated 5- to 7-membered monocyclic heterocycle formed by -CO-N(C1-C3 alkyl)-C1-C3 alkylene- and the attached atoms.

[0137] In another preferred embodiment, in formula Ib, ring A is a partially saturated 5- to 7-membered monocyclic heterocycle formed by -CO-N(C1-C3 alkyl)-C1-C3 alkylene- and the attached atom, preferably connected to the C atom adjacent to X2 via the -CO end.

[0138] In another preferred embodiment, SBM is either formula IIa or formula IIb:

[0139] In Formulas IIa and IIb, ring A is independently selected from saturated or partially saturated C3 to C10 membered carbon rings and saturated or partially saturated 3 to 10 membered heterocycles containing 1 to 3 heteroatoms selected from N, O, S, P and Se. The carbon ring and heterocycle are independently fused rings, spiro rings or bridged rings of monocyclic or bicyclic structures.

[0140] Each of n, m, X2, L3, R3, R4, R5, R6, R 10 B and C are as defined in this invention;

[0141] In another preferred embodiment, SBM is Equation IIIa;

[0142] In Formula IIIa, ring B is independently selected from bonded, saturated or partially saturated C3 to C20 membered carbon rings, saturated or partially saturated 3 to 20 membered heterocycles containing 1 to 3 heteroatoms selected from N, O, S, P and Se, wherein the carbon ring and heterocycle are independently monocyclic, bicyclic or tricyclic fused rings, spirocyclic or bridged rings.

[0143] Each of n, m, X2, L3, R3, R4, R5, R6, R 10 C is as defined in this invention;

[0144] In another preferred embodiment, SBM is Equation IVa:

[0145] In formula IVa, n, m, X2, L3, L4, R3, R4, R5, R6, R 10 B and C are as defined in this invention;

[0146] In another preferred embodiment, SBM is:

[0147] in,

[0148] X2 is selected from N or Se;

[0149] R8 and R9 are independently selected from hydrogen, deuterium, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C3-C6 cycloalkyl; or R8 and R9 together with their attached N atom form a substituted or unsubstituted 5-6 membered heteroaromatic ring with 1, 2 or 3 nitrogen atoms, or a substituted or unsubstituted 5-6 membered heterocyclic ring with 1, 2 or 3 nitrogen atoms; wherein, substitution means that the group is independently substituted by one or more groups selected from the group consisting of: D, halogen, OH, NH2, N (C1-C3 alkyl). 1-2 =CF2;

[0150] R'4 and R”4 are independently selected from hydrogen, deuterium, halogen, C1-C6 alkyl, and C3-C6 cycloalkyl;

[0151] R3 is independently selected from hydrogen, deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, and C3-C6 cycloalkyl;

[0152] Alternatively, R8 can be connected to R'4 or R”4 to form a 5-8 membered heterocyclic group containing at least one N heteroatom;

[0153] Alternatively, one of R8 and R3 may be linked to form a substituted or unsubstituted 9-16 membered heterocyclic group containing at least one N heteroatom; wherein the substitution refers to the group being independently and optionally substituted by one or more groups selected from the group consisting of: D, halogen, halogen or unsubstituted C1-C6 alkyl, halogen or unsubstituted C1-C6 alkoxy, halogen-substituted or unsubstituted C3-C6 cycloalkyl, halogen-substituted or unsubstituted C1-C6 alkyl; or substituents on the same atom, adjacent atoms or alternating atoms may be linked to form a C3-C6 cycloalkyl, or a 3-6 membered heterocyclic group containing 1-3 heteroatoms selected from O, N and S;

[0154] Among them, each m, X2, L3, L4, R3, R5, R6, R 10 A1, B and C are as defined in this invention.

[0155] In another preferred embodiment, X2 is N and R”4 is H.

[0156] In another preferred embodiment, R'4 is H.

[0157] In another preferred embodiment, the SBM is:

[0158] in,

[0159] X2 is selected from N or Se;

[0160] R8 and R9 are independently selected from hydrogen, deuterium, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C3-C6 cycloalkyl; or R8 and R9 together with their attached N atom form a substituted or unsubstituted 5-6 membered heteroaromatic ring with 1, 2 or 3 nitrogen atoms, or a substituted or unsubstituted 5-6 membered heterocyclic ring with 1, 2 or 3 nitrogen atoms; wherein, substitution means that the group is independently substituted by one or more groups selected from the group consisting of: D, halogen, OH, NH2, N (C1-C3 alkyl). 1-2 =CF2;

[0161] R'4 and R”4 are independently selected from hydrogen, deuterium, halogen, C1-C6 alkyl, and C3-C6 cycloalkyl;

[0162] Each of R3, R'3 and R”3 is independently selected from hydrogen, deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, and C3-C6 cycloalkyl;

[0163] Alternatively, R8 can be connected to R'4 or R”4 to form a 5-8 membered heterocyclic group containing at least one N heteroatom;

[0164] Alternatively, R8 and R'3 may be linked to form a substituted or unsubstituted 9-16 membered heterocyclic group containing at least one N heteroatom; wherein the substitution refers to the group being independently and optionally substituted by one or more groups selected from the group consisting of: D, halogen, halogen or unsubstituted C1-C6 alkyl, halogen or unsubstituted C1-C6 alkoxy, halogen-substituted or unsubstituted C3-C6 cycloalkyl, halogen-substituted or unsubstituted C1-C6 alkyl; or substituents on the same atom, adjacent atoms or alternating atoms may be linked to form a C3-C6 cycloalkyl, or a 3-6 membered heterocyclic group containing 1-3 heteroatoms selected from O, N and S;

[0165] Among them, each m, X2, L3, L4, R3, R5, R6, R 10 B and C are as defined in this invention.

[0166] In another preferred embodiment, SBM is:

[0167] in,

[0168] X2 is selected from N or Se;

[0169] R8 and R9 are independently selected from hydrogen, deuterium, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C3-C6 cycloalkyl; or R8 and R9 together with their attached N atom form a substituted or unsubstituted 5-6 membered heteroaromatic ring with 1, 2 or 3 nitrogen atoms, or a substituted or unsubstituted 5-6 membered heterocyclic ring with 1, 2 or 3 nitrogen atoms; wherein, substitution means that the group is independently substituted by one or more groups selected from the group consisting of: D, halogen, OH, NH2, N (C1-C3 alkyl). 1-2 =CF2;

[0170] R'4 and R”4 are independently selected from hydrogen, deuterium, halogen, C1-C6 alkyl, and C3-C6 cycloalkyl;

[0171] R'3 and R”3 are independently selected from hydrogen, deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, and C3-C6 cycloalkyl;

[0172] Alternatively, R8 can be connected to R'4 or R”4 to form a 5-8 membered heterocyclic group containing at least one N heteroatom;

[0173] Alternatively, R8 and R'3 may be linked to form a substituted or unsubstituted 9-16 membered heterocyclic group containing at least one N heteroatom; wherein the substitution refers to the group being independently and optionally substituted by one or more groups selected from the group consisting of: D, halogen, halogen or unsubstituted C1-C6 alkyl, halogen or unsubstituted C1-C6 alkoxy, halogen-substituted or unsubstituted C3-C6 cycloalkyl, halogen-substituted or unsubstituted C1-C6 alkyl; or substituents on the same atom, adjacent atoms or alternating atoms may be linked to form a C3-C6 cycloalkyl, or a 3-6 membered heterocyclic group containing 1-3 heteroatoms selected from O, N and S;

[0174] Among them, each m, X2, L3, L4, R3, R5, R6, R 10 B and C are as defined in this invention.

[0175] In another preferred embodiment, the compound is:

[0176] in,

[0177] X1 is independently selected from N or CH;

[0178] Dashed lines represent single bonds or non-existent bonds, and when the dashed line represents a single bond, X1 ’ The answer is C;

[0179] And when the dashed line does not exist, X1 ’ Selected from N or CH;

[0180] X2 is selected from N or Se;

[0181] R8 and R9 are independently selected from hydrogen, deuterium, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C3-C6 cycloalkyl; or R8 and R9 together with their attached N atom form a substituted or unsubstituted 5-6 membered heteroaromatic ring with 1, 2 or 3 nitrogen atoms, or a substituted or unsubstituted 5-6 membered heterocyclic ring with 1, 2 or 3 nitrogen atoms; wherein, substitution means that the group is independently substituted by one or more groups selected from the group consisting of: D, halogen, OH, NH2, N (C1-C3 alkyl). 1-2 =CF2 replaces;

[0182] R'4 and R”4 are independently selected from hydrogen, deuterium, halogen, C1-C6 alkyl, and C3-C6 cycloalkyl;

[0183] R'3 and R”3 are independently selected from hydrogen, deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, and C3-C6 cycloalkyl;

[0184] Alternatively, R'3 and R'4 may be linked together to form -O-C1-C3 alkylene- or -O-C1-C2 alkylene-O-;

[0185] R 11 Selected from H, C1-C6 alkoxy, C1-C6 alkyl, C1-C6 haloalkyl and halogen;

[0186] Alternatively, R8 can be connected to R'4 or R”4 to form a 5-8 membered heterocyclic group containing at least one N heteroatom;

[0187] Alternatively, R8 and R'3 may be linked to form a substituted or unsubstituted 9-16 membered heterocyclic group containing at least one N heteroatom; wherein the substitution refers to the group being independently and optionally substituted by one or more groups selected from the group consisting of: D, halogen, halogen or unsubstituted C1-C6 alkyl, halogen or unsubstituted C1-C6 alkoxy, halogen-substituted or unsubstituted C3-C6 cycloalkyl, halogen-substituted or unsubstituted C1-C6 alkyl; or substituents on the same atom, adjacent atoms or alternating atoms may be linked together to form a C3-C6 cycloalkyl, or a 3-6 membered heterocyclic group containing 1-3 heteroatoms selected from O, N and S;

[0188] Or R 11 It can be linked with R”3 to form a 5-8 membered heterocyclic group or a C5-C8 cycloalkyl group containing at least one N heteroatom;

[0189] Each of m, X2, L3, L4, R3, R5, R6, R 10 DIM, L1, B and C are as defined in this invention.

[0190] In another preferred embodiment, R8 and R9 are independently selected from hydrogen, deuterium, C1-C6 alkyl, and C3-C6 cycloalkyl.

[0191] In another preferred embodiment, R8 and R9 are independently selected from hydrogen, deuterium, C1-C6 alkyl, -C1-C6 alkyl-OH, -C1-C6 alkyl-NH2, C3-C6 cycloalkyl, or =CF2-substituted C3-C6 cycloalkyl. Preferably, R8 is selected from: -C1-C6 alkyl-OH, -C1-C6 alkyl-NH2, or =CF2-substituted C3-C6 cycloalkyl, and R9 is a C1-C6 alkyl.

[0192] In another preferred embodiment, R8 and R9 together with the N atom attached to them form a substituted or unsubstituted 5-6 membered heterocycle with one nitrogen atom; wherein, the substitution refers to the group being independently replaced by one =CF2 atom.

[0193] In another preferred embodiment, R8 and R9 are independently selected from C1-C6 alkyl groups, preferably from C1-C3 alkyl groups, and more preferably from methyl groups.

[0194] In another preferred embodiment, R8 is connected to R'4 to form a 5-6 membered heterocyclic group containing at least one N heteroatom.

[0195] In another preferred embodiment, R8 is connected to R'3 to form a substituted or unsubstituted 10-15 membered heterocyclic group containing at least one N heteroatom; preferably, the heterocyclic group has 1-3 heteroatoms selected from O, N and P.

[0196] In another preferred embodiment, R8 is connected to R'3 to form substituted or unsubstituted C1-C6 alkylene, C1-C3 alkylene-O-C1-C3 alkylalkyl, C1-C3 alkylene-O-C1-C3 alkylene-O-, C1-C6 alkylene-O-, C1-C6 alkenyl-O-; wherein the substitution refers to the group being independently and optionally substituted by one or more groups selected from the group consisting of: D, halogen, halogen or unsubstituted C1-C6 alkyl, halogen or unsubstituted C1-C6 alkoxy, halogen-substituted or unsubstituted C3-C6 cycloalkyl, halogen-substituted or unsubstituted C1-C6 alkyl; or substituents on the same atom, adjacent atoms or alternating atoms are connected to form C3-C6 cycloalkyl, a 3-6 membered heterocyclic group containing 1-3 heteroatoms selected from O, N and S.

[0197] In another preferred embodiment, R8 is connected to R'3 to form substituted or unsubstituted C1-C6 alkylene, C1-C3 alkylene-O-C1-C3 alkylalkyl, C1-C3 alkylene-O-C1-C3 alkylene-O-, C1-C6 alkylene-O-; wherein the substitution refers to the group being independently and optionally substituted by one or more groups selected from the group consisting of: D, halogen, halogen or unsubstituted C1-C6 alkyl, halogen or unsubstituted C1-C6 alkoxy, halogen-substituted or unsubstituted C3-C6 cycloalkyl, halogen-substituted or unsubstituted C1-C6 alkyl; or substituents on the same atom, adjacent atoms or alternating atoms are connected to form C3-C6 cycloalkyl, a 3-6 membered heterocyclic group containing 1-3 heteroatoms selected from O, N and S.

[0198] In another preferred embodiment, R8 and R'3 are connected to form C5-C6 alkylene, -C4-C5 alkylene-O-, C5-C6 alkenyl, -C4-C5 alkenyl-O-, C5-C6 alkyneyl, -C4-C5 alkyne-O-, -C2 alkylene-O-C2 alkylene-O-; preferably C5 alkylene, -C4 alkylene-O-, C2 alkylene-O-C2 alkylene-O-.

[0199] In another preferred embodiment, R8 is connected to R'3 to form C5-C6 alkylene, -C4-C5 alkylene-O-, C5-C6 alkenylene, -C4-C5 alkenylene-O-, C5-C6 alkyneide, -C4-C5 alkyneide-O-; preferably C5 alkylene or -C4 alkylene-O-.

[0200] In another preferred embodiment, R'3 and R'4 are connected together to form -O-C1-C2 alkylene-.

[0201] In another preferred embodiment, R8 and R9 are independently selected from hydrogen, deuterium, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C3-C6 cycloalkyl; or R8 and R9 together with their attached N atom form a substituted or unsubstituted 5-6 membered heteroaromatic ring having 1, 2, or 3 nitrogen atoms, or a substituted or unsubstituted 5-6 membered heterocyclic ring having 1, 2, or 3 nitrogen atoms; wherein, the substitution refers to the group being independently substituted by one or more groups selected from the group consisting of: D, halogen, OH, NH2, N (C1-C3 alkyl). 1-2 =CF2.

[0202] In another preferred embodiment, SBM is:

[0203] Among them, each m, X2, L3, L4, R3, R5, R6, R 10 B and C are as defined in this invention.

[0204] In another preferred embodiment, Having structure Wherein, R'5 is independently selected from H, =C1-C6 alkyl, =C1-C6 haloalkyl, C1-C6 alkyl, C1-C6 haloalkyl, or two R'5 on any carbon atom connected together with the carbon atom to form a C3-C6 carbon ring, a halogenated C3-C6 carbon ring, a 3-6 membered heterocyclic group containing 1-3 heteroatoms selected from O, N and S, or a halogenated 3-6 membered heterocyclic group containing 1-3 heteroatoms selected from O, N and S.

[0205] In another preferred embodiment, two R'5 on any carbon atom are connected together and together with the carbon atom form a C3-C6 carbon ring, preferably a C4-C5 carbon ring.

[0206] In another preferred embodiment, R'5 is not simultaneously H.

[0207] In another preferred embodiment, R'5 is independently selected from H, =C1-C3 haloalkyl (preferably =CF2), or two R'5 on any carbon atom are connected together and together with the carbon atom to form a C3-C6 carbon ring (preferably a C4-C5 carbon ring).

[0208] In another preferred embodiment, Having structure L4 is selected from: -CF=CH-, -CH=CH-, ethynyl group, -NHCO- (preferably -CF=CH-);

[0209] Selected from the following group: Each R5 is independently selected from: H, halogen, CN, C1-C3 alkyl, C1-C3 haloalkyl, C3-C4 cycloalkyl.

[0210] In another preferred embodiment, In this context, R5 is selected from: H, halogen, CN, C1-C3 alkyl, and C1-C3 haloalkyl.

[0211] In another preferred embodiment, Selected from the following group: R5 is H or C1-C3 alkyl, C3-C4 cycloalkyl.

[0212] In another preferred embodiment, Only one R'5 is replaced by H, or only two R'5 on the same C atom are connected together with the carbon atom to form a ring (preferably a C3-C6 carbon ring, more preferably a C4-C5 carbon ring) and the other R'5 are H.

[0213] In another preferred embodiment, Selected from the following group:

[0214] In another preferred example, L4 is -CF = CH-.

[0215] In another preferred embodiment, L4 is -NHCO-.

[0216] In another preferred embodiment, the SBM is selected from VIa-1, VIa-2, VIa-3, VIa-4, or VIa-5:

[0217] Wherein, m, L3, L4, R5, R6, B, and C are as defined in this invention.

[0218] In another preferred embodiment, the SBM has the following structure:

[0219] L5 is selected from the following group: -CO-N(C1-C6 alkyl)-, -P(O)CH3O-, -heteroaryl containing 1-3 5-6 heteroatoms selected from O, N and S-, -5-6 heterocyclic group containing 1-3 heteroatoms selected from O, N and S-. Where ring E is a 5-8 membered heterocyclic group containing at least one N heteroatom;

[0220] L6 is selected from the following group: substituted or unsubstituted C3-C6 alkylene groups, substituted or unsubstituted C3-C6 alkenyl groups, substituted or unsubstituted C1-C3 alkylene groups -O-C1-C3 alkylene groups, substituted or unsubstituted C1-C3 alkylene groups -NH-C1-C3 alkylene groups, substituted or unsubstituted -O-C3-C6 alkenyl groups, substituted or unsubstituted -O-C3-C6 alkylene groups, substituted or unsubstituted C1-C3 alkylene groups -P(O)CH3-C1-C3 alkylene groups. The group is optionally substituted by one or more groups selected from the group consisting of: D, halogen, halogen or unsubstituted C1-C6 alkyl, halogen or unsubstituted C1-C6 alkoxy, halogen-substituted or unsubstituted C3-C6 cycloalkyl, halogen-substituted or unsubstituted C1-C6 alkyl; or substituents on the same atom, adjacent atoms or alternating atoms are linked to form a C3-C6 cycloalkyl, or a 3-6 membered heterocyclic group containing 1-3 heteroatoms selected from O, N and S;

[0221] X2 is selected from NH or Se, and each of m, L3, L4, R3, R5, R6, R 10 B and C are as defined in this invention.

[0222] In another preferred embodiment, the SBM has a Va structure:

[0223] In formula Va, ring B is independently selected from saturated or partially saturated 9- to 20-membered carbon rings, saturated or partially saturated 9- to 20-membered heterocycles containing 1-3 heteroatoms selected from N, O, S, P, and Se, 10- to 20-membered aromatic rings, or 9- to 20-membered aromatic heterocycles containing 1-3 heteroatoms selected from N, O, S, P, and Se; the carbon ring and heterocycle are independently monocyclic, bicyclic, or tricyclic fused rings, spirocyclic, or bridged rings.

[0224] Each of m, X2, L3, R3, R5, R6, R 10 And C as defined in this invention.

[0225] In another preferred embodiment, the compound has the following structure:

[0226] X2 is selected from NH or Se, and the dashed line represents the presence or absence of the ring. When present, ring G is a partially saturated 5-7 membered heterocycle containing 1-3 heteroatoms selected from N, O, and S, of which at least one is an N heteroatom.

[0227] DIM and L1 are as defined in this invention.

[0228] In another preferred embodiment, the compound has the following structure:

[0229] X2 is selected from NH or Se, and the dashed line indicates its presence or absence. When present, ring G is a partially saturated 5-7 membered heterocycle containing 1-3 heteroatoms selected from N, O, and S, of which at least one is an N heteroatom.

[0230] In another preferred embodiment, ring G is a ring formed by -CH2-O-CH2- and the connected atoms.

[0231] In another preferred embodiment, ring G is a ring formed by -CH2CH2- or -CH2CH2CH2- and the adjacent atoms.

[0232] In another preferred embodiment, X2, X3, and X4 together with the two C atoms on the benzene ring to which they are attached form a 5-membered heteroaromatic ring with 1 or 2 heteroatoms.

[0233] In another preferred embodiment, X2, X3, and X4 together with the two C atoms on the benzene ring to which they are attached form a 5-membered heteroaromatic ring having one or two heteroatoms selected from N and Se.

[0234] In another preferred embodiment, X2, X3, and X4 together with the two C atoms on the benzene ring to which they are attached form a 5-membered heteroaromatic ring with one N heteroatom.

[0235] In another preferred embodiment, X2, X3, and X4 together with the two C atoms on the benzene ring to which they are attached form a 5-membered heteroaromatic ring with one Se heteroatom.

[0236] In another preferred embodiment, ring A1 is selected from the following group:

[0237] Preferably, ring A1 is selected from the following group:

[0238] In another preferred embodiment, ring A1 is

[0239] In another preferred embodiment, Selected from the following group: Preferred More preferably

[0240] In another preferred embodiment, L is:

[0241] In another preferred embodiment, ring E is a saturated or partially saturated C3-C6 membered carbon ring, a saturated or partially saturated 3-6 membered heterocycle containing 1-3 heteroatoms selected from N, O, S, P and Se, a phenyl ring, or a 5-6 membered aromatic heterocycle containing 1-3 heteroatoms selected from N, O, S, P and Se.

[0242] In another preferred embodiment, each of R3, R4, R5, R6, R7 and R 10 Independently selected from the group consisting of: hydrogen, deuterium, halogen, cyano, carbonyl, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C3-C6 cycloalkyl, -CONR8R9, -NR8COR9, -NR8R9, -OR8, -SR8, -S(O)R8, -S(O)2R8.

[0243] In another preferred embodiment, the DIM is selected from the group consisting of:

[0244] Wherein, R1 is a C1-C4 alkyl group;

[0245] Each R2 is independently selected from H, C1-C6 alkoxy, C1-C6 alkyl, C1-C6 haloalkyl, and halogen;

[0246] Each n is independently 0, 1, or 2 (preferably n is 0, or preferably n is 1).

[0247] In another preferred embodiment, each R2 is independently selected from H and halogens, and each R1 is independently as defined in this invention.

[0248] In another preferred embodiment, the DIM is:

[0249] R2 is selected from H, halogens, and C1-C6 alkyl groups, and R1 is as defined in this invention.

[0250] In another preferred embodiment, the DIM is selected from the group consisting of:

[0251] In the selected example, the DIM is

[0252] In another preferred embodiment, R2 is H.

[0253] In another preferred embodiment, R2 is F.

[0254] In another preferred embodiment, R1 is methyl.

[0255] In another preferred example, X is 0.

[0256] In another preferred embodiment, L is connected to DIM via the L1 terminal.

[0257] In another preferred embodiment, L is

[0258] In another preferred example, in L, n is 1, and R 11 Selected from C1-C6 alkoxy, C1-C6 alkyl, C1-C6 haloalkyl, halogen, C1-C6 alkyl= and haloC1-C6 alkyl=.

[0259] In another preferred embodiment, R 11 =CF2.

[0260] In another preferred embodiment, L1 is ethylidene or propyleneide, preferably ethylidene.

[0261] In another preferred embodiment, L1 is zero.

[0262] In another preferred embodiment, L1 is a single bond.

[0263] In another preferred embodiment, X1 is N. In another preferred embodiment, n is 0.

[0264] In another preferred embodiment, the DIM is Furthermore, L1 is ethylene or propylene, and R2 is as defined above. In another preferred embodiment, the DIM is... And L1 is non-existent, and R2 is as defined above.

[0265] In another preferred embodiment, the DIM is

[0266] In another preferred embodiment, the DIM is And L1 is ethylidene or propylidene, and R2 is as defined above.

[0267] In another preferred embodiment, the “C1-C6 alkyl” is a C1-C3 alkyl, preferably methyl.

[0268] In another preferred embodiment, the “C1-C6 alkoxy” is a C1-C3 alkoxy, preferably a methoxy.

[0269] In another preferred embodiment, the “C1-C6 haloalkoxy” is a C1-C3 haloalkoxy, preferably a halomethoxy, and more preferably a difluoromethyl or trifluoromethyl.

[0270] In another preferred embodiment, the halogen refers to F, Cl, Br, I, preferably F or Cl, and more preferably F.

[0271] In another preferred example, X3 is C.

[0272] In another preferred example, X4 is C.

[0273] In another preferred embodiment, X2 is NH.

[0274] In another preferred embodiment, X2 is Se.

[0275] In another preferred embodiment, L3 is a -COC1-C4 alkylene, preferably a -CO ethylene or a -CO propyleneene.

[0276] In another preferred embodiment, L3 is a C1-C4 alkylene, preferably methylene, ethylene, or propylene.

[0277] In another preferred embodiment, L3 is -COC1-C4 alkylene, C1-C4 alkylene, ethynylene, vinylene, bond, -NHCO- or -CF=CH2-.

[0278] In another preferred embodiment, L3 is a -COC1-C4 alkylene or a C1-C4 alkylene and L4 is an ethynylene.

[0279] In another preferred embodiment, L4 is a bond, -NHCO- or -CF=CH2-, preferably L4 is a bond.

[0280] In another preferred embodiment, R3 is independently selected from: hydrogen, deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C3-C6 cycloalkyl; preferably, R3 is independently selected from: H, halogen, C1-C3 alkoxy, C1-C6 haloalkoxy; more preferably, R3 is independently selected from: halogen, methoxy, halomethoxy.

[0281] In another preferred example, R3 is 0.

[0282] In another preferred embodiment, R3 is one molecule, and is a C1-C6 alkoxy group, preferably a methoxy group.

[0283] In another preferred example, R5 is 0.

[0284] In another preferred embodiment, R6 is 0. In another preferred embodiment, R6 is H.

[0285] In another preferred example, X1 is N.

[0286] In another preferred embodiment, ring C is selected from the group consisting of 5-6 membered aromatic heterocycles containing 1-3 heteroatoms selected from N, O and S, preferably 5-6 membered aromatic heterocycles containing 2-3 N heteroatoms.

[0287] In another preferred embodiment, R4 is -CO-N(C1-C6 alkyl)2, preferably -CO-N(C1-C3 alkyl)2, and more preferably -CO-N(methyl)2.

[0288] In another preferred embodiment, in formula Ia or any of its sub-formulas, R3 is located adjacent to the linking site with L, and preferably R3 is a C1-C6 alkoxy group, preferably a methoxy group.

[0289] In another preferred embodiment, R 10 It is F.

[0290] In another preferred embodiment, R 10 For H.

[0291] In another preferred embodiment, -L-DIM is selected from the following group.

[0292] In another preferred embodiment, ring C is selected from the following group:

[0293] In another preferred embodiment, for In another preferred embodiment, ring B is selected from the group consisting of: saturated or partially saturated 5-7 member heterocyclic groups containing 1, 2 or 3 heteroatoms selected from O and N heteroatoms; 5-10 member heteroaryl groups containing 1, 2 or 3 N heteroatoms; saturated or partially saturated 5-7 member heterocyclic groups containing 1, 2 or 3 heterocyclic groups selected from O and N heteroatoms; saturated or partially saturated 5-7 member heterocyclic groups containing 1, 2 or 3 heterocyclic groups selected from O and N heteroatoms; and saturated or partially saturated 5-7 member heterocyclic groups containing 1, 2 or 3 heterocyclic groups selected from O and N heteroatoms.

[0294] In another preferred embodiment, ring B is selected from the group consisting of: saturated or partially saturated 5-7 member heterocyclic groups containing one N heteroatom, saturated or partially saturated 5-7 member heterocyclic groups containing one N heteroatom, saturated or partially saturated 5-7 member heterocyclic groups containing one N heteroatom, and saturated or partially saturated 5-7 member heterocyclic groups containing one N heteroatom, and spirocyclic groups containing one N heteroatom, respectively.

[0295] In another preferred embodiment, ring B is selected from the group consisting of: saturated or partially saturated 6-membered heterocyclic groups containing one N heteroatom, saturated or partially saturated 6-membered heterocyclic groups containing one N heteroatom, saturated or partially saturated 6-membered heterocyclic groups containing one N heteroatom, and saturated or partially saturated 6-membered heterocyclic groups containing one N heteroatom, which are spiro-C4-C6 cycloalkyl groups.

[0296] In another preferred embodiment, ring B is connected to L3 and L4 via the saturated or partially saturated heterocyclic group containing one N heteroatom, and the N atom is connected to L3.

[0297] In another preferred embodiment, ring B contains N atoms and is connected to L3 through the N atoms.

[0298] In another preferred embodiment, ring B or Selected from the following group

[0299] In another preferred embodiment, ring B or Selected from the following group:

[0300] In another preferred embodiment, ring B or Selected from the following group: Preferably ring B or Selected from the following group:

[0301] In another preferred embodiment, ring B or for When A1 is not a phenyl group (i.e., ... (Not substituted or unsubstituted phenyl).

[0302] In another preferred embodiment, ring B or for At the same time, R8 and R9 are not selected from the following groups: substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C3-C6 cycloalkyl.

[0303] In another preferred embodiment, ring B is selected from the following group:

[0304] In another preferred embodiment, ring B is

[0305] In another preferred embodiment, ring B is

[0306] In another preferred embodiment, ring B is In another preferred embodiment, ring B is

[0307] In another preferred embodiment, ring B does not exist.

[0308] In another preferred embodiment, SBM, L, DIM, or combinations thereof are optionally and independently represented as the corresponding groups in any specific compound of the present invention.

[0309] In another preferred embodiment, each of n, m, X1, X1 ’ ,X2,X3,X4,L1,L2,L3,L3,R1,R2,R3,R4,R5,R6,R7,R8,R9,R 10 R 11 R 12 B, C, D, E, and A1 are independently and optionally corresponding to the groups in any specific compound of the present invention.

[0310] In another preferred embodiment, the SBM is selected from the following group:

[0311] .

[0312] In another preferred embodiment, the SBM, L, and DIM of the present invention are optionally and independently selected from the corresponding groups in any specific compound described in the claims and specification of the present invention.

[0313] In a second aspect, the present invention provides a pharmaceutical composition comprising a compound as described in the first aspect of the present invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

[0314] A third aspect of the present invention provides the use of the compounds as described in the first aspect of the present invention or pharmaceutically acceptable salts thereof and the pharmaceutical compositions as described in the second aspect of the present invention in the preparation of STAT6 protein degrading agents.

[0315] In a third aspect, the present invention provides the use of the compounds as described in the first aspect of the invention or pharmaceutically acceptable salts thereof and the pharmaceutical compositions as described in the second aspect of the invention in the preparation of medicaments for the prevention or treatment of STAT6 protein-mediated diseases.

[0316] In another preferred embodiment, the disease is selected from the group consisting of: cancer, neurodegenerative diseases, viral diseases, autoimmune diseases, inflammatory diseases, hereditary diseases, hormone-related diseases, metabolic diseases, organ transplant-related diseases, immunodeficiency diseases, skeletal dysfunction or hypermobility disorders, infectious diseases, thrombosis-induced platelet aggregation, liver diseases, pathological immune diseases involving T cell activation, cardiovascular diseases, or CNS diseases.

[0317] In another preferred embodiment, the cancer is a solid tumor and a hematologic tumor, preferably selected from the group consisting of: solitary fibroma (SFT), colorectal cancer (CRC), neurofibroma, lymphoma, bladder cancer, ovarian cancer, gastric cancer, pancreatic cancer, prostate cancer, lung cancer, bone cancer, brain cancer, neurocytoma, esophageal cancer, lip cancer, laryngeal cancer, hypopharyngeal cancer, tongue cancer, salivary gland cancer, thyroid cancer, kidney cancer, cervical cancer, uterine cancer, choriocarcinoma, testicular cancer, liver cancer, gallbladder cancer, bronchial cancer, melanoma, acute lymphoblastic leukemia, chronic lymphoblastic leukemia, acute myeloid leukemia, chronic myeloid leukemia, multiple myeloma, etc.

[0318] In another preferred embodiment, the cancer is: solitary fibroma (SFT), colorectal cancer (CRC), neurofibroma, or lymphoma.

[0319] It should be understood that, within the scope of this invention, the above-described technical features of this invention and the technical features specifically described below (such as in the embodiments) can be combined with each other to form new or preferred technical solutions. Due to space limitations, they will not be described in detail here. Detailed Implementation

[0320] Through extensive and in-depth research, and by conducting numerous screenings and tests, the inventors have developed a novel diimide-based STAT6 protein degrader with excellent activity. This invention is based on this foundation.

[0321] Definitions and Explanations

[0322] Unless otherwise stated, the definitions of groups and terms recorded in this disclosure and claims, including definitions as examples, exemplary definitions, preferred definitions, definitions recorded in tables, and definitions of specific compounds in the examples, can be arbitrarily combined and combined with each other. Such combinations and combinations of group definitions and compound structures should be understood as being within the scope of this disclosure and / or claims.

[0323] As used herein, the terms “containing” or “including (comprise)” can be open-ended, semi-closed, or closed. In other words, the terms also include “consistently made of” or “composed of”.

[0324] The term "halogen" refers to fluorine, chlorine, bromine, and iodine.

[0325] The term "alkyl" refers to a saturated monovalent hydrocarbon group having a straight chain or branched chains. For example, "C 1-6 "Alkyl" refers to an alkyl group having 1 to 6 carbon atoms in its chain. Examples of alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, and isohexyl. Alkyl groups may be optionally substituted or unsubstituted.

[0326] The term "alkoxy" refers to -O- (alkyl) and -O- (unsubstituted cycloalkyl), where alkyl is defined as described above. Non-limiting examples of alkoxy groups include: methoxy, ethoxy, propoxy, butoxy, cyclopropoxy, cyclobutoxy, cyclopentoxy, and cyclohexyloxy, and alkoxy groups may be optionally substituted or unsubstituted.

[0327] The terms "carbocyclic" or "cycloalkyl" refer to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent, wherein the cycloalkyl ring contains 3 to 20 carbon atoms, preferably 3 to 12 carbon atoms, more preferably 3 to 8 carbon atoms, and even more preferably 5 to 6 carbon atoms. Non-limiting examples of monocyclic cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cyclohepttrienyl, cyclooctyl, etc.; polycyclic cycloalkyl groups include spirocyclic, fused-ring, and bridged-ring cycloalkyl groups, preferably cyclopropyl, cyclobutyl, cyclohexyl, cyclopentyl, and cycloheptyl. The carbocyclic or cycloalkyl group may be optionally substituted or unsubstituted.

[0328] The term "alkylene" refers to a divalent group obtained by removing a hydrogen atom from an alkyl group as defined above. Alkylenes can be straight-chain or branched divalent alkyl groups. For example, "C 1-4 "Alkylene" refers to an alkylene having 1 to 4 carbon atoms. Examples of alkylene include, but are not limited to, methylene (i.e., -CH2-), ethylene (i.e., -CH2CH2- or -CH(CH3)-), and propylene (i.e., -CH2-CH2-CH2-, -CH(CH2CH3)-, or -CH2CH(CH3)-).

[0329] The term "alkenyl" refers to a straight-chain or branched hydrocarbon group containing one or more double bonds, typically ranging in length from 2 to 20 carbon atoms. For example, "C 2-6 "Alkenyl" contains 2 to 6 carbon atoms. Examples of alkenyl include, but are not limited to, vinyl, propenyl, butenyl, 2-methyl-2-buten-1-yl, etc.

[0330] The terms "heterocycle" and "heterocyclic group" refer to a saturated or partially unsaturated monocyclic or polycyclic hydrocarbon substituent comprising 3 to 20 ring atoms, wherein one or more ring atoms are selected from heteroatoms of N, O, S, P, and Se (preferably N, O, and S), but excluding ring portions of -OO-, -OS-, or -SS-, and the remaining ring atoms are carbon (which may include 1 or 2 C=O atoms). Preferably, it comprises 3 to 12 ring atoms, of which 1 to 4 are heteroatoms; more preferably, it comprises 3 to 8 ring atoms or 6 to 12 ring atoms; most preferably, it comprises 3 to 6 ring atoms; even more preferably, it is a 3-8 membered heterocyclic group comprising 1-3 nitrogen atoms, optionally substituted with 1-2 oxygen atoms, sulfur atoms, or oxo groups, including monocyclic heterocyclic groups, spirocyclic groups, or fused heterocyclic groups. The heterocycle or heterocyclic group may be optionally substituted or unsubstituted.

[0331] The term "aryl" or "aromatic ring" refers to a 6- to 20-membered all-carbon monocyclic or fused polycyclic (i.e., a ring sharing adjacent carbon atom pairs) group having a conjugated π-electron system, preferably 6- to 14-membered, such as phenyl and naphthyl. Phenyl is more preferred. The aryl ring may be fused to a heteroaryl, heterocyclic, or cycloalkyl ring (with the connection site to other parts of the molecule located on the aromatic ring), including benzo5- to 10-membered heteroaryl, benzo3- to 8-membered cycloalkyl, and benzo3- to 8-membered heteroalkyl, preferably benzo5- to 6-membered heteroaryl, benzo3- to 6-membered cycloalkyl, and benzo3- to 6-membered heteroalkyl, wherein the heterocyclic group is a heterocyclic group containing 1-3 nitrogen, oxygen, and sulfur atoms; or may also include a three-membered nitrogen-containing fused ring containing a benzene ring. The aryl group may be substituted or unsubstituted.

[0332] The term "aromatic heterolyl" or "aromatic heterocycle" refers to a heteroaromatic system comprising 1 to 3 heteroatoms and 5 to 20 ring atoms, wherein the heteroatoms are selected from N, O, S, P, and Se (preferably N, O, and S). The heteroaryl group is preferably a 5-6 member monocyclic heteroaryl or an 8-12 member bicyclic heteroaryl, such as imidazolyl, furanyl, thiophene, thiazolyl, pyrazolyl, oxazolyl, pyrroleyl, triazolyl, tetrazolyl, pyridinyl, pyrimidinyl, thiadiazole, pyrazinyl, etc., preferably pyridinyl, oxadiazolyl, triazolyl, thiophene, imidazolyl, pyrazolyl, oxazolyl, thiazolyl, pyrimidinyl, or thiazolyl; more preferably tetrazolyl, pyridinyl, oxadiazolyl, pyrazolyl, pyrroleyl, thiazolyl, and oxazolyl. The heteroaryl group may be fused to an aryl, heterocyclic, or cycloalkyl ring (with the connection site to other parts of the molecule located on the heteroaryl ring), including 5-6-membered heteroarylphenyl, 5-6-membered heteroaryl-3-8-membered cycloalkyl, and 5-6-membered heteroaryl-3-8-membered heteroalkyl, preferably 5-6-membered heteroarylphenyl, 5-6-membered heteroaryl-3-6-membered cycloalkyl, and 5-6-membered heteroaryl-3-6-membered heteroalkyl. The aromatic heterol group may be optionally substituted or unsubstituted.

[0333] As used herein, the term "substituted" means that a particular group or part thereof has one or more substituents. The term "unsubstituted" means that a particular group does not have any substituents. The term "optionally substituted" means that a particular group is unsubstituted or substituted by one or more substituents. When using the term "substituted" to describe a structural system, substitution can occur at any position allowed by the valence state in the system. Unless otherwise specified, the groups of the present invention may optionally be substituted by one or more groups selected from the group consisting of: D, oxo, halogen, -CO-, thio, -NO2, -CN, -N3, OH, COOH, SF5, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkyl-ON=, substituted or unsubstituted C1-C6 alkyl-S-, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C2-C6 alkynyl, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted C1-C6 alkoxy, amino, substituted or unsubstituted C1-C6 alkyl NH-, substituted or unsubstituted (C1-C6 alkyl)2N-, substituted or unsubstituted C1-C6 alkyl CO-, substituted or unsubstituted C1-C6 alkyl COO-, substituted or unsubstituted C1-C6 alkyl OCO-, substituted or unsubstituted C1-C 6-alkylCONH-, substituted or unsubstituted C1-C6 alkylNHCO-, substituted or unsubstituted substituted or unsubstituted C6-C10 aryl, substituted or unsubstituted 5-10-membered heteroaryl containing 1-3 heteroatoms selected from N, O, S, substituted or unsubstituted 3-8-membered heterocyclic group containing 1-3 heteroatoms selected from N, O, S, or the two adjacent substituents on the cycloalkyl, heterocyclic, aryl, or heteroaryl group optionally form a substituted or unsubstituted C3-8 cycloalkyl or a substituted or unsubstituted 3-8-membered heterocyclic group containing 1-3 heteroatoms selected from N, O, S together with the atoms attached thereto; wherein “substituted” means that one or more H on the group are independently substituted by a group selected from the group consisting of: D, halogen, -CN, OH, amino, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy.

[0334] As used herein, the term "independently" means when more than one substituent is selected from a large number of possible substituents, which may be the same or different. That is, each substituent is individually selected from the entire group of listed possible substituents. In this invention, when two or more groups have the same label, both are defined independently, that is, each substituent is individually selected from the entire group of listed possible substituents.

[0335] As used herein, unless otherwise defined, the definitions of groups and substituents on groups that have the same marking or, although different markings, correspond to each other, may be inherited from each other.

[0336] As used herein, a cyclic group is defined as the portion formed by the connection of group a and group b, together with other atoms sandwiched between group a and group b, constituting the specified cyclic group, wherein the number of ring atoms in the cyclic group is the case where the number of other atoms sandwiched between group a and group b is minimized.

[0337] When used herein for a class of substituents, the nomenclature "Ci-j" (where j>i) denotes an embodiment of the invention that independently implements each number of carbon atoms from i to j (inclusive). For example, the term C 1-3 The embodiments having one carbon atom (C1), two carbon atoms (C2), and three carbon atoms (C3) are represented independently.

[0338] As used herein, the term “optionally” means that the event described below may or may not occur, and includes both events that occur and events that do not occur.

[0339] "Hydroxy" refers to the -OH group. "Amino" refers to -NH2. "Cyano" refers to -CN. "Boc2O" refers to di-tert-butyl dicarbonate. "DCE" refers to 1,2-dichloroethane. "DCM" refers to dichloromethane. "DMA" refers to N,N-dimethylacetamide. "DMF" refers to N,N-dimethylformamide. "dppf" refers to 1,1'-bis(diphenylphosphine)ferrocene. "EA" refers to ethyl acetate. "Et3N" refers to triethylamine. "EtOH" refers to ethanol. "MeCN" refers to acetonitrile. "MeLi" refers to methyllithium. "MeOH" refers to methanol. "NaBH(OAc)3" refers to sodium triacetoxyborohydride. "NCS" refers to N-chlorosuccinimide. "LiHMDS" refers to bis(trimethylsilylaminolithium). "PE" refers to petroleum ether. "TFA" refers to trifluoroacetic acid. "THF" refers to tetrahydrofuran.

[0340] The term "multiple" refers to two or more, such as 2, 3, 4, 5 or 6.

[0341] The terms "active ingredient," "therapeutic agent," "active substance," or "active agent" refer to a chemical entity that can effectively treat a target disorder, disease, or symptom. Preferably, the active ingredient of the present invention is a compound of formula I of the present invention, or a pharmaceutically acceptable salt thereof.

[0342] "Optional" or "optionally" means that the event or condition described below may occur but is not required to occur, and the description includes both the scenario in which said event or condition occurs and the scenario in which said event or condition does not occur.

[0343] The wavy lines used in this article This indicates the connection point between the group and the rest of the molecule.

[0344] The wavy lines in molecules used in this article It refers to a bond; the term "bond" can refer to a single or double bond, and it includes chiral properties. or

[0345] When the ring of the present invention is connected to other parts of a molecule, those skilled in the art will understand that the ring will correspondingly lose H atoms to connect to other parts of the molecule at the desired positions. Preferably, each connection site may be located independently on a C or N atom.

[0346] The compounds of the present invention can be prepared by a variety of synthetic methods known to those skilled in the art, including the specific embodiments listed below, embodiments formed by combining them with other chemical synthetic methods, and equivalent substitutions known to those skilled in the art. Preferred embodiments include, but are not limited to, the embodiments of the present invention.

[0347] Formula I compound

[0348] This invention provides a compound having the structure of formula (I): SBM-L-DIM (I)

[0349] Wherein, DIM is the degradation-inducing moiety (which can be the ligand moiety bound by E3 ubiquitin ligases known in the art, preferably those listed in this invention);

[0350] SBM is the STAT6-binding moiety that can bind to the STAT6 protein;

[0351] L is a divalent linker group; used to connect the SBM and DIM moieties.

[0352] SBM, L, and DIM are optionally defined independently as described in any part of this invention.

[0353] The term "pharmaceutical-grade salt" refers to the salt of the compounds of this invention, prepared by reacting a compound having specific substituents discovered in this invention with a pharmaceutically acceptable acid or base. When the compounds of this invention contain relatively acidic functional groups, base addition salts can be obtained by contacting such compounds with a sufficient amount of base in a pure solution or a suitable inert solvent. When the compounds of this invention contain relatively basic functional groups, acid addition salts can be obtained by contacting such compounds with a sufficient amount of acid in a pure solution or a suitable inert solvent. Certain specific compounds of this invention contain both basic and acidic functional groups, and thus can be converted into either a base or an acid addition salt. The pharmaceutically acceptable salts of this invention can be synthesized from parent compounds containing acid radicals or bases by conventional chemical methods. Generally, such salts are prepared by reacting these compounds in their free acid or base form with a stoichiometric amount of a suitable base or acid in water or an organic solvent or a mixture of both. Typical acids that can form salts include acetic acid (such as acetic acid or trihaloacetic acid, such as trifluoroacetic acid), adipic acid, ascorbic acid, aspartic acid, benzoic acid, benzenesulfonic acid, hydrogen sulfate, boric acid, butyric acid, citric acid, camphor, camphor sulfonic acid, cyclopentanepropionic acid, diethylene glycol, dodecyl sulfate, ethanesulfonic acid, fumaric acid, glucoheponic acid, glycerophosphate, hemisulfonic acid, heptanoic acid, hexanoic acid, hydrobromic acid, hydroiodic acid, hydroxyethanesulfonic acid (such as 2-hydroxyethanesulfonic acid), lactic acid, maleic acid, methanesulfonic acid, naphthalenesulfonic acid (such as 2-naphthalenesulfonic acid), nicotinic acid, nitric acid, oxalic acid, pectic acid, persulfate, phenylpropionic acid (such as 3-phenylpropionic acid), phosphoric acid, picric acid, neopentanoic acid, propionic acid, salicylic acid, succinic acid, sulfuric acid (such as that formed with sulfuric acid), sulfonic acid, tartaric acid, thiocyanate, toluenesulfonic acid such as p-toluenesulfonic acid, dodecanoic acid, etc.

[0354] Some compounds of this invention may contain acidic fragments, including but not limited to carboxylic acids, which may form salts with various organic or inorganic bases. Typical base-formed salts include ammonium salts, alkali metal salts such as sodium, lithium, and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, and salts formed with organic bases (such as organic amines), such as N-methyl-D-glucosamine, N-methyl-D-glucosamide, tert-butylamine, dimethylamine, diethylamine, and salts formed with amino acids such as arginine, lysine, etc.

[0355] In addition to the salt form, the compounds provided by this invention also exist in prodrug form. The prodrugs of the compounds described herein readily undergo chemical changes under physiological conditions to be converted into the compounds of this invention. Furthermore, the prodrugs can be converted into the compounds of this invention in the in vivo environment via chemical or biochemical methods.

[0356] Some compounds of this invention may exist in non-solventized or solvated forms, including hydrated forms. Generally, solvated and non-solventized forms are equivalent and both are included within the scope of this invention.

[0357] The compounds of this invention can exist in specific geometric or stereoisomeric forms. This invention contemplates all such compounds, including cis and trans isomers, (-)- and (+)- enantiomers, (R)- and (S)- enantiomers, diastereomers, (D)- isomers, (L)- isomers, transisomers, racemic mixtures thereof, and other mixtures, such as mixtures enriched with enantiomers or diastereomers, all of which are within the scope of this invention. Additional asymmetric carbon atoms may be present in substituents such as alkyl groups. All such isomers and mixtures thereof are included within the scope of this invention.

[0358] Optically active (R)- and (S)- isomers, as well as D- and L- isomers, transisomers, etc., can be prepared by chiral synthesis, chiral reagents, or other conventional techniques. To obtain an enantiomer of a compound of the present invention, it can be prepared by asymmetric synthesis or derivatization with a chiral auxiliary, wherein the resulting diastereomeric mixture is separated, and the auxiliary group is cleaved to provide the desired enantiomer in pure form. Alternatively, when the molecule contains a basic functional group (such as an amino group) or an acidic functional group (such as a carboxyl group), a salt of the diastereomeric isomer is formed with a suitable optically active acid or base, followed by diastereomeric resolution using conventional methods known in the art, and then the pure enantiomer is recovered. Furthermore, the separation of enantiomers and diastereomeric isomers is typically accomplished by using chromatography employing a chiral stationary phase and optionally combined with chemical derivatization (e.g., from amines to carbamates).

[0359] The compounds of the present invention may contain atomic isotopes in non-natural proportions on one or more atoms constituting the compound. For example, the compounds may be labeled with radioactive isotopes, such as deuterium (₂H) and iodine-125 (₂H). 125 I) or C-14 14 C). All isotopic variations of the compounds of the present invention, regardless of radioactivity, are included within the scope of the present invention. Further, one or more hydrogen atoms in the compounds of the present invention are coated with the isotope deuterium (… 2 The deuteration of the compounds of the present invention, by substitution with H), has the effects of prolonged half-life, reduced clearance rate, metabolic stabilization, and improved in vivo activity. The preparation method of the isotope derivative typically includes a phase-transfer catalytic method. For example, a preferred deuteration method employs a phase-transfer catalyst (e.g., tetraalkylammonium salt, NBu4HSO4). Using a phase-transfer catalyst to exchange the methylene protons of a diphenylmethane compound results in the introduction of higher deuterium levels than reduction with deuterated silanes (e.g., triethyldeuterated silane) in the presence of an acid (e.g., methanesulfonic acid) or with Lewis acids such as aluminum trichloride using sodium deuterated borate.

[0360] Compositions and Applications

[0361] The present invention provides a pharmaceutical composition comprising a compound of formula (I) above, or a pharmaceutically acceptable salt, stereoisomer or isotope thereof; and a pharmaceutically acceptable carrier.

[0362] The compounds of the present invention have STAT6 protein ubiquitination and / or degradation activities, and therefore can be used to prevent and / or treat STAT6-mediated diseases, especially those mediated by increased STAT6 expression and / or activity, such as cancer, neurodegenerative diseases, viral diseases, autoimmune diseases, inflammatory diseases, genetic diseases, hormone-related diseases, metabolic diseases, organ transplant-related diseases, immunodeficiency diseases, skeletal dysfunction or hypermobility disorders, infectious diseases, thrombosis-induced platelet aggregation, liver diseases, pathological immune diseases involving T cell activation, cardiovascular diseases, or CNS diseases.

[0363] The compound of formula (I) can be used in combination with other known drugs for treating or improving similar conditions. When used in combination, the administration method and dosage of the original drug can remain unchanged, while the compound of formula (I) is taken simultaneously or subsequently. When the compound of formula (I) is taken concurrently with one or more other drugs, a pharmaceutical composition containing one or more known drugs and the compound of formula (I) is preferred. Drug combination also includes taking the compound of formula (I) with one or more other known drugs during overlapping time periods. When the compound of formula (I) is used in combination with one or more other drugs, the dosage of the compound of formula (I) or the known drug may be lower than the dosage of either drug alone. The pharmaceutical composition may also contain one or more anticancer agents, for example, selected from (but not limited to): PARP1 / 2 inhibitors, chemotherapeutic agents that induce DNA damage in cancer cells, DNA alkylation agents, DNA or RNA synthesis inhibitors, EGFR, ALK, or FGFR tyrosine receptor kinase inhibitors, KRAS, MEK, or ERK tumor signaling pathway inhibitors, and tumor immunotherapy drugs (such as PD-1 antibodies, PD-L1 antibodies, etc.).

[0364] "Pharmaceutically acceptable excipients" and "pharmaceutically acceptable carriers" refer to substances that facilitate the formulation and / or administration and / or absorption of the active agent by an individual and can be included in the compositions disclosed herein without causing significant adverse toxicological effects on that individual. Non-limiting examples of pharmaceutically acceptable carriers and excipients include water, NaCl, physiological saline solutions, lactated Ringer's solution, conventional sucrose, conventional glucose, binders, fillers, disintegrants, lubricants, coatings, sweeteners, flavorings, salt solutions (e.g., Ringer's solution), alcohols, oils, gelatin, carbohydrates such as lactose, amylose or starch, fatty acid esters, hydroxymethyl cellulose, polyvinylpyrrolidone, and pigments. Such formulations can be sterilized and, if desired, mixed with adjuvants such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts affecting osmotic pressure, buffers, colorants, and / or aromatic substances that will not harmfully react with or interfere with the activity of the compounds provided herein. Those skilled in the art will recognize that other pharmaceutical carriers and excipients are suitable for the disclosed compounds.

[0365] In some embodiments, the pharmaceutical compositions of the present invention may be in solid or liquid form.

[0366] The pharmaceutical product containing the active ingredient of this invention can be a suitable oral dosage form, such as tablets, pills, lozenges, water-soluble or oily suspensions, dispersed latex powders or granules, emulsions, hard or soft capsules, or syrups or elixirs. Orally administered pharmaceutical products can be prepared according to known process methods of the pharmaceutical ingredient manufacturer. These compositions may include one or more of the following agents: sweeteners, flavoring agents, coloring agents, and protective agents, to provide an elegant and palatable pharmaceutical formulation. The tablet contains the active ingredient mixed with non-toxic, pharmaceutically acceptable excipients suitable for tablet production. Examples of such excipients include inert diluents such as calcium carbonate, sodium carbonate, lactose, calcium phosphate, or sodium phosphate; granulating agents, disintegrants such as corn starch or alginic acid; binding agents such as starch, gelatin, or gum arabic; and lubricants such as magnesium stearate, stearic acid, or talc. The tablet may be uncoated or coated to delay degradation and absorption in the gastrointestinal tract, thereby maintaining its activity over a longer period.

[0367] The active compound may be administered to a subject via any suitable route, including orally, parenterally, by inhalation spray, locally, rectally, nasally, sublingually, vaginally, or via an implantable cartridge. As used herein, the term "parenterally" includes subcutaneous, intravenous, intramuscular, intra-articular, intrasynovial, intrasternal, intrasheathic, intrahepatic, intralesional, and intracranial injection or infusion techniques. Preferably, the composition is administered orally, intraperitoneally, or intravenously.

[0368] Pharmaceutical compositions suitable for use in this invention are typically in the form of discrete units in solid form, such as tablets, capsules, pouches, powders, granules, lozenges, patches, suppositories, pills, or in liquid form, such as liquid formulations, injectable or infusionable solutions or suspensions.

[0369] The precise amount of compound provided to an individual for therapeutic efficacy will depend on the route of administration, the type and severity of the disease and / or condition, and individual characteristics such as general health, age, sex, weight, and tolerance to the drug. Those skilled in the art will be able to determine the appropriate dosage based on these and other factors. When administered in combination with other therapeutic agents, the “therapeutic efficacy” of any other therapeutic agent will depend on the type of drug used. Appropriate dosages are known for approved therapeutic agents and can be adjusted by those skilled in the art based on the individual’s condition, the type of condition being treated, and the amount of the compound of the invention used below, for example, the dosages reported in the literature and recommended in Physician's Desk Reference (57th edition, 2003). Preferably, the compositions should be formulated such that an inhibitory dose of 0.01-100 mg / kg body weight / day can be administered to patients receiving these compositions. In some embodiments, the compositions of the invention provide doses from 0.01 mg to 50 mg. In other embodiments, doses of 0.1 mg-25 mg or 5 mg-40 mg are provided.

[0370] Examples of subjects to which the pharmaceutical compositions or therapeutic agents of the present invention are administered include mammals (e.g., humans, mice, rats, hamsters, rabbits, cats, dogs, cattle, sheep, monkeys, etc.).

[0371] The present invention also provides a treatment method comprising the steps of: administering to a subject requiring treatment a compound of general formula (I) as described in the present invention, or a pharmaceutically acceptable salt thereof, or administering a pharmaceutical composition as described in the present invention for selectively degrading STAT6 protein, or for preventing or treating STAT6-mediated diseases (such as STAT6 protein-mediated cancer).

[0372] The main advantages of this invention include:

[0373] 1. This invention provides a class of STAT6 protein degraders with novel structure, excellent activity and high specificity.

[0374] 2. The compounds of the present invention have excellent pharmaceutical properties and can be used to prepare drugs for the prevention or treatment of STAT6 protein-mediated diseases.

[0375] The present invention will be further illustrated below with reference to specific embodiments. It should be understood that these embodiments are for illustrative purposes only and are not intended to limit the scope of the invention. Experimental methods in the following embodiments, unless otherwise specified, are generally performed under conventional conditions or as recommended by the manufacturer. Percentages and parts are by weight unless otherwise stated.

[0376] Preparation method:

[0377] The method used in preparing compounds of formulas (I-VIa) or their salts depends on the desired compound. Factors such as the selection of specific substituents and the various possible sites of those substituents all play a role in the pathway followed in preparing the specific compounds of this invention. Those factors are readily identified by those skilled in the art.

[0378] Generally, the compounds of the present invention can be prepared using standard techniques and similar methods known in the art. General methods for preparing compounds of formulas (I–VIa) are described below. The starting materials and reagents described in the overall experimental scheme below are commercially available or can be prepared using methods known to those skilled in the art.

[0379] An exemplary method for synthesizing the compounds of the present invention can be found in Scheme I below.

[0380] Option I

[0381] Compound (h) is prepared as shown in Scheme I. First, under standard coupling conditions, compound a and compound b are substituted under strong base conditions to produce compound c. Compound c is borated to produce compound d. Compound e and compound f undergo a Suzuki coupling reaction to produce compound g. Finally, compound d and g undergo a Suzuki coupling reaction to produce compound h.

[0382] Example

[0383] The present invention is further illustrated below by way of examples, but these examples do not limit the invention to the scope of the embodiments described. Experimental methods not specifically described in the following examples were performed according to conventional methods and conditions, or as selected according to the trade instructions. Furthermore, those skilled in the art will recognize that the following synthetic reactions and schemes can be modified by selecting suitable starting materials and reagents to obtain the compounds of the present invention.

[0384] The following abbreviations are used in the examples and biological examples:

[0385] "MS" refers to mass spectrometry; "M" refers to molar concentration; "m" refers to multiplet; "M+H+" refers to proton peak + hydrogen; "Me" refers to methyl; "mg" refers to milligram; "MHz" refers to megahertz; "min" refers to minute; "mL" refers to milliliter; "mM" refers to millimolecular concentration; "mmol" refers to millimole; "MS" refers to mass spectrometry; "Ms" is methyl sulfonyl; "nBu / Bu" refers to butyl; "NBS" refers to N-bromosuccinimide; "nL" refers to nanoliter; "nm" refers to nanometer; "NMR" refers to nuclear magnetic resonance; "Pd / C" is... Palladium / carbon; "PE" refers to petroleum ether; "Ph" refers to phenyl; "PS" refers to polystyrene; "q" refers to a quartet; "rt" refers to room temperature; "s" refers to a singlet; "t" refers to a triplet; "t-Bu" refers to tert-butyl; "Tf" refers to trifluoromethanesulfonyl; "TFA" refers to trifluoroacetic acid; "TFAA" refers to trifluoroacetic anhydride; "THF" refers to tetrahydrofuran; "Tpl2" refers to tumor progression locus 2; "TNF" refers to tumor necrosis factor; "δ" refers to chemical shift (ppm); "μL" refers to microliters; "μM" refers to micromolar concentration.

[0386] In the preparative HPLC purification method of the examples, the chromatographic column was a Pursuit XRs 10C18 (10 μm, 21.2 × 250 mm); the mobile phase was acetonitrile / 0.01% FTA aqueous solution, 5% to 100%.

[0387] The structures of the compounds in the examples were determined by nuclear magnetic resonance (NMR) and / or mass spectrometry (MS). The NMR shift was expressed in units of 10⁶ ppm. The solvents used for NMR measurements were deuterated dimethyl sulfoxide, deuterated chloroform, deuterated methanol, etc., with tetramethylsilane (TMS) as the internal standard.

[0388] Example 1 3-(4-(4-(8-(3-(1H-pyrazol-1-yl)propionyl)-1,2,5,6-tetrahydropyridin-3-yl)-7-fluoro-2-methyl-1-oxo-2,3,4-5-tetrahydro-1H-[1,4]diaza[1,2-a]indol-10-yl)-3-methoxyphenyl)piperazin-1-yl)ethyl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione

[0389] Step 1: (E)-3-(4-(2-ethoxyvinyl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione 1-b

[0390] 1-a (250 mg, 0.74 mmol) and (E)-2-(2-ethoxyvinyl)-4,4,5,5-tetramethyl-1,3,2-dioxacyclopentaborane (950 mg, 2.81 mmol) were added to a stirred solution in DMF / H2O (32 mL / 8 mL) along with Pd(dtbpf)Cl2 (182 mg, 0.281 mmol) and CsF (854 mg, 5.62 mmol). The resulting mixture was stirred at 80 °C under nitrogen atmosphere for 2 hours. The reaction solution was diluted with water (100 mL) and extracted with ethyl acetate (50 mL x 3). The organic layers were combined, washed with water and brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure to give a crude product, which was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 1) to give solid 1-b (900 mg, yield 97.4%). MS m / z (ESI): 330.1 [M+H] + .

[0391] Step 2: (E)-3-(4-(2-ethoxyvinyl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione 1-c

[0392] 1-b (150 mg, 0.456 mmol) was dissolved in formic acid (3.0 mL). The resulting solution was stirred at room temperature for 2 hours. The reaction solution was concentrated under reduced pressure to give solid 1-c (137 mg, 100% yield), which was used directly in the next step. MS m / z (ESI): 302.2 [M+H] + .

[0393] Step 3: 4-(4-bromo-3-methoxyphenyl)piperazine-1-carboxylic acid tert-butyl ester 1-e

[0394] To a solution of 1-d (25.0 g, 80.1 mmol) in dimethyl sulfoxide (250 mL), N-Boc-piperazine (35.5 g, 191 mmol), potassium carbonate (33.1 g, 240 mmol), cuprous iodide (3.40 g, 17.8 mmol), and L-proline (1.83 g, 16.0 mmol) were added. The mixture was stirred at 80 °C for 3 hours under nitrogen protection. After the reaction was complete, the reaction solution was diluted with water (900 mL) and extracted with ethyl acetate (600 mL x 3). The combined organic phases were washed with saturated sodium chloride aqueous solution (600 mL), dried over anhydrous sodium sulfate, filtered, concentrated, and the crude product was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 8 / 1) to give a white solid product 1-e (16.0 g, yield 53.8%).

[0395] 1H NMR (400MHz, CDCl3) δ1.49(s,9H),3.13(t,J=5.0Hz,4H),3.58(t,J=5.0Hz,4H),3. 87(s,3H),6.41(dd,J=8.7,2.6Hz,1H),6.45-6.51(m,1H),7.38(d,J=8.6Hz,1H).MS m / z(ESI):373.0[M+H] + .

[0396] Step 4: (4-(4-(tert-Butoxycarbonyl)piperazin-1-yl)-2-methoxyphenyl)boronic acid (1-f)

[0397] Compound 1-e (5.00 g, 13.5 mmol) was dissolved in anhydrous tetrahydrofuran (100 mL) at room temperature. The mixture was cooled to -70 °C, and n-butyllithium (12.0 mL, 30.0 mmol, 2.5 mol / L n-hexane solution) was slowly added dropwise. After the addition was complete, the mixture was stirred at -70 °C for 40 minutes, and then triisopropyl borate (5.08 g, 27.0 mmol) was added. The mixture was heated to 0 °C and stirred for 1 hour. At 0 °C, saturated ammonium chloride aqueous solution (100 mL) was slowly poured into the reaction mixture, and the mixture was extracted with ethyl acetate (200 mL x 3). The organic phases were combined and dried over anhydrous sodium sulfate. The mixture was filtered, concentrated under reduced pressure, and the residue was slurried with a mixture of petroleum ether and ethyl acetate (1 / 1, 40 mL). The residue was filtered, the filter cake was collected, and dried under vacuum to give a white solid product 1-f (3.50 g, yield 77.2%). MS m / z(ESI): 337.2 [M+H] + .

[0398] Step 5: 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborhecyclopentan-2-yl)-1,2,3,6-tetrahydropyridine hydrochloride (1-h)

[0399] To a solution of 1-g (15.0 g, 48.5 mmol) dichloromethane (92 mL), a solution of dioxane (75 mL, 4 M) was added. The resulting mixture was stirred at room temperature for 18 hours. The mixture was then concentrated under reduced pressure to give a white solid product 1-h (11.9 g, 100% yield). MS m / z (ESI): 210.3 [M+H] + .

[0400] Step 6: 3-(1H-pyrazol-1-yl)-1-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborane-2-yl)-3,6-dihydropyridin-1(2H)-yl)prop-1-one(1-i)

[0401] At room temperature, 1-h (5.00 g, 20.3 mmol), 3-(1-pyrazolyl)propionic acid (3.00 g, 21.4 mmol), EDCI (5.00 g, 26.1 mmol), and pyridine (30 mL) were added to a 100 mL round-bottom flask and stirred at room temperature for 2 hours. The resulting mixture was distilled under reduced pressure, and the residue was extracted with saturated ammonium chloride aqueous solution (50 mL) and ethyl acetate (50 mL x 3). The organic phases were combined and dried over anhydrous sodium sulfate. The mixture was filtered, concentrated under reduced pressure, and the crude product was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to give a white solid product 1-i (3.84 g, yield 57.1%). MS m / z (ESI): 332.3 [M+H] + .

[0402] Step 7: Methyl 2-azido-3-(4-bromo-2-chloro-5-fluorophenyl)acrylate (1-k)

[0403] A solution of sodium methoxide (37.4 mL, 202 mmol, 30% MeOH solution) in methanol (160 mL) was cooled to -10 °C. Then, a solution of 2-chloro-4-bromo-5-fluorobenzaldehyde (12.0 g, 50.6 mmol) and ethyl azide (26.1 g, 202 mmol) in methanol (160 mL) was slowly added dropwise. After the addition was complete, the mixture was stirred at room temperature for 12 hours, then poured into a saturated ammonium chloride aqueous solution (400 mL) cooled to 0 °C. The mixture was filtered, the filter cake was collected, evaporated to dryness under reduced pressure, and the crude product was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 100 / 1 to 4 / 1) to give a white solid product 1-k (6.50 g, yield 38.5%).

[0404] 1 H NMR (400MHz, DMSO-d6) δ8.21 (d, J = 9.6 Hz, 1H), 8.06 (d, J = 6.8 Hz, 1H), 7.03 (s, 1H), 3.94 (s, 3H).

[0405] Step 8: Methyl 6-bromo-4-chloro-7-fluoro-1H-indole-2-carboxylate (1-l)

[0406] A solution of 1-k (13.0 g, 39.0 mmol) in xylene (500 mL) was heated to 140 °C and stirred for 3 hours. The mixture was then cooled to 0 °C, filtered, and the filter cake was collected and dried under reduced pressure to give a white solid product 1-l (9.50 g, yield 79.5%). 1 H NMR (400MHz, DMSO-d6) δ13.09 (s, 1H), 7.43 (d, J = 4.2Hz, 1H), 7.15 (d, J = 2.4Hz, 1H), 3.90 (s, 3H).

[0407] Step 9: Methyl 6-bromo-1-(3-((tert-butoxycarbonyl)(methyl)amino)propyl)-4-chloro-7-fluoro-1H-indole-2-carboxylic acid (1-m)

[0408] 3-Bromo-N-methyl-N-Boc-propylamine (1.20 g, 4.78 mmol) and cesium carbonate (3.20 g, 9.84 mmol) were added to a 1-l (1.00 g, 3.27 mmol) solution of DMF (30 mL). The mixture was stirred at 70 °C for 3 hours under nitrogen protection. After the reaction was complete, the reaction solution was diluted with water (100 mL) and extracted with ethyl acetate (100 mL x 3). The combined organic phases were washed with saturated sodium chloride aqueous solution (100 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 8 / 1) to give a white solid product 1-m (1.50 g, yield 96.0%). MS m / z (ESI): 378.8 [M-100+H] + .

[0409] Step 10: 6-Bromo-4-chloro-7-fluoro-1-(3-(methylamino)propyl)-1H-indole-2-carboxylic acid methyl ester hydrochloride (1-n)

[0410] To a solution of 1-l (1.41 g, 3.73 mmol) dioxane (10 mL), a solution of dioxane chloride (10 mL, 4 M) was added. The resulting mixture was stirred at room temperature for 18 hours. The mixture was then concentrated under reduced pressure to give a white solid product 1-m (1.40 g, 100% yield). MS m / z (ESI): 376.9 [M+H] + .

[0411] Step 11: 8-Bromo-10-chloro-7-fluoro-2-methyl-2,3,4-5-tetrahydro-1H-[1,4]diaza[1,2-a]indol-1-one (1-o)

[0412] At room temperature, trimethylaluminum (6.90 mL, 13.8 mmol, 2.0 M toluene solution) was added to a mixed solution of 1-n (1.90 g, 4.61 mmol) of toluene (20 mL) and THF (20 mL). The resulting mixture was stirred at 80 °C for 16 hours. The reaction mixture was poured into an aqueous sodium hydroxide solution (50 mL, 2 M) and extracted with dichloromethane (80 mL x 3). The organic layer was washed with a saturated aqueous sodium chloride solution (100 mL), dried over anhydrous sodium sulfate, filtered, concentrated, and the residue was slurried with a mixed solvent of petroleum ether and ethyl acetate (1 / 1, 5 mL), filtered, and the filter cake was collected and dried under vacuum to give a yellow solid product 1-o (700 mg, yield 43.9%). MS m / z (ESI): 347.0 [M+H] + .

[0413] Step 12: 8-(1-(3-(1H-pyrazol-1-yl)propionyl)-1,2,5,6-tetrahydropyridin-3-yl)-10-chloro-7-fluoro-2-methyl-2,3,4,5-tetrahydro-1H-[1,4]diaza[1,2-a]indol-1-one (1-p)

[0414] Potassium carbonate (600 mg, 4.35 mmol), 1,1'-bis(diphenylphosphino)ferrocene palladium chloride (159 mg, 0.218 mmol), and 1-o (500 mg, 1.45 mmol), 1-i (578 mg, 1.74 mmol), and water (4 mL) were added to a mixture. The mixture was stirred at 60 °C for 2 hours under nitrogen protection. After the reaction was complete, the reaction solution was diluted with water (20 mL) and extracted with dichloromethane (50 mL x 3). The combined organic phases were washed with saturated sodium chloride aqueous solution (50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by silica gel column chromatography (dichloromethane / methanol = 100 / 1 to 20 / 1) to give a yellow solid product 1-p (475 mg, yield 70.0%). MS m / z (ESI): 470.2 [M+H] + .

[0415] Step 13: 4-(4-(8-(1-(3-(1H-pyrazol-1-yl)propionyl)-1,2,5,6-tetrahydropyridin-3-yl)-7-fluoro-2-methyl-1-oxo-2,3,4-5-tetrahydro-1H-[1,4]diaza[1,2-a]indol-10-yl)-3-methoxyphenyl)piperazine-1-carboxylic acid tert-butyl ester (1-q)

[0416] Potassium phosphate (753 mg, 3.41 mmol), XPhos Pd G3 (150 mg, 0.128 mmol), and dioxane (30 mL) and water (10 mL) of 1-p (400 mg, 0.853 mmol) and 1-f (716 mg, 2.13 mmol) were added. The mixture was stirred at 65 °C for 2 hours under nitrogen protection. After the reaction was complete, the reaction solution was diluted with water (50 mL) and extracted with ethyl acetate (50 mL x 3). The combined organic phases were washed with saturated sodium chloride aqueous solution (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was purified by silica gel column chromatography (dichloromethane / methanol = 100 / 1 to 20 / 1) to give a yellow solid product 1-q (443 mg, yield 71.6%). MS m / z (ESI): 726.2 [M+H] + .

[0417] Step 14: 8-(1-(3-(1H-pyrazol-1-yl)propionyl)-1,2,5,6-tetrahydropyridin-3-yl)-7-fluoro-10-(2-methoxy-4-(piperazin-1-yl)phenyl)-2-methyl-2,3,4-5-tetrahydro-1H-[1,4]diaza[1,2-a]indol-1-one (1-r)

[0418] To a solution of 1-q (200 mg, 0.276 mmol) in dichloromethane (2.0 mL), add 0.40 mL of trifluoroacetic acid. The resulting mixture is stirred at room temperature for 1 hour, then concentrated under reduced pressure to give a yellow, oily crude product, 1-r (200 mg, 100% yield), which is used directly. MS m / z (ESI): 626.4 [M+H] + .

[0419] Step 15: 3-(4-(4-(8-(3-(1H-pyrazol-1-yl)propionyl)-1,2,5,6-tetrahydropyridin-3-yl)-7-fluoro-2-methyl-1-oxo-2,3,4-5-tetrahydro-1H-[1,4]diaza[1,2-a]indol-10-yl)-3-methoxyphenyl)piperazin-1-yl)ethyl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione

[0420] At room temperature, acetic acid (66.0 mg, 1.10 mmol) and potassium acetate (65.0 mg, 0.663 mmol) were added to a solution of DMSO (1.0 mL) and THF (1.0 mL) containing 1-r (200 mg, 0.276 mmol) and 1-c (91.5 mg, 0.304 mmol). The mixture was stirred at room temperature for 1 hour, cooled to 0 °C, and then sodium cyanoborohydride (175 mg, 0.858 mmol) was added in portions. The resulting mixture was stirred at room temperature for 18 hours, filtered, and purified by preparative HPLC to obtain trifluoroacetate of compound 1 as a white solid (38.0 mg, yield 13.7%).

[0421] MS m / z (ESI): 911.2 [M+H] + ;

[0422] 1 H NMR (400MHz, DMSO-d6) δ11.11(s,1H),10.10(s,1H),7.74–7.68(m,1H),7.45–7.35(m,1H),7.19(d,J=8.4Hz,1H),7.11–7.01(m, 2H),7.00–6.92(m,1H),6.80(dd,J=21.6,6.0Hz,1H),6.78(s,1H),6.69(d,J=6.8Hz,1H),6.53(s,1H),6.22–6.15(m,1H),6.12–6 .02(m,1H),5.45–5.34(m,1H),4.47(t,J=6.0Hz,2H),4.40–4.29(m,3H),4.26(s,1H),4.05(d,J=12.8Hz,2H),3.82–3.57(m,11H) ,3.40–3.23(m,6H),3.18–3.06(m,2H),3.05(s,3H),3.02–2.80(m,3H),2.80–2.59(m,3H),2.36–2.16(m,4H),2.03–1.94(m,1H).

[0423] Example 2 3-(4-(4-(7-(3-(1H-1,2,3-triazol-1-yl)propionyl)-1,2,5,6-tetrahydropyridin-3-yl)-6-fluoro-2-methyl-1-oxo-1,2,3,4-tetrahydropyrazino[1,2-a]indol-9-yl)-3-methoxyphenyl)piperazin-1-yl)ethyl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione 2

[0424] Step 1: 1-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborane-2-yl)-3,6-dihydropyridin-1(2H)-yl)-3-(1H-1,2,3-triazol-1-yl)prop-1-one 2-b

[0425] At room temperature, 1-h (3.00 g, 14.3 mmol), 3-(1H-1,2,3-triazol-1-yl)propionic acid (2.00 g, 14.2 mmol), EDCI (3.00 g, 10.5 mmol), and pyridine (22.4 mL) were added to a 100 mL round-bottom flask and stirred at room temperature for 2 hours. The resulting mixture was distilled under reduced pressure, and the residue was extracted with saturated ammonium chloride aqueous solution (50 mL) and ethyl acetate (50 mL × 3). The organic phases were combined and dried over anhydrous sodium sulfate. The mixture was filtered, concentrated under reduced pressure, and the crude product was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to give a white solid product 2-b (1.50 g, yield 31.8%). MS m / z (ESI): 333.3 [M+H] + .

[0426] Step 2: 6-Bromo-4-chloro-7-fluoro-N-methyl-1H-indole-2-carboxamide 2-c

[0427] Compound 1-l (300 mg, 0.977 mmol) was dissolved in methanol (2 mL), and methylamine methanol solution (5 mL, 30%) was added. The reaction mixture was stirred overnight at 100 °C. After the reaction was complete, the mixture was concentrated under reduced pressure, and the crude product was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 2 / 1) to give compound 2-c (240 mg, white solid, yield 80.2%). MS m / z (ESI): 302.8.1 [MH] - .

[0428] Step 3: 7-Bromo-9-chloro-6-fluoro-2-methyl-3,4-dihydropyrazino[1,2-a]indol-1(2H)-one 2-d

[0429] Compound 2-c (240 mg, 0.784 mmol) was dissolved in dichloromethane (3 mL). Under nitrogen protection at 0 °C, potassium hydroxide (110 mg, 1.96 mmol) was added. Maintaining the temperature, after 10 minutes, a dichloromethane (1.0 mL) solution of diphenyl(vinyl)sulfonium trifluoromethanesulfonate (341 mg, 0.941 mmol) was added dropwise to the above system, and the reaction was allowed to proceed at room temperature for 1 hour. After the reaction was complete, the solution was concentrated under reduced pressure, and the crude product was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 1) to give a white solid product 2-d (180 mg, yield 69.2%). MS m / z (ESI): 333.0 [M+H+2] + .

[0430] Step 4: 7-(1-(3-(1H-1,2,3-triazol-1-yl)propionyl)-1,2,5,6-tetrahydropyridin-3-yl)-9-chloro-6-fluoro-2-methyl-3,4-dihydropyrazino[1,2-a]indol-1(2H)-one 2-e

[0431] Potassium carbonate (124 mg, 0.90 mmol) and 1,1'-bis(diphenylphosphino)ferrocene palladium chloride (22.0 mg, 0.030 mmol) were added to a mixture of 2-d (100 mg, 0.30 mmol) and 2-b (100 mg, 0.30 mmol) in dioxane (8 mL) and water (2 mL). The mixture was stirred at 60 °C for 2 hours under nitrogen protection. After the reaction was complete, the reaction solution was diluted with water (20 mL) and extracted with dichloromethane (50 mL x 3). The combined organic phases were washed with saturated sodium chloride aqueous solution (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was purified by silica gel column chromatography (dichloromethane / methanol = 100 / 1 to 20 / 1) to give a yellow solid product 2-e (120 mg, yield 87.7%). MS m / z (ESI): 457.2 [M+H] + .

[0432] Step 5: 7-(1-(3-(1H-1,2,3-triazol-1-yl)propionyl)-1,2,5,6-tetrahydropyridin-3-yl)-9-chloro-6-fluoro-2-methyl-3,4-dihydropyrazino[1,2-a]indol-1(2H)-one 2-e

[0433] Potassium phosphate (296 mg, 139 mmol), XPhos Pd G3 (44 mg, 0.052 mmol), and dioxane (6 mL) of 2-e (160 mg, 0.351 mmol), 1-f (235 mg, 0.700 mmol), and water (2 mL) were added to the mixture. The mixture was stirred at 65 °C for 2 hours under nitrogen protection. After the reaction was complete, the reaction solution was diluted with water (10 mL) and extracted with ethyl acetate (20 mL x 3). The combined organic phases were washed with saturated sodium chloride aqueous solution (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was purified by silica gel column chromatography (dichloromethane / methanol = 100 / 1 to 20 / 1) to give a yellow solid product 2-f (240 mg, yield 96.0%). MS m / z (ESI): 713.4 [M+H] + .

[0434] Step 6: 2 g of 7-(1-(3-(1H-1,2,3-triazol-1-yl)propionyl)-1,2,5,6-tetrahydropyridin-3-yl)-6-fluoro-9-(2-methoxy-4-(piperazin-1-yl)phenyl)-2-methyl-3,4-dihydropyrazino[1,2-a]indol-1(2H)-one

[0435] To a solution of 2-f (240 mg, 0.337 mmol) dichloromethane (3.0 mL), add 0.60 mL of trifluoroacetic acid. The resulting mixture is stirred at room temperature for 1 hour, then concentrated under reduced pressure to give 2 g (220 mg, 100% yield) of a yellow oily crude product, which is used directly. MS m / z (ESI): 613.3 [M+H] + .

[0436] Step 7: 3-(4-(4-(7-(3-(1H-1,2,3-triazol-1-yl)propionyl)-1,2,5,6-tetrahydropyridin-3-yl)-6-fluoro-2-methyl-1-oxo-1,2,3,4-tetrahydropyrazino[1,2-a]indol-9-yl)-3-methoxyphenyl)piperazin-1-yl)ethyl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione 2

[0437] At room temperature, acetic acid (80.4 mg, 1.34 mmol) and potassium acetate (79.0 mg, 0.806 mmol) were added to a solution of 2-g (206 mg, 0.336 mmol) and 1-c (111 mg, 0.369 mmol) in DMSO (1.0 mL) and THF (1.0 mL). The mixture was stirred at room temperature for 1 hour, cooled to 0°C, and then sodium borohydride acetate (213 mg, 1.01 mmol) was added in portions. The resulting mixture was stirred at room temperature for 18 hours, filtered, and analyzed by preparative HPLC (prep-HPLC (Waters 2767 / Qda, Column: Pursuit XRs 10C18, 250*21.2 mm, 10 μm; Mobile Phase A: 0.1% TFA / H2O, B: ACN; flow rate: 20 mL / min; gradient: 43%–48%; retention time: 8.3–11.2 min of The trifluoroacetate of compound 2 was isolated and purified by the 16 min method to obtain a white solid (25.0 mg, yield 8.4%).

[0438] MS m / z (ESI): 898.4 [M+H] +

[0439] 1H NMR (400MHz, DMSO-d6) δ11.10(s,1H),10.09(s,1H),7.74–7.68(m,1H),7.45–7.35(m,1H),7.19(d,J=8.4Hz,1H),7.11–7.01(m, 2H),7.00–6.92(m,1H),6.80(dd,J=21.6,6.0Hz,1H),6.78(s,1H),6.69(d,J=6.8Hz,1H),6.53(s,1H),6.22–6.15(m,1H),6.12–6 .02(m,1H),5.45–5.34(m,1H),4.47(t,J=6.0Hz,2H),4.40–4.29(m,3H),4.26(s,1H),4.05(d,J=12.8Hz,2H),3.82–3.57(m,11H) ,3.40–3.23(m,6H),3.18–3.06(m,2H),3.04(s,3H),3.01–2.81(m,3H),2.81–2.60(m,3H),2.36–2.16(m,2H),2.03–1.94(m,1H).

[0440] Example 3 3-(4-(4-(7-(3-(1H-1,2,3-triazol-1-yl)propionyl)-1,2,5,6-tetrahydropyridin-3-yl)-8-fluoro-2-methyl-1-oxo-2,3,4-9-tetrahydro-1H-pyrido[3,4-b]indol-5-yl)-3-methoxyphenyl)piperazin-1-yl)ethyl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidin-2,6-dione 3

[0441] Step 1: 3-Bromo-5-chloro-2-fluorobenzenediazotetrafluoroborate 3-b

[0442] Starting material 3-a (10.0 g, 44.6 mmol) was dissolved in a mixed solution of tetrafluoroboric acid (50 mL) and water (50 mL) until completely dissolved. Under nitrogen protection, an aqueous solution of sodium nitrite (1.32 g, 19.9 mmol) (20 mL) was slowly added dropwise to the reaction mixture at 0 °C, and the mixture was stirred for 1 hour while maintaining the temperature. After the reaction was complete, the mixture was filtered, washed three times with diethyl ether, and dried to obtain crude product 3-b (8.00 g, yield 55.5%). MS m / z (ESI): 235.1 [M+H] + .

[0443] Step 2: 3-(2-(3-bromo-5-chloro-2-fluorophenyl)hydrazone)piperidin-2-one 3-d

[0444] Under nitrogen protection, at 0°C, 3-b (4.00 g, 12.4 mmol) was dissolved in 40 mL of water, and acetic acid (1.14 g, 24.8 mmol) was added to adjust the pH to approximately 3. Then, a 5 mL solution of 3-c (1.77 g, 12.4 mmol) in water was added. The reaction mixture was stirred at 0°C for 2 hours. After filtration, the filter cake was washed with a small amount of water and dried at low temperature to obtain crude product 3-d (3.50 g, 58% purity). MS m / z (ESI): 336.0 [M+H+2] + .

[0445] Step 3: 7-Bromo-5-chloro-8-fluoro-2,3,4-9-tetrahydro-1H-pyrido[3,4-b]indol-1-one 3-e

[0446] 3-d (3.50 g, 10.5 mmol) was dissolved in formic acid (15 ml). Under nitrogen protection, the reaction mixture was stirred at 100 °C for 3 hours. After concentrating the reaction solution, the crude product was purified by column chromatography (silica gel, (petroleum ether / tetrahydrofuran / ethyl acetate = 2 / 1 / 1) to give 3-e (600 mg, yield: 18.6%). MS m / z (ESI): 318.9 [M+H+2] + .

[0447] Step 4: 7-Bromo-5-chloro-8-fluoro-9-(2-(trimethylsilyl)ethoxy)methyl)-2,3,4-9-tetrahydro-1H-pyrido[3,4-b]indol-1-one 3-f

[0448] 3-e (600 mg, 1.89 mmol) was dissolved in tetrahydrofuran (8 mL), and sodium hydride (151 mg, 3.78 mmol) was added in portions at 0 °C. The temperature was maintained at 0–5 °C, and after stirring the mixture for half an hour, a tetrahydrofuran solution of 2-(trimethylsilyl)ethoxymethyl chloride (378 mg, 2.27 mmol) (3 mL) was added. The system was slowly raised to room temperature and stirred for 2 hours. After the reaction was complete, the system was quenched dropwise with water, and extracted three times with ethyl acetate (10 mL × 3). The organic phases were combined and dried over anhydrous sodium sulfate. After concentrating the organic phase, the crude product was purified by column chromatography (petroleum ether / ethyl acetate, 7:3) to give 3-f (500 mg, yield 59.2%, brown oil). MS m / z (ESI): 471.1 [M + Na + 2). + .

[0449] Step 5: 3 g of 7-bromo-5-chloro-8-fluoro-2-methyl-9-(2-(trimethylsilyl)ethoxy)methyl)-2,3,4-9-tetrahydro-1H-pyrido[3,4-b]indol-1-one

[0450] 3-f (500 mg, 1.12 mmol) was dissolved in tetrahydrofuran (8 mL), and sodium hydride (89.6 mg, 2.24 mmol) was added in portions at 0 °C. While maintaining the temperature, the mixture was stirred for half an hour, and then a tetrahydrofuran solution of iodomethane (477 mg, 3.36 mmol) (2 mL) was added. The system was slowly raised to room temperature and stirred for 16 hours at room temperature. After the reaction was complete, the system was quenched with water, extracted multiple times with ethyl acetate (10 mL x 3), and the organic phases were combined, washed with saturated brine, and dried over anhydrous sodium sulfate. The organic phase was concentrated, and the crude product was purified by column chromatography (petroleum ether / ethyl acetate, 3:1) to give 3-g (400 mg, yield 77.4%). MS m / z (ESI): 463.1 [M+H+2] + .

[0451] Step 6: 7-(1-(3-(1H-1,2,3-triazol-1-yl)propionyl)-1,2,5,6-tetrahydropyridin-3-yl)-5-chloro-8-fluoro-2-methyl-9-(2-(trimethylsilyl)ethoxy)methyl)-2,3,4-9-tetrahydro-1H-pyrido[3,4-b]indol-1-one 3-h

[0452] To a mixture of 3-g (400 mg, 0.866 mmol), 2-b (575 mg, 1.73 mmol), dioxane (15 mL), and water (1.5 mL), potassium carbonate (358 mg, 2.60 mmol) and 1,1'-bis(diphenylphosphine)ferrocene palladium chloride (63.4 mg, 0.0866 mmol) were added. The mixture was stirred at 90 °C for 16 hours under nitrogen protection. After the reaction was complete, the mixture was concentrated under reduced pressure, and the crude product was purified by silica gel column chromatography (petroleum ether / ethyl acetate, 1:4) to give product 3-h (310 mg, yield 61.0%). MS m / z (ESI): 587.3 [M+H] + .

[0453] Step 7: 4-(4-(7-(1-(3-(1H-1,2,3-triazol-1-yl)propionyl)-1,2,5,6-tetrahydropyridin-3-yl)-8-fluoro-2-methyl-1-oxo-9-(2-(trimethylsilyl)ethoxy)methyl)-2,3,4-9-tetrahydro-1H-pyrido[3,4-b]indol-5-yl)-3-methoxyphenyl)piperazine-1-carboxylic acid tert-butyl ester 3-i

[0454] Potassium phosphate (448 mg, 2.11 mmol), X Phos Pd G3 (67.0 mg, 0.0792 mmol), and dioxane (15 mL) of 3-h (310 mg, 0.528 mmol), 1-f (444 mg, 1.32 mmol), and water (5 mL) were added. The mixture was stirred at 65 °C for 2 hours under nitrogen protection. After the reaction was complete, the reaction solution was diluted with water (10 mL) and extracted with dichloromethane (20 mL). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by silica gel column chromatography (ethyl acetate) to give product 3-i (385 mg, yield 86.5%). MS m / z (ESI): 867.3 [M+H+2] + .

[0455] Step 8: 7-(1-(3-(1H-1,2,3-triazol-1-yl)propionyl)-1,2,5,6-tetrahydropyridin-3-yl)-8-fluoro-5-(2-methoxy-4-(piperazin-1-yl)phenyl)-2-methyl-2,3,4-9-tetrahydro-1H-pyrido[3,4-b]indol-1-one 3-j

[0456] To a solution of 3-i (234 mg, 0.277 mmol) in dichloromethane (4.0 mL), 2.0 mL of trifluoroacetic acid was added. The resulting mixture was stirred at room temperature for 1 hour, then concentrated under reduced pressure to give 3-j (170 mg, crude product, yellow oil), which was used directly. MS m / z (ESI): 613.3 [M+H] + .

[0457] Step 9: 3-(4-(4-(7-(3-(1H-1,2,3-triazol-1-yl)propionyl)-1,2,5,6-tetrahydropyridin-3-yl)-8-fluoro-2-methyl-1-oxo-2,3,4-9-tetrahydro-1H-pyridino[3,4-b]indol-5-yl)-3-methoxyphenyl)piperazin-1-yl)ethyl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidin-2,6-dione 3

[0458] At room temperature, 3-j (170 mg, 0.277 mmol) and 1-c (125 mg, 0.416 mmol) were dissolved in dichloromethane (5.0 mL). The mixture was stirred at room temperature for 1 hour. Sodium triacetoxyborohydride (176 mg, 0.831 mmol) was added in portions. The resulting mixture was stirred at room temperature for 18 hours and concentrated to obtain a crude product. The crude product was purified by preparative HPLC (prep-HPLC (Waters 2767 / Qda, Column: Pursuit XRs 10C18, 250*21.2 mm, 10 μm; Mobile Phase A: 0.1% FA / H2O, B: ACN; flow rate: 20 mL / min; gradient: 21%–25%; Retention Time: 8.6–11 min of 16 min) to obtain trifluoroacetate of compound 3 (31.88 mg, yield 24.5%).

[0459] MS m / z (ESI): 898.2 [M+H] + .

[0460] 1 H NMR (400MHz, CD3OD) δ8.00(d,J=5.6Hz,1H),7.68(d,J=10.0Hz,1H),7.09(dt,J=14.8,8.4Hz,4H),6.72(d t,J=18.0,7.2Hz,3H),6.12(s,1H),5.35(dd,J=12.0,5.6Hz,1H),4.76(q,J=6.8Hz,2H),4.39(d,J=28.8Hz ,2H),3.74(s,3H),3.71(s,3H),3.65(d,J=6.0Hz,2H),3.61–3.47(m,6H),3.40–3.29(m,8H),3.15(dt,J= 5.2,4.0Hz,2H),3.06(s,3H),2.86–2.83(m,3H),2.59–2.52(m,1H),2.39–2.34(m,3H),2.23–2.09(m,1H).

[0461] Example 4 6-(1-(3-(1H-1,2,3-triazol-1-yl)propionyl)-1,2,5,6-tetrahydropyridin-3-yl)-4-(4-(2-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)ethyl)piperazin-1-yl)-2-methoxyphenyl)-N,N-dimethylbenzo[b]selenophene-2-carboxamide 4

[0462] Step 1: 4-Bromo-2-(Butylseleno)-6-chlorobenzaldehyde 4-b

[0463] In a dry three-necked flask, selenium powder (1.00 g, 12.7 mmol) and anhydrous tetrahydrofuran (20 mL) were added dropwise under an argon atmosphere, maintaining the temperature at 0 °C. The mixture was then stirred at room temperature for 30 minutes. 4-a (3.22 g, 12.7 mmol) was added, and the reaction mixture was refluxed for 4 hours. After the starting material had reacted completely, the system was cooled to 0 °C, and a saturated ammonium chloride solution (15 mL) was added. The mixture was then extracted with ethyl acetate (3 x 15 mL), the organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The product was purified by rapid column chromatography (hexane / ethyl acetate, 100:0) to give 4-b (2.50 g, 42% purity). 1 H NMR (400MHz, CDCl3) δ10.55(s,1H),7.47(s,1H),7.42(d,J=1.6Hz,1H),2.87(t,J= 7.5Hz,2H),1.78–1.71(m,2H),1.52(dd,J=14.9,7.4Hz,2H),0.98(t,J=7.3Hz,3H).

[0464] Step 2: ethyl 2-((5-bromo-3-chloro-2-formylphenyl)selenoethyl)4-c

[0465] A solution of 4-b (2.50 g, crude product) in ethyl bromoacetate (30 mL) was heated to 140 °C and stirred for 16 hours under an argon atmosphere. The solution was then concentrated under reduced pressure to obtain the crude product. The product was purified by rapid column chromatography (hexane / ethyl acetate, 100:6) to give 4-c (1.40 g, yield 43.0%). 1 H NMR (400MHz, CDCl3) δ10.56 (d, J = 0.7Hz, 1H), 7.85 (d, J = 0.9Hz, 1H), 7.48 (d, J = 1.6Hz, 1H), 4.20 (q, J = 7.1Hz, 2H), 3.56 (s, 2H), 1.29 (t, J = 7.1Hz, 3H).

[0466] Step 3: Ethyl 6-bromo-4-chlorobenzo[b]selenophen-2-carboxylic acid ester 4-d

[0467] Potassium carbonate (1.50 g, 10.9 mmol) was added to a solution of 4-c (1.40 g, 3.64 mmol) in acetonitrile (15 mL). The resulting mixture was refluxed and stirred for 2 hours under argon atmosphere, and then concentrated under reduced pressure to obtain the crude product. The product was purified by rapid column chromatography (hexane / ethyl acetate, 100:6) to give 4-d (500 mg, yield 37.5%). 1 H NMR (400MHz, CDCl3) δ8.41(t,J=1.7Hz,1H),8.07–7.83(m,1H),7.64–7.46(m,1H),4.40(q,J=7.1Hz,2H),1.41(t,J=7.1Hz,3H).

[0468] Step 4: 6-Bromo-4-chloro-N,N-dimethylbenzo[b]selenophen-2-carboxamide 4-e

[0469] In a sealed tube, a methanol solution (2 M, 30 mL) of dimethylamine (500 mg, 1.37 mmol) of 4-d was heated to 50 °C and stirred for 16 hours. The solution was then concentrated under reduced pressure to obtain the crude product. The product was purified by rapid column chromatography (hexane / ethyl acetate, 100:20) to give 4-e (450 mg, yield 90.0%). MS m / z (ESI): 366.3 [M+H] + .

[0470] Step 5: 6-(1-(3-(1H-1,2,3-triazol-1-yl)propionyl)-1,2,5,6-tetrahydropyridin-3-yl)-4-chloro-N,N-dimethylbenzo[b]selenophen-2-carboxamide 4-f

[0471] To a mixture of 10 mL of dioxane (10 mL) and water (1 mL) containing 4-e (150 mg, 0.410 mmol) and 2-b (163 mg, 0.492 mmol), potassium carbonate (170 mg, 1.23 mmol) and 1,1'-bis(diphenylphosphine)ferrocene palladium chloride (30.0 mg, 0.0410 mmol) were added. The mixture was stirred at 90 °C for 16 hours under nitrogen protection. After the reaction was complete, the mixture was concentrated under reduced pressure, and the crude product was purified by silica gel column chromatography (dichloromethane / methanol = 100 / 1 to 20 / 1) to give product 4-f (200 mg, yield 99.5%). MS m / z (ESI): 491.9 [M+H] + .

[0472] Step 6: 4-(4-(6-(1-(3-(1H-1,2,3-triazol-1-yl)propionyl)-1,2,5,6-tetrahydropyridin-3-yl)-2-(dimethylcarbamoyl)benzo[b]selenophenyl-4-yl)-3-methoxyphenyl)piperazine-1-carboxylic acid tert-butyl ester 4-h

[0473] Potassium phosphate (346 mg, 1.63 mmol), XPhos Pd G3 (34.4 mg, 0.0407 mmol), and dioxane (15 mL) of 4-f (200 mg, 0.407 mmol), 1-f (274 mg, 0.814 mmol), and water (5 mL) were added. The mixture was stirred at 65 °C for 2 hours under nitrogen protection. After the reaction was complete, the reaction solution was diluted with water (10 mL) and extracted with dichloromethane (10 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by silica gel column chromatography (dichloromethane / methanol = 100 / 1 to 20 / 1) to give product 4-h (200 mg, yield 65.8%, yellow solid). MS m / z (ESI): 748.3 [M+H] + .

[0474] Step 7: 6-(1-(3-(1H-1,2,3-triazol-1-yl)propionyl)-1,2,5,6-tetrahydropyridin-3-yl)-4-(2-methoxy-4-(piperazin-1-yl)phenyl)-N,N-dimethylbenzo[b]selenophen-2-carboxamide 4-i

[0475] To a solution of 4-h (100 mg, 0.134 mmol) in dichloromethane (2.0 mL), add 1.0 mL of trifluoroacetic acid. Stir the resulting mixture at room temperature for 1 hour, then concentrate under reduced pressure to obtain 4-I (90 mg, crude product), which can be used directly. MS m / z (ESI): 648.2 [M+H] + .

[0476] Step 8: 6-(1-(3-(1H-1,2,3-triazol-1-yl)propionyl)-1,2,5,6-tetrahydropyridin-3-yl)-4-(4-(2-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)ethyl)piperazin-1-yl)-2-methoxyphenyl)-N,N-dimethylbenzo[b]selenophene-2-carboxamide 4

[0477] At room temperature, 4-i (90.0 mg, 0.139 mmol) and 1-c (62.9 mg, 0.209 mmol) were dissolved in dichloromethane (4.0 mL). The mixture was stirred at room temperature for 1 hour. Sodium triacetoxyborohydride (88.4 mg, 0.417 mmol) was added in portions. The resulting mixture was stirred at room temperature for 18 hours, filtered, and purified by preparative HPLC (prep-HPLC (Waters 2767 / Qda, Column: Pursuit XRs 10C18, 250*21.2 mm, 10 μm; Mobile Phase A: 0.05% TFA / H2O, B: ACN; flow rate: 20 mL / min; gradient: 31%–36%; Retention Time: 7.3–9.8 min of 16 min) to obtain trifluoroacetate of compound 4 (white solid, 31.88 mg, yield 24.5%).

[0478] MS m / z (ESI): 933.4 [M+H] + .

[0479] 1 H NMR (400MHz, DMSO-d6) δ11.11(s,1H),9.89(s,1H),8.16–8.09(m,2H),7.69(d,J=3.9Hz,1H),7.36(s,1H),7.29(dd,J=27.9,1.5Hz,1H),7.2 0(d,J=8.3Hz,1H),7.07(q,J=7.5Hz,2H),6.98(dd,J=6.9,1.9Hz,1H),6.79(s,1H),6.72(d,J=8.5Hz,1H),6.44(d,J=17.5Hz,1H),5.41(dd,J =12.8,5.4Hz,1H),4.64(t,J=6.8Hz,2H),4.41(d,J=10.0Hz,2H),4.07(d,J=11.0Hz,2H),3.79(d,J=12.0Hz,2H),3.71(d,J=2.7Hz,3H),3.66 (s,6H),3.61(dd,J=6.2,2.0Hz,8H),3.58(s,3H),3.13(dd,J=11.4,7.0Hz,4H),2.75–2.60(m,3H),2.37–2.23(m,2H),2.01(d,J=5.6Hz,1H).

[0480] Example 5 6-(1-(3-(1H-1,2,3-triazol-1-yl)propionyl)-1,2,5,6-tetrahydropyridin-3-yl)-4-(3-(2-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)ethyl)-10-methoxy-1,2,3,4,4a,5-hexahydro-7H-benzo[e]pyrazino[2,1-c][1,4]oxazine -9-yl)-N,N-dimethylbenzo[b]selenophen-2-carboxamide 5

[0481] Step 1: 6-(1-(3-(1H-1,2,3-triazol-1-yl)propionyl)-1,2,5,6-tetrahydropyridin-3-yl)-4-chloro-N,N-dimethylbenzo[b]selenophen-2-carboxamide 5-b

[0482] 4-e (300 mg, 0.82 mmol) was dissolved in 1,4-dioxane (4 mL), and 2-b (545 mg, 1.64 mmol), [1,1'-bis(diphenylphosphine)ferrocene]palladium dichloride (60 mg, 0.08 mmol), potassium carbonate (340 mg, 2.46 mmol), and water (0.4 mL) were added. The reaction mixture was reacted overnight at 90°C under nitrogen protection. The reaction solution was diluted with water, extracted with dichloromethane (3 x 20 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The product was purified by rapid column chromatography (4% methanol / dichloromethane) to give 5-b (390 mg, yield 96.8%). MS m / z (ESI): 492.0 [M+H] + .

[0483] Step 2: 2-Fluoro-4-methoxy-5-nitrobenzaldehyde 5-d

[0484] At room temperature, 2-fluoro-4-methoxybenzaldehyde (10 g, 65 mmol) was dissolved in concentrated sulfuric acid (100 mL) in a 250 mL single-necked flask, followed by the dropwise addition of concentrated nitric acid (5.3 g, 84.5 mmol). After the addition was complete, the mixture was stirred for 1 hour. TLC (PE / EA = 5 / 1) showed that the starting material disappeared and a principal spot (Rf = 0.5) was formed. The reaction solution was added dropwise to ice water (500 mL), and a white solid precipitated out. The mixture was filtered, the filter cake was washed with water, and dried under vacuum to give compound 5-d (11.7 g, yield: 90%).

[0485] Step 3: 4-(2-formyl-5-methoxy-4-nitrophenyl)-3-(hydroxymethyl)piperazine-1-carboxylic acid tert-butyl ester 5-f

[0486] In a 100 mL single-necked flask, 2-fluoro-4-methoxy-5-nitrobenzaldehyde (7.2 g, 36 mmol) and potassium carbonate (9.9 g, 72 mmol) were mixed in acetonitrile (200 mL). The mixture was heated in an oil bath to 60 °C for 3 minutes. Then, tert-butyl 3-(hydroxymethyl)piperazine-1-carboxylate (7.8 g, 36 mmol) was added, and the mixture was stirred for another 3 hours. A sample was then sent for LC-MS analysis. LC-MS showed no starting material peak (note: the starting material did not exit the MS), but the target product peak was detected. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure. The concentrate was purified by silica gel column chromatography (0–30% ethyl acetate / petroleum ether) to give compound 5-f (3.75 g, yield: 26.4%). MS m / z (ESI): 396.2 [M+H] +

[0487] Step 4: 5 g of tert-butyl 3-hydroxymethyl-4-(2-hydroxymethyl-5-methoxy-4-nitrophenyl)piperazine-1-carboxylate

[0488] At room temperature, 5-f (3.75 g, 9.5 mmol) was dissolved in MeOH (40 mL), cooled to -15 °C with acetone / ice bath, and then sodium borohydride (1.08 g, 28.5 mmol) was added. The mixture was stirred at this temperature for 2 minutes. LC-MS showed that the starting material disappeared, and the main peak was the target product. The reaction mixture was purified by silica gel column chromatography (0–50% ethyl acetate / petroleum ether) to give 5-f (2.75 g, yield: 73%). MS m / z (ESI): 398.2 [M+H) +

[0489] Step 5: 10-Methoxy-9-nitro-1,2,3,4,4a,5-hexahydro-7H-benzo[e]pyrazino[2,1-c][1,4]oxazapine 5-h

[0490] At room temperature, 5-g (2.1g, 5.2mmol) was added to sulfuric acid (20%, 21mL). The reaction solution was stirred at 60°C for 2.5 hours. LC-MS showed that the starting material disappeared and the main peak was the target peak. The pH of the reaction solution was adjusted to 6-8 under ice bath conditions to obtain a 5-h aqueous solution, which was directly used in the next step. MS m / z (ESI): 280.1 [M+H] +

[0491] Step 6: 10-Methoxy-9-nitro-1,2,4-,5-tetrahydro-7H-benzo[e]pyrazino[2,1-c][1,4]oxazapine-3(4H)-carboxylic acid tert-butyl ester 5-i

[0492] At room temperature, 21 mL of the aqueous solution of 5-h (5.3 mmol) obtained in the previous step was placed in a 100 mL single-necked flask, and 10 mL of THF and 1.34 g (15.9 mmol) of sodium bicarbonate solid were added. The reaction solution was stirred at room temperature for 4 h. LC-MS showed that the starting material disappeared and the main peak was the target peak. The reaction solution was extracted with ethyl acetate (10 mL x 3), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and the residue was purified by silica gel column chromatography (0–50% ethyl acetate / petroleum ether) to give compound 5-i (1.46 g, yield: 73%). MS m / z (ESI): 380.1 [M+H] +

[0493] Step 7: 9-Amino-10-methoxy-1,2,4a,5-tetrahydro-7H-benzo[e]pyrazino[2,1-c][1,4]oxazono-3(4H)-carboxylic acid tert-butyl ester 5-j

[0494] 5-i (1.68 g, 4.43 mmol) was dissolved in dichloromethane (56 mL) and methanol (56 mL), and 10% palladium on carbon (0.34 g) was added. The reaction mixture was reacted at room temperature under hydrogen atmosphere for 2.5 hours. The reaction solution was filtered, and the filtrate was concentrated under reduced pressure. The product was purified by rapid column chromatography (35% ethyl acetate / petroleum ether) to give 5-j (1.50 g, yield 97.0%, yellow oily liquid). MS m / z (ESI): 350.2 [M+H] + ; 1 H NMR (400MHz, CDCl3) δ6.64(s,1H),6.49(s,1H),4.87(d,J=11.6Hz,1H),4.49(d,J=11.6Hz,1H),3.90–3.82(m,4 H),3.80–3.71(m,2H),3.64–3.56(m,1H),3.47–3.23(m,3H),3.14–3.05(m,1H),2.85–2.76(m,1H),1.48(s,9H).

[0495] Step 8: 9-Bromo-10-methoxy-1,2,4a,5-tetrahydro-7H-benzo[e]pyrazino[2,1-c][1,4]oxazapyro-3(4H)-carboxylic acid tert-butyl ester 5-k

[0496] 5-J (700 mg, 2.00 mmol) was dissolved in acetonitrile (14 mL), and p-toluenesulfonic acid (414 mg, 2.40 mmol), cuprous bromide (29 mg, 0.20 mmol), and tetrabutylammonium bromide (1.29 g, 4.00 mmol) were added dropwise. A solution of tert-butyl nitrite (248 mg, 2.40 mmol) in acetonitrile (5 mL) was added dropwise under ice bath. The reaction was carried out at 0°C under nitrogen protection for 30 minutes, at room temperature for 2 hours, and at 60°C overnight. The reaction solution was diluted with water, extracted with ethyl acetate (3 × 40 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The product was purified by rapid column chromatography (10% ethyl acetate / petroleum ether) to give 5-K (440 mg, yield 53.1%). MS m / z (ESI): 413.1 [M+H] + .

[0497] Step 9: 10-Methoxy-9-(4,4,5,5-Tetramethyl-1,3,2-dioxaborhecyclopentan-2-yl)-1,2,4a,5-tetrahydro-7H-benzo[e]pyrazino[2,1-c][1,4]oxazono-3(4H)-carboxylic acid tert-butyl ester 5-l

[0498] 5-K (440 mg, 1.06 mmol) was dissolved in 1,4-dioxane (9 mL), and pinacol diboronate (811 mg, 3.19 mmol), [1,1'-bis(diphenylphosphine)ferrocene]palladium dichloride (156 mg, 0.21 mmol), and potassium acetate (1.04 g, 10.60 mmol) were added. The reaction mixture was reacted overnight at 100°C under nitrogen protection. The reaction solution was diluted with water, extracted with ethyl acetate (3 x 30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The product was purified by rapid column chromatography (40% ethyl acetate / petroleum ether) to give 5-L (280 mg, yield 57.1%). MS m / z (ESI): 461.3 [M+H] + .

[0499] Step 10: 9-(6-(1-(3-(1H-1,2,3-triazol-1-yl)propionyl)-1,2,5,6-tetrahydropyridin-3-yl)-2-(dimethylcarbamoyl)benzo[b]selenophenol-4-yl)-10-methoxy-1,2,4a,5-tetrahydro-7H-benzo[e]pyrazino[2,1-c][1,4]oxazono-3(4H)-tert-butyl carboxylate 5-m

[0500] 5-l (80 mg, 0.16 mmol) was dissolved in 1,4-dioxane (2 mL), and 5-b (83 mg, 0.18 mmol), methanesulfonic acid (2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)(2'-amino-1,1'-biphenyl-2-yl)palladium(II) (14 mg, 0.02 mmol), potassium phosphate (104 mg, 0.49 mmol), and water (0.4 mL) were added. The reaction mixture was reacted at 65°C under nitrogen protection for 3 hours. The reaction solution was diluted with water, extracted with ethyl acetate (3 x 20 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The product was purified by rapid column chromatography (6% methanol / dichloromethane) to give 5-m (85 mg, yield 65.9%). MS m / z (ESI): 790.1 [M+H] + .

[0501] Step 11: 6-(1-(3-(1H-1,2,3-triazol-1-yl)propionyl)-1,2,5,6-tetrahydropyridin-3-yl)-4-(10-methoxy-1,2,3,4,4a,5-hexahydro-7H-benzo[e]pyrazino[2,1-c][1,4]oxazono-9-yl)-N,N-dimethylbenzo[b]selenophen-2-carboxamide 5-n

[0502] 5-m (85 mg, 0.11 mmol) was dissolved in dichloromethane (1 mL), and trifluoroacetic acid (1 mL) was added. The reaction mixture was reacted at room temperature for 1 hour. The reaction solution was concentrated under reduced pressure to give product 5-n (75 mg, crude product). MS m / z (ESI): 690.0 [M+H] + .

[0503] Step 12: 6-(1-(3-(1H-1,2,3-triazol-1-yl)propionyl)-1,2,5,6-tetrahydropyridin-3-yl)-4-(3-(2-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)ethyl)-10-methoxy-1,2,3,4,4a,5-hexahydro-7H-benzo[e]pyrazino[2,1-c][1,4]oxazono-9-yl)-N,N-dimethylbenzo[b]selenophen-2-carboxamide 5

[0504] 5-n (75 mg, 0.11 mmol) was dissolved in dichloromethane (3 mL), alkalized with N,N-diisopropylethylamine, and then 5-b (49 mg, 0.16 mmol) was added. The reaction was carried out at room temperature for 1 hour. Then, sodium triacetoxyborohydride (69 mg, 0.33 mmol) was added, and the reaction was carried out at room temperature overnight. The reaction solution was diluted with water, extracted with dichloromethane (3 × 30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The formate of compound 5 (30.57 mg, yield 28.8%) was isolated and purified by preparative HPLC (prep-HPLC (Waters 2767 / QDA, Column: Atlatis T3 Prep OBD, 19*250mm, 10µm; Mobile Phase A: 0.1% FA / H2O, B: ACN; flow rate: 20 ml / min; gradient: 27%-32%; retention time: 7.6-11.4 min of 16 min) method).

[0505] MS m / z (ESI): 975.1 [M+H] + .

[0506] 1 H NMR(400MHz,DMSO-d6)δ11.10(s,1H),8.14–8.08(m,2H),7.71–7.67(m,1H),7.40–7.27(m,2H),7.13–7.08 (m,1H),7.02–6.92(m,3H),6.71(s,1H),6.50–6.40(m,1H),5.38(dd,J=12.8,5.6Hz,1H),4.78–4.71(m,1H ),4.68–4.61(m,3H),4.48–4.35(m,2H),3.83–3.76(m,1H),3.73–3.66(m,4H),3.64–3.55(m,5H),3.46–3. 39(m,2H),3.19–2.83(m,15H),2.75–2.59(m,5H),2.46–2.41(m,2H),2.29–2.22(m,1H),2.04–1.97(m,1H).

[0507] Example 6 6-(1-(3-(1H-1,2,3-triazol-1-yl)propionyl)-1,2,5,6-tetrahydropyridin-3-yl)-4-(3-(2-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)ethyl)-10-methoxy-1,2,3,4,4a,5-hexahydro-7H-benzo[e]pyrazino[2,1-c][1,4]oxazine -9-yl)-7-fluoro-N,N-dimethyl-1H-indole-2-carboxamide 6

[0508] Step 1: 6-(1-(3-(1H-1,2,3-triazol-1-yl)propionyl)-1,2,5,6-tetrahydropyridin-3-yl)-4-chloro-7-fluoro-N,N-dimethyl-1H-indole-2-carboxamide 6-b

[0509] 6-a (500 mg, 1.56 mmol) was dissolved in 1,4-dioxane (8 mL), and 2-b (780 mg, 2.35 mmol), [1,1'-bis(diphenylphosphine)ferrocene]palladium dichloride (114 mg, 0.16 mmol), potassium carbonate (649 mg, 4.70 mmol), and water (0.8 mL) were added. The reaction mixture was stirred overnight at 90 °C under nitrogen protection. The reaction mixture was diluted with water, extracted with dichloromethane (3 x 30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The product was purified by rapid column chromatography (4% methanol / dichloromethane) to give 6-b (550 mg, yield 79.0%). MS m / z (ESI): 445.2 [M+H] + .

[0510] Step 2: 9-(6-(1-(3-(1H-1,2,3-triazol-1-yl)propionyl)-1,2,5,6-tetrahydropyridin-3-yl)-2-(dimethylcarbamoyl)-7-fluoro-1H-indol-4-yl)-10-methoxy-1,2,4a,5-tetrahydro-7H-benzo[e]pyrazino[2,1-c][1,4]oxazine -3(4H)-tert-butyl carboxylate 6-c

[0511] 6-b (75 mg, 0.17 mmol) was dissolved in 1,4-dioxane (2.2 mL), and 5-i (116 mg, 0.25 mmol), methanesulfonic acid (2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)(2'-amino-1,1'-biphenyl-2-yl)palladium(II) (14 mg, 0.02 mmol), potassium phosphate (107 mg, 0.51 mmol), and water (0.66 mL) were added. The reaction mixture was reacted at 80 °C under nitrogen protection for 2 hours. The reaction solution was diluted with water, extracted with ethyl acetate (3 x 20 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The product was purified by rapid column chromatography (6% methanol / dichloromethane) to give 6-c (100 mg, yield 80.0%). MS m / z (ESI): 743.3 [M+H] + .

[0512] Step 3: 6-(1-(3-(1H-1,2,3-triazol-1-yl)propionyl)-1,2,5,6-tetrahydropyridin-3-yl)-7-fluoro-4-(10-methoxy-1,2,3,4,4a,5-hexahydro-7H-benzo[e]pyrazino[2,1-c][1,4]oxazine -9-yl)-N,N-dimethyl-1H-indole-2-carboxamide 6-d

[0513] 6-c (100 mg, 0.13 mmol) was dissolved in dichloromethane (1 mL), and trifluoroacetic acid (1 mL) was added. The reaction mixture was reacted at room temperature for 1 hour. The reaction solution was concentrated under reduced pressure to give product 6-d (90 mg, crude product). MS m / z (ESI): 643.3 [M+H] + .

[0514] Step 4: 6-(1-(3-(1H-1,2,3-triazol-1-yl)propionyl)-1,2,5,6-tetrahydropyridin-3-yl)-4-(3-(2-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)ethyl)-10-methoxy-1,2,3,4,4a,5-hexahydro-7H-benzo[e]pyrazino[2,1-c][1,4]oxazine -9-yl)-7-fluoro-N,N-dimethyl-1H-indole-2-carboxamide 6

[0515] Dissolve 6-d (90 mg, 0.14 mmol) in dichloromethane (3 mL), basify with N,N-diisopropylethylamine, add 1-c (63 mg, 0.21 mmol), and react at room temperature for 1 hour. Then add sodium triacetoxyborohydride (89 mg, 0.42 mmol), and react overnight at room temperature. Dilute the reaction solution with water, extract with dichloromethane (3 × 30 mL), dry the organic phase with anhydrous sodium sulfate, filter, and concentrate the filtrate under reduced pressure. The trifluoroacetate of compound 6 (33.43 mg, yield 25.7%) was isolated and purified by preparative HPLC (prep-HPLC (Waters 2767 / QDA, Column: Atlatis T3 Prep OBD, 19*250mm, 10µm; Mobile Phase A: 0.1% FA / H2O, B: ACN; flow rate: 20 ml / min; gradient: 26%-31%; retention time: 6.4-8.6 min of 16 min) method).

[0516] MS m / z (ESI): 928.7 [M+H] + .

[0517] 1 H NMR (400MHz, DMSO-d6) δ12.02–11.93(m,1H),11.10(s,1H),8.13–8.09(m,1H),7.72–7.65(m,1H) ),7.14(s,1H),7.02–6.98(m,2H),6.91–6.82(m,1H),6.71(s,1H),6.49–6.45(m,1H),6.15–6.08 (m,1H),5.38(dd,J=12.4,5.2Hz,1H),4.68–4.58(m,3H),4.40–4.27(m,2H),3.83–3.71(m,4H), 3.68–3.54(m,8H),3.21–2.83(m,16H),2.79–2.59(m,5H),2.38–2.23(m,3H),2.05–1.96(m,1H).

[0518] Example 7 6-(1-(3-(1H-1,2,3-triazol-1-yl)propionyl)-1,2,5,6-tetrahydropyridin-3-yl)-4-(4-(2-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)ethyl)piperazin-1-yl)-2-methoxyphenyl)-7-fluoro-N,N-dimethylbenzo[b]selenophene-2-carboxamide 7

[0519] Step 1: 6-Bromo-4-chloro-2,3-difluorobenzaldehyde 7-b

[0520] Under argon protection and at -78°C, a solution of lithium diisopropylamino (2M, 40 mL, 79.7 mmol) was added dropwise to a tetrahydrofuran solution (150 mL) of 7-a (15.0 g, 66.4 mmol). After reacting at -78°C for 1 hour, N,N-dimethylformamide (15.0 mL, 199 mmol) was added dropwise. The reaction was continued at -78°C for 3 hours. After the starting material had reacted completely, a saturated ammonium chloride solution was slowly added dropwise at low temperature, and the mixture was extracted with ethyl acetate (3 × 100 mL). The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to dryness under reduced pressure. The crude product was purified by silica gel chromatography (petroleum ether) to give 7-b (6.60 g, yield 82.1%, yellow oil). 1 H NMR (400MHz, CDCl3) δ10.25 (s, 1H), 7.58 (dd, J = 5.6, 2.2Hz, 1H).

[0521] Step 2: 6-Bromo-2-(Butylselenoalkyl)-4-chloro-3-fluorobenzaldehyde 7-c

[0522] In a dry three-necked flask, selenium powder (544 mg, 6.89 mmol) and anhydrous tetrahydrofuran (8 mL) were added dropwise under an argon atmosphere, maintaining the temperature at 0 °C. The mixture was then stirred at room temperature for 30 minutes. A solution of 7-b (1.60 g, 6.27 mmol) in anhydrous tetrahydrofuran (5 mL) was added, and stirring continued at room temperature for 1 hour. After the starting material had reacted completely, the system was cooled to 0 °C, and a saturated ammonium chloride solution (15 mL) was added. The mixture was then extracted with ethyl acetate (3 x 10 mL), the organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The product was purified by rapid column chromatography (hexane / ethyl acetate, 100:0) to give 7-c (730 mg, purity 31.2%, yellow oil). 1 H NMR (400MHz, CDCl3) δ10.28(s,1H),7.64(d,J=6.4Hz,1H),3.10–3.01(m,2H),1.62(dd,J=14.8,7.2Hz,2H),1.41–1.38(m,2H),0.91(t,J=7.2Hz,3H).

[0523] Step 3: Ethyl 2-((3-bromo-5-chloro-6-fluoro-2-formylphenyl)selenoethyl) 7-d

[0524] A solution of 7-c (900 mg, crude) in ST-047-4 (15 mL) was heated to 140 °C and stirred for 16 hours under an argon atmosphere. The solution was then concentrated under reduced pressure to obtain the crude product. The product was purified by rapid column chromatography (hexane / ethyl acetate, 93:7) to give 7-d (400 mg, yield 41.2%, yellow solid). 1 H NMR (400MHz, CDCl3) δ10.29 (s, 1H), 7.66 (d, J = 6.4Hz, 1H), 4.11 (d, J = 7.2Hz, 2H), 3.72 (d, J = 2.0Hz, 2H), 1.19 (t, J = 7.2Hz, 3H).

[0525] Step 4: 4-Bromo-6-chloro-7-fluorobenzo[b]selenophen-2-carboxylic acid ethyl ester 7-e

[0526] Potassium carbonate (411 mg, 2.98 mmol) was added to a 10 mL solution of acetonitrile containing 400 mg (0.993 mmol). The resulting mixture was refluxed and stirred for 2 hours under argon atmosphere, and then concentrated under reduced pressure to obtain the crude product. The product 7-e (350 mg, 91.9% yield, white solid) was purified by rapid column chromatography (hexane / ethyl acetate, 91:9). 1 H NMR (400MHz, CDCl3) δ8.41(d,J=3.6Hz,1H),7.63(d,J=6.0Hz,1H),4.42(q,J=7.2Hz,2H),1.42(t,J=7.2Hz,3H).

[0527] Step 5: 4-Bromo-6-chloro-7-fluoro-N,N-dimethylbenzo[b]selenophen-2-carboxamide 7-f

[0528] In a sealed tube, a methanol solution (2M, 20 mL) of 7-e (350 mg, 0.911 mmol) of dimethylamine was heated to 50 °C and stirred for 16 hours. The solution was then concentrated under reduced pressure to obtain the crude product. The product was purified by rapid column chromatography (hexane / ethyl acetate, 80:20) to give 7-f (300 mg, yield 85.7%, white solid). MS m / z (ESI): 383.9 [M+H] + .

[0529] Step 6: 7-g of 4-(4-(6-chloro-2-(dimethylcarbamoyl)-7-fluorobenzo[b]selenophenyl-4-yl)-3-methoxyphenyl)piperazine-1-carboxylic acid tert-butyl ester

[0530] A mixture of 7-f (300 mg, 0.781 mmol), 1-f (524 mg, 1.56 mmol) of dioxane (15 mL) and water (1.5 mL) was added with potassium carbonate (323 mg, 2.34 mmol) and 1,1'-bis(diphenylphosphine)ferrocene palladium chloride (57.2 mg, 0.0781 mmol). The mixture was stirred at 90 °C for 3 hours under nitrogen protection. The product was concentrated under reduced pressure and purified by rapid column chromatography (hexane / ethyl acetate, 30:70) to give product 7-g (300 mg, yield 64.5%, yellow oil). MS m / z (ESI): 618.0 [M+Na] + .

[0531] Step 7: 4-(4-(6-(1-(3-(1H-1,2,3-triazol-1-yl)propionyl)-1,2,5,6-tetrahydropyridin-3-yl)-2-(dimethylcarbamoyl)-7-fluorobenzo[b]selenophenyl-4-yl)-3-methoxyphenyl)piperazine-1-carboxylic acid tert-butyl ester 7-h

[0532] Potassium phosphate (428 mg, 2.02 mmol), XPhos Pd G3 (64.0 mg, 0.0756 mmol), and 2-b (335 mg, 1.014 mmol) in 18 mL of dioxane and 6 mL of water were added. The mixture was stirred at 65 °C for 5 hours under nitrogen protection. The reaction solution was diluted with water (10 mL) and extracted with dichloromethane (10 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by silica gel column chromatography (dichloromethane / methanol = 95:5) to give product 7-h (150 mg, yield 38.9%, yellow oil). MS m / z (ESI): 766.1 [M+H] + .

[0533] Step 8: 6-(1-(3-(1H-1,2,3-triazol-1-yl)propionyl)-1,2,5,6-tetrahydropyridin-3-yl)-7-fluoro-4-(2-methoxy-4-(piperazin-1-yl)phenyl)-N,N-dimethylbenzo[b]selenophen-2-carboxamide 7-i

[0534] To a solution of 7-g (150 mg, 0.196 mmol) in dichloromethane (3.0 mL), add trifluoroacetic acid (1.0 mL). Stir the mixture at room temperature for 1 hour, then concentrate under reduced pressure to give 7-i (130 mg, crude, yellow oil), which can be used directly without purification. MS m / z (ESI): 666.1 [M+H] + .

[0535] Step 9: 6-(1-(3-(1H-1,2,3-triazol-1-yl)propionyl)-1,2,5,6-tetrahydropyridin-3-yl)-4-(4-(2-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)ethyl)piperazin-1-yl)-2-methoxyphenyl)-7-fluoro-N,N-dimethylbenzo[b]selenophene-2-carboxamide 7

[0536] At room temperature, 7-i (130 mg, 0.196 mmol) and 1-c (88.3 mg, 0.296 mmol) were dissolved in dichloromethane (6.0 mL). The mixture was stirred at room temperature for 1 hour. Sodium triacetoxyborohydride (124 mg, 0.585 mmol) was added in portions. The resulting mixture was stirred at room temperature for 18 hours and then evaporated to dryness to obtain the crude product. The crude product was purified by preparative HPLC (prep-HPLC (Waters 2767 / Qda, Column: Pursuit XRs10C18, 250*21.2 mm, 10 μm; Mobile Phase A: 0.05% TFA / H2O, B: ACN; flow rate: 20 mL / min; gradient: 32%–38%; Retention Time: 7.0–9.2 min of 16 min) to obtain the trifluoroacetate of compound 7 (white solid, 32.41 mg, yield 17.5%).

[0537] MS m / z (ESI): 951.3 [M+H] + .

[0538] 1 H NMR (400MHz, DMSO-d6) δ11.10(s,1H),8.20(s,1H),8.10(d,J=10.4Hz,1H),7.68(d,J=11.2Hz,1H),7.48–7 .42(m,1H),7.28–7.11(m,2H),7.02–6.92(m,3H),6.68(s,1H),6.62(d,J=8.4Hz,1H),6.23(s,1H),5.38(d d,J=12.4,5.6Hz,1H),4.62(dd,J=16.0,6.8Hz,2H),4.35(d,J=13.6Hz,2H),3.70(d,J=3.2Hz,3H),3.65–3 .58(m,5H),3.32(s,6H),3.11(dt,J=14.0,7.2Hz,8H),2.77–2.57(m,9H),2.37–2.26(m,2H),2.00(s,1H).

[0539] Example 8 3-(4-(2-(4-(4-(6-(1-(3-(1H-1,2,3-triazol-1-yl)propionyl)-1,2,5,6-tetrahydropyridin-3-yl)-5-fluoro-2-methyl-3-oxo-1,2,3,4-tetrahydropyrrolo[3,4-b]indol-8-yl)-3-methoxyphenyl)piperazin-1-yl)ethyl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione 8

[0540] Step 1: Methyl 6-bromo-4-chloro-7-fluoro-3-formyl-1H-indole-2-carboxylic acid ester 8-b

[0541] Under argon protection and at 0°C, POCl3 (7.45 mL, 80.0 mmol) was added dropwise to a tetrahydrofuran solution (150 mL) of N-methylbenzamide (15.0 g, 66.4 mmol). After reacting at 0°C for 30 minutes, a 1,2-dichloroethane solution (15.0 mL) of 8-a (1 g, 3.2 mmol) was added. The reaction was continued at 90°C for 12 hours. After the starting material had reacted completely, a saturated ammonium chloride solution was slowly added dropwise under ice bath conditions, and the mixture was extracted with ethyl acetate (3 × 100 mL). The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to dryness under reduced pressure. The crude product was subjected to rapid silica gel column chromatography (0-50% ethyl acetate / petroleum ether) to give 8-b (1 g, 90% yield, white solid). 1H NMR (400MHz, DMSO-d6) δ13.84 (s, 1H), 10.58 (s, 1H), 7.58 (d, J = 5.2Hz, 1H), 3.95 (s, 3H).

[0542] Step 2: 8-Chodomethyl 6-bromo-4-chloro-7-fluoro-3-((methylamino)methyl)-1H-indole-2-carboxylic acid ester

[0543] In a dry 100 mL single-necked flask, 8-b (1 g, 3.0 mmol) and MeOH (50 mL) were added. A 2 M methylaminetetrahydrofuran solution (1.5 mL, 3.0 mmol) was added at room temperature, and the mixture was stirred for 30 minutes at room temperature. Sodium cyanoborohydride (1.89 g, 9.0 mmol) was added, and stirring continued for 1 hour at room temperature. After the starting material had reacted completely, the mixture was extracted with ethyl acetate (3 x 50 mL), the organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. Purification was performed by rapid silica gel column chromatography (0–100% petroleum ether / ethyl acetate) to give 8-c (800 mg, yellow solid). MS m / z (ESI): 348.9 & 350.9 [M+H] +

[0544] Step 3: 6-Bromo-4-chloro-7-fluoro-3-((methylamino)methyl)-1H-indole-2-carboxylic acid 8-d

[0545] 8-c (800 mg, 2.29 mmol) was dissolved in (MeOH:THF:H2O = 4:4:1), and lithium hydroxide monohydrate (274 mg, 11.45 mmol) was added at room temperature. The mixture was heated to 60 °C and stirred for 16 hours. After concentration under reduced pressure, the pH was adjusted to acidic with dilute hydrochloric acid, and the solution was lyophilized. No further purification was required to obtain 8-d (400 mg, crude product, white solid). MS m / z (ESI): 334.9 [M+H] +

[0546] Step 4: 6-Bromo-8-chloro-5-fluoro-2-methyl-1,4-dihydropyrrole[3,4-b]indol-3(2H)-one 8-e

[0547] To a solution of 8-d (400 mg, 11.9 mmol) in acetonitrile (10 mL), TCFH (1.3 g, 47.9 mmol) and NMI (7.8 g, 95.2 mmol) were added, and the mixture was reacted at room temperature for 4 h. The mixture was extracted with ethyl acetate (3 × 50 mL), the organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The solution was purified by rapid silica gel column chromatography (100% ethyl acetate) to give 8-e (150 mg, two-step yield: 20.7%, yellow solid). 1 H NMR (400MHz, DMSO-d6) δ12.94 (s, 1H), 7.46 (d, J = 5.2Hz, 1H), 4.59 (s, 3H), 3.10 (s, 4H).

[0548] Step 5: 6-(1-(3-(1H-1,2,3-thiazolyl-1-yl)propionyl)-1,2,5,6-tetrahydropyridin-3-yl)-8-chloro-5-fluoro-2-methyl-1,4-dihydropyrrolol[3,4-b]indol-3(2H)-one 8-f

[0549] 8-e (150 mg, 0.47 mmol) was added to a 50 mL single-necked flask, dissolved in dioxane (5 mL) and H₂O (1 mL), followed by 2-b (235 mg, 0.75 mmol), Pd(dppf)Cl₂ (39.2 mg, 0.047 mmol), and potassium carbonate (194 mg, 1.47 mmol). The mixture was stirred at 90 °C for 16 hours. The mixture was extracted with ethyl acetate (3 × 10 mL), and the organic layer was dried over anhydrous sodium sulfate. The mixture was filtered and concentrated under reduced pressure. Purification was achieved by rapid silica gel column chromatography (0–10% methanol / dichloromethane) to give 8-f (70 mg, yield: 33.5%, yellow solid). MS m / z (ESI): 443.1 [M+H] +

[0550] Step 6: 8 g of tert-butyl 4-(4-(6-(1-(3-(1H-1,2,3-triazol-1-yl)propionyl)-1,2,5,6-tetrahydropyridin-3-yl)-5-fluoro-2-methyl-3-oxo-1,2,3,4-tetrahydropyrrole[3,4-b]indol-8-yl)-3-methoxyphenyl)piperazine-1-carboxylic acid ester

[0551] 8-f (70 mg, 0.16 mmol) was added to a 50 mL single-necked flask, dissolved in dioxane (5 mL) and H₂O (1 mL), followed by the addition of 1-f (100 mg, 0.24 mmol), Xphos Pd G3 (13.5 mg, 0.016 mmol), and potassium phosphate (101 mg, 0.48 mmol). The mixture was stirred at 90 °C for 16 hours. The mixture was extracted with ethyl acetate (3 × 10 mL), and the organic layer was dried over anhydrous sodium sulfate. The mixture was filtered and concentrated under reduced pressure. The solution was purified by rapid silica gel column chromatography (0–5% methanol / dichloromethane) to give 8-g (70 mg, yield: 63.4%, yellow solid). 1H NMR (400MHz, DMSO-d6) δ12.33(d,J=7.2Hz,1H),8.11(d,J=9.2Hz,1H),7.69(d,J=11.2Hz,1H),7.16(d ,J=8.4Hz,1H),6.90(dd,J=22.4,6.4Hz,1H),6.71–6.57(m,2H),6.14(d,J=11.6Hz,1H),4.63–4.59(m, 2H),4.50(s,1H),4.34(d,J=20.0Hz,2H),4.23(s,1H),4.02(s,2H),3.70(d,J=4.0Hz,3H),3.63–3.59 (m,3H),3.50(s,2H),3.22(s,3H),3.10(t,J=6.4Hz,2H),3.01(s,2H),2.34-2.27(m,2H),1.44(s,9H).

[0552] Step 7: 2,2,2-Trifluoroacetaldehyde compound and 6-(1-(3-(1H-1,2,3-trifluoroazol-1-yl)propionyl)-1,2,5,6-tetrahydropyridin-3-yl)-5-fluoro-8-(2-methoxy-4-(piperazin-1-yl)phenyl)-2-methyl-1,4-dihydropyrrolo[3,4-b]indol-3(2H)-one 8-h

[0553] Dissolve 8-g (70 mg, 0.1 mmol) in 5 mL of DCM, add 5 mL of TFA mixture, and stir at room temperature for 2 hours. After the reaction is complete, evaporate to dryness and use immediately; no further purification is required to give product 8-h (60 mg, yellow solid). MS m / z (ESI): 599.3 [M+H] + .

[0554] Step 8: 3-(4-(2-(4-(4-(6-(1-(3-(1H-1,2,3-triazol-1-yl)propionyl)-1,2,5,6-tetrahydropyridin-3-yl)-5-fluoro-2-methyl-3-oxo-1,2,3,4-tetrahydropyrrole[3,4-b]indol-8-yl)-3-methoxyphenyl)piperazin-1-yl)ethyl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione

[0555] At room temperature, 8-h (60 mg, 0.1 mmol) and 1-c (30.1 mg, 0.1 mmol) were dissolved in dichloromethane (3.0 mL). The mixture was stirred at room temperature for 1 hour. Sodium cyanoborohydride (18.9 mg, 0.3 mmol) was added in portions. The resulting mixture was stirred at room temperature for 18 hours and then evaporated to dryness to obtain the crude product. The crude product was purified by preparative HPLC (prep-HPLC (Waters 2767 / Qda, Column: Pursuit XRs 10C18, 250*21.2 mm, 10 μm; Mobile Phase A: 0.05% TFA / H2O, B: ACN; flow rate: 20 mL / min; gradient: 32%–38%; Retention Time: 7.0–9.2 min of 16 min) to obtain the trifluoroacetate of compound 8 (white solid, 3.12 mg, yield 3.5%).

[0556] MS m / z(ESI): 884.80 [M+H] +

[0557] 1 H NMR (400MHz, DMSO-d6) δ12.34(s,1H),11.11(s,1H),8.12(d,J=8.8Hz,1H),7.70(d,J=10.4Hz,1H),7.15(d, J=8.4Hz,1H),6.99(s,1H),6.93–6.89(m,2H),6.67(s,1H),6.60(d,J=9.2Hz,1H),6.13(d,J=11.8Hz,1H),5 .38(d,J=7.6Hz,1H),4.62(d,J=8.4Hz,2H),4.37–4.32(m,2H),4.04(s,2H),3.70(d,J=3.6Hz,3H),3.62(s, 3H),3.12–3.08(m,9H),3.01(s,3H),2.89–2.87(m,2H),2.67(s,7H),2.34(s,2H),2.27(s,1H),2.01(s,2H).

[0558] Example 9 6-(1-(3-(1H-1,2,3-triazol-1-yl)propionyl)-1,2,5,6-tetrahydropyridin-3-yl)-4-(2-(4-(2-(1-(2,6-dioxoperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)ethyl)piperazin-1-yl)benzo[d][1,3]selenozol-6-yl)-7-fluoro-N,N-dimethyl-1H-indole-2-carboxamide 9

[0559] Step 1: N-(2-bromo-4-chlorophenyl)formamide 9-b

[0560] Starting material 9-a (20.0 g, 96.9 mmol) was dissolved in formic acid (50 mL) until completely dissolved. Sodium methoxide (3.3 g, 61.1 mmol) was added to the reaction mixture at room temperature, and the mixture was stirred for 16 hours. After complete reaction, the mixture was concentrated, quenched with saturated sodium bicarbonate solution (100 mL), and extracted three times with ethyl acetate (50 mL × 3). The combined organic phases were dried over anhydrous sodium sulfate. The organic phase was concentrated and dried to give the crude product (15 g, 66.1% yield, purple solid). MS m / z (ESI): 277.0 [M+H] + .

[0561] Step 2: 2-Bromo-4-chloro-1-isocyanobenzene 9-c

[0562] Under nitrogen protection, at 0°C, starting material 9-b (3.0 g, 12.8 mmol) and triethylamine (7.8 g, 76.92 mmol) were dissolved in tetrahydrofuran (30 mL), and phosphorus oxychloride (3.9 g, 25.64 mmol) was added. The reaction mixture was stirred at 0°C for 1 hour, and the reaction solution was slowly poured into a saturated sodium bicarbonate solution (50 mL). The mixture was extracted three times with ethyl acetate (30 mL x 3), and the organic phases were combined and dried over anhydrous sodium sulfate. After concentrating the organic phase, the crude product was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 3 / 1) to give 9-c (1.80 g, yield: 65.2%, black solid).

[0563] 1 H NMR (400MHz, DMSO-d) 6, )δ8.06(d,J=2.0Hz,1H),7.80(d,J=8.4Hz,1H),7.63(dd,J=8.4,2.0Hz,1H).

[0564] Step 3: Tert-butyl-4-(6-chlorobenzo[D][1,3]seleno-2-yl)piperazine-1-carboxylate 9-d

[0565] 9-c (2.0 g, 9.3 mmol) was dissolved in tetrahydrofuran (20 mL), and then selenium (660 mg, 8.44 mmol), 1,8-diazobispyrocyclo[5.4.0]undec-7-ene (1.28 g, 8.44 mmol), 1-tert-butyloxycarbonylpiperazine (1.88 g, 10.14 mmol), and cuprous iodide (20 mg, 0.084 mmol) were added sequentially. The reaction mixture was stirred at room temperature for 12 hours under nitrogen protection. The reaction solution was slowly poured into a saturated sodium bicarbonate solution (30 mL), and extracted three times with ethyl acetate (10 mL x 3). The organic phases were combined and dried over anhydrous sodium sulfate. After concentrating the organic phase, the crude product was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 5 / 1) to give 9-d (1.40 g, yield: 37.8%, yellow solid). MS m / z (ESI): 402.0 [M+H] + .

[0566] Step 4: tert-butyl-4-(6-(4,4,5,5-tetramethyl-1,3,2-dioxoborane-2-yl)benzo[d][1,3]seleno-2-yl)piperazine-1-carboxylate 9-e

[0567] 9-d (1.20 g, 3.0 mmol) was dissolved in dioxane (10 mL), and tris(bis(benzylacetone)bispalladium) (36 mg, 0.04 mmol), 2-dicyclohexylphosphine-2',4',6'-triisopropylbiphenyl (60 mg, 0.13 mmol), pinacol diborate (900 mg, 3.56 mmol), and potassium acetate (876 mg, 8.94 mmol) were added sequentially. The reaction mixture was stirred at 110 °C for 12 hours under nitrogen protection. After concentration, the crude product was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 3 / 1) to give 9-e (730 mg, yield: 49.7%, yellow solid). MS m / z (ESI): 494.0 [M+H] + .

[0568] Step 5: tert-butyl 4-(6-(6-(1-(3-(1H-1,2,3-triazol-1-yl)propionyl)-1,2,5,6-tetrahydropyridin-3-yl)-2-(dimethylcarbamoyl)-7-fluoro-1H-indole-4-yl)benzo[d][1,3]selenozol-2-yl)piperazine-1-carboxylate 9-f

[0569] Sodium carbonate (215 mg, 2.03 mmol), X Phos Pd G3 (57 mg, 0.0675 mmol), and water (3 mL) were added to a mixture of 9-e (500 mg, 1.01 mmol), 6-b (300 mg, 0.675 mmol), and water. The mixture was stirred at 85 °C for 12 hours under nitrogen protection. After the reaction was complete, the reaction solution was diluted with water (10 mL) and extracted with dichloromethane (20 mL). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 1) to give product 9-f (300 mg, yield 57.4%, yellow solid). MS m / z (ESI): 776.3 [M+H+2] + .

[0570] Step 6: 9 g of tert-butyl 4-(6-(6-(1-(3-(1H-1,2,3-triazol-1-yl)propionyl)-1,2,5,6-tetrahydropyridin-3-yl)-2-(dimethylcarbamoyl)-7-fluoro-1H-indole-4-yl)benzo[d][1,3]selenozol-2-yl)piperazine-1-carboxylate

[0571] To a solution of 9-f (280 mg, 0.361 mmol) in dichloromethane (2.0 mL), trifluoroacetic acid (2.0 mL) was added. The resulting mixture was stirred at room temperature for 1 hour, then concentrated under reduced pressure to give 9-g (220 mg, crude product, yellow oil), which was used directly. MS m / z (ESI): 676.3 [M+H] + .

[0572] Step 7: 6-(1-(3-(1H-1,2,3-triazol-1-yl)propionyl)-1,2,5,6-tetrahydropyridin-3-yl)-4-(2-(4-(2-(1-(2,6-dioxoperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)ethyl)piperazin-1-yl)benzo[d][1,3]selenozol-6-yl)-7-fluoro-N,N-dimethyl-1H-indole-2-carboxamide 9-h

[0573] At room temperature, 9-h (100 mg, 0.129 mmol) and 1-c (68 mg, 0.222 mmol) were dissolved in dichloromethane (5.0 mL). The mixture was stirred at room temperature for 1 hour, and sodium triacetoxyborohydride (94 mg, 0.444 mmol) was added in portions. The resulting mixture was stirred at room temperature for 18 hours and concentrated to obtain a crude product. The crude product was purified by preparative HPLC (prep-HPLC (Waters 2767 / Qda, Column: Pursuit XRs 10C18, 250*21.2 mm, 10 μm; Mobile Phase A: 0.1% FA / H2O, B: ACN; flow rate: 20 mL / min; gradient: 21%–25%; Retention Time: 8.6–11 min of 16 min) to obtain the formate salt of compound 9 (pale yellow solid, 14.82 mg, yield 11.9%).

[0574] MS m / z (ESI): 961.1 [M+H] + ; 1 H NMR (400MHz, DMSO-d) 6, )δ12.19(s,1H),11.10(s,1H),8.43(s,1H),8.18–8.06(m,2H),7.69(d,J=12.0Hz,1H ),7.62–7.50(m,2H),7.05(m,1H),7.00–6.89(m,4H),6.22–6.10(m,1H),5.37(dd,J= 12.4,5.6Hz,1H),4.67–4.55(m,2H),4.37(d,J=20.0Hz,2H),3.59(m,9H),3.15–3.04 (m,8H),2.96–2.82(m,2H),2.73–2.59(m,9H),2.38–2.25(m,2H),2.03–1.97(m,1H).

[0575] Example 10 6-(6-(3-(1H-1,2,3-triazol-1-yl)propionyl)-6-azaspiro[3.5]non-8-en-8-yl)-4-(4-(4-(2-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)ethyl)piperazin-1-yl)-2-methoxyphenyl)-7-fluoro-N,N-dimethyl-1H-indole-2-carboxamide

[0576] Step 1: 1-Allylcyclobutane-1-acrylonitrile 10-b

[0577] The starting material 10-a (15.0 g, 185 mmol) was dissolved in tetrahydrofuran (300 mL) in an ultra-dry solvent until completely dissolved. Under nitrogen protection, LDA (2 mol / L, 111 mL, 222 mol) was slowly added dropwise to the reaction solution at -70 °C, and the reaction was stirred for 2 hours while maintaining the temperature. Then, 3-bromopropene (27 g, 222 mmol) was added dropwise, and the reaction was stirred for 0.5 hours while maintaining the temperature. After the starting material had reacted completely, the reaction solution was slowly poured into a saturated ammonium chloride aqueous solution (400 mL) under rapid stirring. The mixture was extracted three times with ethyl acetate (300 mL * 3), the organic phases were combined, concentrated to remove most of the solvent (water separation occurred), and then diluted with ethyl acetate to separate the organic phase. The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product (27 g, yield 123%, pale yellow liquid).

[0578] Step 2: (1-Allylcyclobutyl)methylamine 10-c

[0579] The crude raw material 10-b (27 g, 185 mmol) was dissolved in the ultra-dry solvent tetrahydrofuran (100 mL) for later use.

[0580] Under nitrogen protection, at 0°C, tetrahydrofuran (300 mL), an ultra-dry solvent, was slowly added to a 1 L three-necked flask containing 17.2 g (400 mmol) of lithium aluminum hydride while stirring. After the addition was complete, a prepared solution of 10-b was slowly added dropwise, and the reaction was maintained at the temperature with stirring for 2 hours. After the reaction was complete, water (~60 mL) was slowly added dropwise until no obvious bubbles were produced, followed by the slow addition of an equal volume of sodium hydroxide aqueous solution (15 wt%). After stirring for 3 minutes, an equal volume of water was added again. The mixture was filtered, the filter cake was washed with tetrahydrofuran, the filtrate was concentrated under reduced pressure, diluted with ethyl acetate (300 mL), the aqueous phase was separated, and the organic phase was dried over anhydrous sodium sulfate. The mixture was filtered again, and the filtrate was concentrated under reduced pressure to obtain crude product 10-c (22 g, pale yellow liquid). MS m / z (ESI): 126.3 [M+H] + .

[0581] Step 3: N-((1-allylcyclobutyl)methyl)-4-methylbenzenesulfonamide 10-d

[0582] The crude 10-c starting material (22 g, 179 mmol) was dissolved in ultradry solvent dichloromethane (300 mL), and triethylamine (50 mL, 359 mmol) was added. Under nitrogen protection and stirring at 0 °C, p-toluenesulfonyl chloride (37.7 g, 197 mmol) was added in portions, and the reaction mixture was stirred at room temperature for 12 hours. After the reaction was complete, the reaction solution was diluted with dichloromethane (300 mL), washed once with water (300 mL), and the organic phase was dried over anhydrous sodium sulfate. The mixture was filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (ethyl acetate / petroleum ether = 0 / 1 to 1 / 9) to obtain 10-d (31 g, three-step yield: 60%, pale yellow liquid). MS m / z (ESI): 280.3 [M+H] + .

[0583] Step 4: 6-Toluenesulfonyl-6-azaspiro[3.5]non-8-ylacetate 10-e

[0584] 10-d (31 g, 111 mmol) was dissolved in hexafluoroisopropanol (500 mL) under nitrogen protection. At 0 °C, glacial acetic acid (12.7 mL, 222 mmol) was added, followed by fractional addition of diacetoxyiodobenzene (71.7 g, 222 mmol). The reaction mixture was stirred at room temperature for 12 hours. After the reaction was complete, the reaction mixture was concentrated under reduced pressure [the concentrate was diluted with a mixture of ethyl acetate / petroleum ether (1 / 9, 200 mL), allowed to stand until a large amount of white solid precipitated, filtered, and washed with the same mixture; the filtrate was then concentrated under reduced pressure]. The crude product was purified by column chromatography (ethyl acetate / petroleum ether, 2:8) to give 10-e (36 g, 97% yield, colorless liquid). MS m / z (ESI): 338.2 [M+H] + .

[0585] Step 5: 6-Toluenesulfonyl-6-azaspiro[3.5]nonane-8-ol 10-f

[0586] 10-e (36 g, 106 mmol) was dissolved in tetrahydrofuran (80 mL), followed by the addition of methanol (80 mL) and water (80 mL). Lithium hydroxide (26 g, 1.06 mol) was added in portions at 0 °C. The mixture was allowed to warm naturally to room temperature and stirred for 2 hours. After the reaction was complete, the mixture was extracted three times with dichloromethane (300 mL x 3). The combined organic phases were washed with saturated brine and dried over anhydrous sodium sulfate. The organic phase was concentrated to give 10-f (29 g, 92% yield, white solid). MS m / z (ESI): 296.2 [M+H] + .

[0587] Step 6: 10-g of 6-azaspiro[3.5]non-8-ol

[0588] Under nitrogen protection, sodium (8.7 g, 379 mmol) was shredded and added to an ultra-dry solvent, tetrahydrofuran (350 mL). Naphthalene (73 g, 569 mmol) was added in portions, and the mixture was stirred at room temperature for 3 hours. The temperature was then lowered to -70 °C, and a 10-f (14 g, 47.4 mmol) solution of tetrahydrofuran (50 mL) was slowly added dropwise, maintaining the temperature and stirring for 1 hour. After the reaction was complete, hydrochloric acid was added dropwise to quench the reaction and the pH of the reaction solution was adjusted to 6. The resulting solution was used directly for the next reaction without further treatment. MS m / z (ESI): 142.3 [M+H] + .

[0589] Step 7: 8-Hydroxy-6-azaspiro[3.5]nonane-6-carboxylic acid tert-butyl ester 10-h

[0590] Triethylamine (40 mL, pH ~9) and di-tert-butyl dicarbonate (21.8 mL, 94.8 mmol) were added to the previous step solution containing 10-g (47.4 mmol). The mixture was stirred at room temperature for 12 hours under nitrogen protection. After the reaction was complete, the organic phase was separated, and the aqueous phase was extracted twice with ethyl acetate (100 mL × 2). All organic phases were combined and concentrated under reduced pressure. The crude product was dissolved in dichloromethane (300 mL), and the aqueous phase (water dissolved in THF) was separated. The organic phase was dried over anhydrous sodium sulfate. The organic phase was concentrated, and the crude product was purified by column chromatography (ethyl acetate / petroleum ether, 7:13) to give 10-h (5.8 g, yield 50.8%, colorless liquid). MS m / z (ESI): 186.2 [Mt-Bu] + .

[0591] Step 8: 8-oxo-6-azaspiro[3.5]nonane-6-carboxylic acid tert-butyl ester 10-i

[0592] DMP (20.4 g, 48 mmol) was added in portions to a 10-h (5.8 g, 24 mmol) solution of dichloromethane (116 mL), and the mixture was stirred at room temperature for 2 hours. The mixture was concentrated under reduced pressure at low temperature, and an ethyl acetate / petroleum ether mixture (1:3, 60 mL) was added. The mixture was then sonicated and filtered. The filtrate was concentrated under reduced pressure, and the crude product was purified by column chromatography (ethyl acetate / petroleum ether, 3:7) to give 10-i (5.0 g, 87% yield, colorless oil). MS m / z (ESI): 184.2 [Mt-Bu] + .

[0593] Step 9: 8-(((trifluoromethyl)sulfonyl)oxy)-6-azaspiro[3.5]non-8-ene-6-carboxylic acid tert-butyl ester 10-j

[0594] To a solution of 10-i (2 g, 8.36 mmol) in dichloromethane (20 mL), triethylamine (7 mL, 50.14 mmol), DMAP (102 mg, 0.84 mmol), and PhNTf2 (5.97 g, 16.71 mmol) were added sequentially under nitrogen protection. The resulting mixture was stirred at room temperature for 16 hours. After the reaction was complete, the mixture was diluted with dichloromethane (30 mL) and washed sequentially with saturated sodium bicarbonate aqueous solution (30 mL), water (30 mL), and saturated brine (30 mL). The organic phase was then dried over an appropriate amount of anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by column chromatography (ethyl acetate / petroleum ether, 3:17) to give 10-j (1.26 g, 39% yield, colorless oil). MS m / z (ESI): 357.1 [Mt-Bu+ACN] + .

[0595] Step 10: 8-(4,4,5,5-tetramethyl-1,3,2-dioxaborphane-2-yl)-6-azaspiro[3.5]non-8-ene-6-carboxylic acid tert-butyl ester 10-k

[0596] To a solution of 10-J (1.26 g, 3.39 mmol) in 25 mL of dioxane, B2pin2 (1.46 g, 5.77 mmol), Pd(dppf)Cl2 (248 mg, 0.34 mmol), and potassium acetate (700 mg, 7.12 mmol) were added sequentially under nitrogen protection. The resulting mixture was stirred at 80 °C for 16 hours. After the reaction was complete, the reaction solution was concentrated under reduced pressure. The crude product was purified by column chromatography (ethyl acetate / petroleum ether, 1:9) to give 10-K (600 mg, yield 50.6%, colorless oil). MS m / z (ESI): 294.3 [Mt-Bu] + .

[0597] Step 11: 8-(4-chloro-2-(dimethylcarbamoyl)-7-fluoro-1H-indol-6-yl)-6-azaspiro[3.5]non-8-ene-6-carboxylic acid tert-butyl ester 10-l

[0598] To a 10-K (600 mg, 1.72 mmol) solution of dioxane (9 mL), under nitrogen protection, 10-M (458 mg, 1.43 mmol), Pd(dppf)Cl2 (105 mg, 0.14 mmol), potassium carbonate (594 mg, 4.29 mmol), and water (1.8 mL) were added sequentially. The resulting mixture was stirred at 100 °C for 16 hours. After the reaction was complete, the mixture was diluted with dichloromethane (30 mL), the aqueous phase was separated, and the organic phase was dried over anhydrous sodium sulfate. The mixture was filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by column chromatography (ethyl acetate / petroleum ether, 2:8) to give 10-L (450 mg, 68% yield, pale yellow solid). MS m / z (ESI): 462.2 [M+H] + .

[0599] Step 12: 4-Chloro-7-fluoro-N,N-dimethyl-6-(6-azaspiro[3.5]non-8-en-8-yl)-1H-indole-2-carboxamide 10-m

[0600] To a solution of 10⁻¹ (40 mg, 0.0866 mmol) in 2.0 mL of dichloromethane, 0.5 mL of trifluoroacetic acid was added. The resulting mixture was stirred at room temperature for 1 hour, then concentrated under reduced pressure to give 10⁻¹ (31 mg, crude product, yellow oil), which was used directly. MS m / z (ESI): 361.9 [M+H⁺] + .

[0601] Step 13: 6-(6-(3-(1H-1,2,3-triazol-1-yl)propionyl)-6-azaspiro[3.5]non-8-en-8-yl)-4-chloro-7-fluoro-N,N-dimethyl-1H-indole-2-carboxamide 10-n

[0602] 10-m (31 mg, crude) was dissolved in N,N-dimethylformamide (2 mL), and 2-a (15 mg, 0.104 mmol), HATU (39 mg, 0.104 mmol), and N,N-diisopropylethylamine (34 mg, 0.260 mmol) were added sequentially. The reaction mixture was stirred at room temperature for 2 hours under nitrogen protection. The reaction solution was slowly extracted three times with ethyl acetate (5 mL x 3) in water (5 mL). The combined organic phases were dried over anhydrous sodium sulfate. After concentrating the organic phase, the crude product was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 5 / 1) to give 10-n (26 mg, two-step yield: 61.90%, yellow solid). MS m / z (ESI): 485.1 [M+H] + .

[0603] Step 14: 4-(4-(6-(6-(3-(1H-1,2,3-triazol-1-yl)propionyl)-6-azaspiro[3.5]non-8-en-8-yl)-2-(dimethylcarbamoyl)-7-fluoro-1H-indole-4-yl)-3-methoxyphenyl)piperazine-1-carboxylic acid tert-butyl ester 10-o

[0604] Sodium carbonate (20 mg, 0.186 mmol), X Phos Pd G3 (6 mg, 0.00619 mmol), and dioxane (2 mL) of 10-n (30 mg, 0.0619 mmol), 1-f (52 mg, 0.124 mmol), and water (0.2 mL) were added to the mixture. The mixture was stirred at 90 °C for 12 hours under nitrogen protection. After the reaction was complete, the reaction solution was diluted with water (5 mL) and extracted with dichloromethane (5 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 2) to give product 10-o (20 mg, yield 43.48%, yellow solid). MS m / z (ESI): 741.5 [M+H] + .

[0605] Step 15: 6-(6-(3-(1H-1,2,3-triazol-1-yl)propionyl)-6-azaspiro[3.5]non-8-en-8-yl)-7-fluoro-4-(2-methoxy-4-(piperazin-1-yl)phenyl)-N,N-dimethyl-1H-indole-2-carboxamide 10-p

[0606] To a solution of 10-a (20 mg, 0.0270 mmol) in dichloromethane (2.0 mL), trifluoroacetic acid (2.0 mL) was added. The resulting mixture was stirred at room temperature for 1 hour, then concentrated under reduced pressure to give 10-p (20 mg, crude product, yellow oil), which was used directly. MS m / z (ESI): 641.1 [M+H] +

[0607] Step 16: 6-(6-(3-(1H-1,2,3-triazol-1-yl)propionyl)-6-azaspiro[3.5]non-8-en-8-yl)-4-(4-(4-(2-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)ethyl)piperazin-1-yl)-2-methoxyphenyl)-7-fluoro-N,N-dimethyl-1H-indole-2-carboxamide 10

[0608] At room temperature, 10-p (20 mg, 0.0312 mmol) and 1-c (28 mg, 0.0936 mmol) were dissolved in dichloromethane (2.0 mL). The mixture was stirred at room temperature for 1 hour, and sodium triacetoxyborohydride (13 mg, 0.0624 mmol) was added in portions. The resulting mixture was stirred at room temperature for 18 hours and concentrated to obtain a crude product. The crude product was purified by preparative HPLC (prep-HPLC (Waters 2767 / Qda, Column: Pursuit XRs10C18, 250*21.2 mm, 10 μm; Mobile Phase A: 0.1% FA / H2O, B: ACN; flow rate: 20 mL / min; gradient: 30%–35%; Retention Time: 8.6–11 min of 16 min) to obtain the formate of compound 10 (white solid, 2.22 mg, two-step yield 8.88%).

[0609] MS m / z(ESI): 927.0 [M+H] + .

[0610] 1 H NMR (400MHz, CD3OD) δ8.02(d,J=8.3Hz,1H),7.69(d,J=12.0Hz,1H),7.23(dd,J=8.4,4.8H z,1H),7.08–6.88(m,5H),6.72–6.60(m,3H),5.35–5.32(m,1H),4.79(dd,J=12.8,6.4Hz, 4H),3.73(d,J=6.4Hz,6H),3.27–3.24(m,3H),2.79(s,5H),2.62(s,2H),2.48(t,J=7.2Hz ,1H),2.31(s,1H),2.21–2.12(m,4H),2.06–1.98(m,4H),1.94–1.80(m,6H),1.59(s,6H).

[0611] Example 11 63-(4-(4-(7-(3-(1H-1,2,3-triazol-1-yl)propionyl)-1,2,5,6-tetrahydropyridin-3-yl)-8-fluoro-2-methyl-1-oxo-2,3,4-9-tetrahydro-1H-pyridino[3,4-b]indol-5-yl)-3-methoxyphenyl)piperazin-1-yl)ethyl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione 11

[0612] Step 1: tert-butyl(4-bromobutyl)(methyl)carbamate 11-b

[0613] The starting material, tert-butyl(4-hydroxybutyl)(methyl)carbamate 11-a (4.0 g, 19.68 mmol), was dissolved in tetrahydrofuran (120 mL) to ensure complete dissolution. Under nitrogen protection, triphenylphosphine (9.8 g, 37.39 mmol) and carbon tetrabromide (12.4 g, 37.39 mmol) were added sequentially to the reaction solution, and the mixture was stirred at room temperature for 1 hour. After the reaction was complete, the mixture was filtered and washed three times with tetrahydrofuran. The filtrate was concentrated under reduced pressure, and the crude product was purified by column chromatography (petroleum ether / ethyl acetate, 9:1) to give 11-b (4.74 g, 90% yield, colorless oil).

[0614] MS m / z(ESI): 251.1 [M-Bu+ACN] + ;

[0615] 1 H NMR (400MHz, CDCl3) δ3.44(t,J=6.8Hz,2H),3.25(t,J=6.0Hz,2H),2.84(s,3H),1.89–1.81(m,2H),1.67(t,J=7.2Hz,2H),1.46(s,9H).

[0616] Step 2: Tert-butyl(4-(2-bromo-5-iodophenoxy)butyl)(methyl)carbamate 11-f

[0617] Under nitrogen protection, 2-bromo-5-iodophenol 11-e (3.1 g, 10.35 mmol) was dissolved in N,N-dimethylformamide (50 mL), and tert-butyl(4-bromobutyl)(methyl)carbamate 11-b (3.58 g, 13.45 mmol) and cesium carbonate (5.06 g, 15.52 mmol) were added. The reaction mixture was stirred at 60 °C for 2 hours. After the reaction was complete, the reaction solution was diluted with water (150 mL) and extracted three times with ethyl acetate (75 mL × 3). The organic phases were combined and washed twice with water (75 mL × 2) and twice with saturated brine (50 mL × 2). The organic phase was dried over an appropriate amount of anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by column chromatography (petroleum ether / ethyl acetate, 9:1) to give crude product ST-033-2 (6.76 g, crude product, yellow oil). MS m / z(ESI): 427.9 [M-Bu] + .

[0618] Step 3: 11-g of benzyl 4-(4-bromo-3-(4-((tert-butoxycarbonyl)(methyl)amino)butoxy)phenyl)piperazine-1-carboxylic acid ester

[0619] tert-butyl(4-(2-bromo-5-iodophenoxy)butyl)(methyl)carbamate 11-f (6.76 g, 13.96 mmol) was dissolved in ultradry solvent dimethyl sulfoxide (68 mL), followed by the addition of benzylpiperazine-1-carboxylic acid ester (6.15 g, 27.92 mmol), cuprous iodide (532 mg, 2.79 mmol), L-proline (321 mg, 2.79 mmol), and potassium carbonate (5.79 g, 41.89 mmol). Under nitrogen protection, the reaction mixture was stirred at 80 °C for 16 hours. The reaction solution was concentrated and poured into water (200 mL), then extracted three times with ethyl acetate (100 mL × 3). The combined organic phases were washed twice with water (100 mL × 2), and then twice with saturated brine (100 mL × 2). The organic phase was then dried with an appropriate amount of anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 4 / 1) to obtain 11 g (3.82 g, two-step yield: 59%, colorless oil). MS m / z (ESI): 576.2 [M+H+] + .

[0620] 1 H NMR (400MHz, CDCl3) δ7.38–7.32(m,6H),6.45(s,1H),6.39(dd,J=8.8,2.4Hz,1H),5.16(s,2H),4.01(t, J=5.6Hz,2H),3.68–3.63(m,4H),3.30(s,2H),3.12(s,4H),2.86(s,3H),1.83–1.73(m,4H),1.45(s,9H).

[0621] Step 4: Benzyl 4-(3-(4-((tert-butoxycarbonyl)(methyl)amino)butoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborane-2-yl)phenyl)piperazine-1-carboxylic acid ester 11-h

[0622] 11 g (1.73 mmol) of benzyl 4-(4-bromo-3-(4-((tert-butoxycarbonyl)(methyl)amino)butoxy)phenyl)piperazine-1-carboxylic acid ester was dissolved in dioxane (10 mL), followed by the addition of 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bis(1,3,2-dioxoborane) (881 mg, 3.47 mmol), X-Phos-Pd-G3 (147 mg, 0.17 mmol), and potassium acetate (511 mg, 5.20 mmol). The mixture was stirred in an oil bath at 60 °C for 16 hours under nitrogen protection. After the reaction was complete, the mixture was diluted with water (20 mL), extracted three times with ethyl acetate (10 mL × 3), and all organic phases were combined and washed once with saturated brine (10 mL). The organic phase was then dried with an appropriate amount of anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by column chromatography (ethyl acetate / petroleum ether, 1:3) to give 11-h (700 mg, yield 64.7%, yellow solid). MS m / z (ESI): 624.4 [M+H+] + .

[0623] 1 H NMR (400MHz, CDCl3) δ7.51(d,J=8.2Hz,1H),7.31–7.24(m,5H),6.41(d,J=7.9Hz,1H),6.32(s,1H),5.09(s,2H),3.90( t,J=5.3Hz,2H),3.60(s,4H),3.23(s,2H),3.15(s,4H),2.78(s,3H),1.71(d,J=3.1Hz,4H),1.37(s,9H),1.24(s,12H).

[0624] Step 5: Methyl 6-(1-(3-(1H-1,2,3-triazol-1-yl)propionyl)-1,2,5,6-tetrahydropyridin-3-yl)-4-chloro-7-fluoro-1H-indole-2-carboxylic acid ester 11-c

[0625] Methyl 6-bromo-4-chloro-7-fluoro-1H-indole-2-carboxylic acid ester 11-c (500 mg, 1.63 mmol) was dissolved in dioxane (5 mL), and then 1-(5-(4,4,5,5-tetramethyl-1,3,2-dioxoborocyclo-2-yl)-3,6-dihydropyridin-1(2H)-yl)-3-(1H-1,2,3-triazol-1-yl)acetone 11-b (651 mg, 1.96 mmol), 1,1'-bis(diphenylphosphine)ferrocene palladium chloride (120 mg, 0.16 mmol), potassium carbonate (677 mg, 4.89 mmol), and water (0.5 mL) were added sequentially. Under nitrogen protection, the mixture was stirred in an oil bath at 90 °C for 16 hours. After the reaction was complete, the mixture was diluted with water (20 mL), extracted three times with ethyl acetate (10 mL * 3), and all organic phases were combined and washed once with saturated brine (10 mL). The organic phase was then dried over an appropriate amount of anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the crude product was purified by column chromatography (methanol / dichloromethane, 1:9) to give 11-d (288 mg, yield 40.9%, yellow solid). MS m / z (ESI): 432.2 [M + H +] + .

[0626] Step 6: 7-(1-(3-(1H-1,2,3-triazol-1-yl)propionyl)-1,2,5,6-tetrahydropyridin-3-yl)-5-chloro-8-fluoro-2-methyl-9-(2-(trimethylsilyl)ethoxy)methyl)-2,3,4-9-tetrahydro-1H-pyrido[3,4-b]indol-1-one 11-i

[0627] Sodium carbonate (158 mg, 1.494 mmol) and X-Phos-Pd-G3 (43 mg, 0.050 mmol) were added to a mixture of benzyl 4-(3-(4-((tert-butoxycarbonyl)(methyl)amino)butoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborin-2-yl)phenyl)piperazine-1-carboxylate 11-d (404 mg, 0.647 mmol), methyl 6-(1-(3-(1H-1,2,3-triazol-1-yl)propionyl)-1,2,5,6-tetrahydropyridin-3-yl)-4-chloro-7-fluoro-1H-indole-2-carboxylate 11-h (215 mg, 0.498 mmol) in dioxane (5 mL) and water (1 mL). The mixture was stirred at 65 °C for 16 hours under nitrogen protection. After the reaction was complete, the mixture was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (methanol / dichloromethane, 1:9) to give product 11-i (284 mg, yield 63.9%, a pale yellow oil). MS m / z (ESI): 893.2 [M+H] + .

[0628] Step 7: 6-(1-(3-(1H-1,2,3-triazol-1-yl)propionyl)-1,2,5,6-tetrahydropyridin-3-yl)-4-(4-(4-((benzyloxy)carbonyl)piperazin-1-yl)-2-(4-(methylamino)butoxy)phenyl)-7-fluoro-1H-indole-2-carboxylic acid methyl ester 11-j

[0629] 11-i (950 mg, 1.06 mmol) was dissolved in dichloromethane (10 mL), and trifluoroacetic acid (2 mL) was added. The mixture was stirred at room temperature for 2 hours. After the reaction was complete, the reaction solution was concentrated under reduced pressure to give 11-j (1.0 g, crude product, yellow oil). MS m / z (ESI): 793.3 [M+H) + .

[0630] Step 8: 6-(1-(3-(1H-1,2,3-triazol-1-yl)propionyl)-1,2,5,6-tetrahydropyridin-3-yl)-4-(4-(4-((benzyloxy)carbonyl)piperazin-1-yl)-2-(4-(methylamino)butoxy)phenyl)-7-fluoro-1H-indole-2-carboxylic acid 11-k

[0631] 11-j (1.0 g, 1.26 mmol) was dissolved in tetrahydrofuran (8 mL), methanol (4 mL), and water (2 mL), and then lithium hydroxide (121 mg, 5.05 mmol) was added. The reaction mixture was reacted at room temperature for 16 hours. After the reaction was complete, the reaction solution was concentrated under reduced pressure, and the residue was purified by reversed-phase column chromatography (0-100% acetonitrile / water, 0.1% HCl) to give 11-k (750 mg, two-step yield: 90.52%, white solid). MS m / z (ESI): 779.3 [M+H] + .

[0632] Step 9: (Z)-4-(16-(1-(3-(1H-1,2,3-triazol-1-yl)propionyl)-1,2,5,6-tetrahydropyridin-3-yl)-17-fluoro-8-methyl-9-oxo-11H-3-oxa-8-aza-1(4,2)-indole-2(1,2-phenylcyclononane-24-yl)piperazine-1-carboxylic acid benzyl ester 11-l

[0633] 11-k (700 mg, 0.899 mmol) was dissolved in anhydrous N,N-dimethylformamide (50 mL), and N,N,N′,N′-tetramethyl-O-(7-azabenzotriazol-1-yl)hexafluorophosphate urea (1.43 g, 3.779 mmol) and N,N-diisopropylethylamine (348 mg, 2.697 mmol) were added. The reaction mixture was reacted at room temperature for 2 hours. After the reaction was completed, the reaction solution was concentrated under reduced pressure and purified by reversed-phase column chromatography (0-100% acetonitrile / water, 0.1% FA) to give 11-l (170 mg, yield: 24.86%, white solid). MS m / z (ESI): 761.5 [M+H] + .

[0634] Step 10: (Z)-16-(1-(3-(1H-1,2,3-triazol-1-yl)propionyl)-1,2,5,6-tetrahydropyridin-3-yl)-17-fluoro-8-methyl-24-(piperazin-1-yl)-11H-3-oxa-8-aza-1(4,2)-indole-2(1,2)-phenylcyclononane-9-one 11-m

[0635] 11-l (60 mg, 0.079 mmol) was dissolved in anhydrous acetonitrile (2 mL), and then trimethyliodosilane (16 mg, 0.789 mmol) was slowly added dropwise to the reaction mixture. The reaction mixture was stirred at room temperature for 5 hours. After the reaction was completed, the reaction mixture was directly purified by reversed-phase column chromatography (0-100% acetonitrile / water, 0.1% FA) to give 11-m (20 mg, yield 40.47%, yellow solid). MS m / z (ESI): 627.2 [M+H] + .

[0636] Step 11: 3-(4-(2-(4-(16-(1-(3-(1H-1,2,3-triazol-1-yl)propionyl)-1,2,5,6-tetrahydropyridin-3-yl)-17-fluoro-8-methyl-9-oxo-11H-3-oxa-8-aza-1(4,2)-indole-2(1,2-benzocyclononane-24-yl)piperazin-1-yl)ethyl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione 11

[0637] 1-C (30 mg, 0.0479 mmol) was dissolved in dichloromethane (3 mL), and alkalized with N,N-diisopropylethylamine. 11-M (29 mg, 0.0958 mmol) was added, and the reaction was carried out at room temperature for 1 hour. Then, sodium triacetoxyborohydride (89 mg, 0.42 mmol) was added, and the reaction was carried out at room temperature overnight. The reaction solution was diluted with water, extracted with dichloromethane (3 × 5 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The trifluoroacetate of compound 11 (4.34 mg, yield 14.91%, white solid) was isolated and purified by preparative HPLC (prep-HPLC (Waters 2767 / QDA, Column: Boston C18 30×150mm×5um; Mobile Phase A: 0.05% TFA / H2O, B: ACN; Gradient: 31-34%; Retention Time: 8.9-10.0 min of 17 min) method.

[0638] MS m / z (ESI): 912.7 [M+H] + .

[0639] 1 H NMR (400MHz, DMSO-d6) δ11.83(d,J=12.4Hz,1H),11.11(s,1H),9.94(s,1H),8.12(d,J=7.2Hz,1H),7.70(d,J=11.2H z,1H),7.53(s,1H),7.41(dd,J=16.4,8.2Hz,1H),7.10–7.02(m,3H),7.01–6.95(m,1H),6.85(dd,J=25.6,6.4Hz,1H ),6.79–6.68(m,3H),5.49–5.33(m,1H),4.73–4.56(m,2H),4.11–3.68(m,6H),3.65(s,5H),3.47(s,3H),3.27–3.05 (m,9H),3.03(s,3H),2.97–2.84(m,2H),2.75–2.69(m,1H),2.66–2.59(m,1H),2.15–1.80(m,4H),1.71–1.48(m,4H).

[0640] Example 12 4-(4-(2-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)ethyl)piperazin-1-yl)-2-methoxyphenyl)-7-fluoro-N,N-dimethyl-6-(1-methyl-2-oxy-1,2-dihydropyridine-3-carboxamido)-1H-indole-2-carboxamide 12

[0641] Step 1: tert-butyl 6-bromo-4-chloro-2-(dimethylcarbamoyl)-7-fluoro-1H-indole-1-carboxylic acid 12-a

[0642] At room temperature, 6-a (1.00 g, 3.13 mmol) was dissolved in 10 mL of dichloromethane. Triethylamine (1.00 g, 3.13 mmol), 4-dimethylaminopyridine (1.00 g, 3.13 mmol), and finally di-tert-butyl dicarbonate (1.00 g, 3.13 mmol) were added dropwise. The reaction was allowed to proceed at room temperature for 3 hours. After the reaction was complete, the mixture was quenched with water, extracted with dichloromethane (3 × 10 mL), and the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to dryness under reduced pressure. The concentrate was purified by rapid silica gel column chromatography (0-20% ethyl acetate / petroleum ether) to give 12-a (800 mg, yield 60.8%, yellow oil). MS m / z (ESI): 364.9 [M+H-56] + .

[0643] Step 2: 4-Chloro-2-(dimethylcarbamoyl)-6-((diphenylmethylene)amino)-7-fluoro-1H-indole-1-carboxylic acid tert-butyl ester 12-b

[0644] At room temperature, 12-a (1.00 g, 2.38 mmol) was dissolved in dioxane solution (10 mL), followed by the addition of benzophenone imine (646 mg, 3.57 mmol), tris(dibenzylene-BASE-acetone)dipalladium (109 mg, 0.119 mmol), 4,5-bis(diphenylphosphine-9,9-dimethyloxanthracene) (138 mg, 0.238 mmol), and cesium carbonate (1.55 g, 4.76 mmol). The mixture was stirred at 100 °C for 16 hours under an argon atmosphere. After the starting materials had reacted completely, the system was cooled, and water (10 mL) was added. The mixture was then extracted with ethyl acetate (3 x 10 mL), the organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain crude 12-b (1.00 g, crude product, brown oil). MS m / z (ESI): 520.2 [M+H] + .

[0645] Step 3: 6-Amino-4-chloro-7-fluoro-N,N-dimethyl-1H-indole-2-carboxamide 12-c

[0646] At room temperature, 1.00 g of crude 12-b was dissolved in tetrahydrofuran solution (5 mL), and hydrochloric acid (6 M, 6 mL) was added. The mixture was stirred for 5 hours, and the pH was adjusted to 8 with saturated sodium carbonate aqueous solution. Ethyl acetate (3 x 10 mL) was then added to extract the mixture. The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified by rapid silica gel column chromatography (0-30% ethyl acetate / petroleum ether) to give 12-c (350 mg, yield 57.7%, yellow-brown solid). MS m / z (ESI): 256.1 [M+H] + .

[0647] Step 4: 4-Chloro-7-fluoro-N,N-dimethyl-6-(1-methyl-2-oxo-1,2-dihydropyridine-3-carboxamido)-1H-indole-2-carboxamide 12-d

[0648] At room temperature, 2-oxo-1-methyl-nicotinic acid (220 mg, 0.859 mmol) was added to a mixture of 12-c (131 mg, 0.859 mmol), N,N-diisopropylethylamine (554 mg, 4.30 mmol), and N,N,N′,N′-tetramethyl-O-(7-azabenzotriazol-1-yl)hexafluorophosphate urea (655 mg, 1.72 mmol) in N,N-dimethylformamide solution (5 mL). The mixture was stirred at room temperature for 2 hours. The reaction solution was poured into ice water, filtered to obtain a solid, and dried under reduced pressure to give 12-d (320 mg, 80% purity, pale yellow solid). MS m / z (ESI): 391.0 [M+H] + .

[0649] Step 5: 4-(4-(2-(dimethylcarbamoyl)-7-fluoro-6-(1-methyl-2-oxo-1,2-dihydropyridine-3-carbamate)-1H-indol-4-yl)-3-methoxyphenyl)piperazine-1-carboxylic acid tert-butyl ester 12-e

[0650] Potassium phosphate (477 mg, 2.25 mmol), methanesulfonic acid (2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)(2'-amino-1,1'-biphenyl-2-yl)palladium(II) (71.5 mg, 0.0845 mmol), were added to a mixture of 12-d (220 mg, 0.563 mmol), 1-f (353 mg, 0.845 mmol), dioxane (12 mL), and water (4 mL). The mixture was stirred at 65 °C for 2 hours under nitrogen protection. The reaction mixture was diluted with water (10 mL) and extracted with dichloromethane (10 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by silica gel column chromatography (dichloromethane / methanol, 9:1) to give product 12-e (230 mg, yield 63.2%, yellow oil). MS m / z (ESI): 647.3 [M+H] + .

[0651] Step 6: 7-Fluoro-4-(2-methoxy-4-(piperazin-1-yl)phenyl)-N,N-dimethyl-6-(1-methyl-2-oxo-1,2-dihydropyridine-3-carbamate)-1H-indole-2-carbamate 12-f

[0652] To a solution of 12-e (130 mg, 0.201 mmol) in dichloromethane (3.0 mL), 1.0 mL of trifluoroacetic acid was added. The resulting mixture was stirred at room temperature for 1 hour, then concentrated under reduced pressure to give 12-f (100 mg, crude product, yellow oil), which could be used directly without purification. MS m / z (ESI): 547.2 [M+H] + .

[0653] Step 7: 4-(4-(2-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)ethyl)piperazin-1-yl)-2-methoxyphenyl)-7-fluoro-N,N-dimethyl-6-(1-methyl-2-oxy-1,2-dihydropyridine-3-carboxamido)-1H-indole-2-carboxamide 12

[0654] At room temperature, 12-f (100 mg, 0.183 mmol) and 1-c (82.8 mg, 0.275 mmol) were dissolved in dichloromethane (6.0 mL). The mixture was stirred at room temperature for 1 hour. Sodium triacetoxyborohydride (116 mg, 0.549 mmol) was added in portions. The resulting mixture was stirred at room temperature for 18 hours. The reaction solution was concentrated under reduced pressure to obtain a crude product, which was then purified by high performance liquid chromatography (Gilson, Column: Sunfire C18, 19*250 mm, 10 μm; Mobile Phase A: 0.1% FA / H2O, B: ACN; flow rate: 20 mL / min; gradient: 20%–30%; retention time: 8.5–10.7 min of 18 min) to obtain the formate of compound 12 (white solid, 42.19 mg, yield 27.6%).

[0655] MS m / z (ESI): 832.8 [M+H] + .

[0656] 1 H NMR (400MHz, DMSO-d6) δ12.46(s,1H),12.00(s,1H),11.12(s,1H),9.88(s,1H),8.45(dd,J=7.2,2.0Hz,1H),8.18 (d,J=4.6Hz,1H),8.04(d,J=6.4Hz,1H),7.23(d,J=8.4Hz,1H),7.07(s,2H),6.98(d,J=6.0Hz,1H),6.79(s,1H),6. 70(s,1H),6.64–6.57(m,1H),6.48(s,1H),5.45–5.31(m,1H),4.30–3.75(m,4H),3.75(s,3H),3.66(s,6H),3.56–3 .37(m,4H),3.26(d,J=7.3Hz,2H),3.15(d,J=6.8Hz,6H),3.01–2.80(m,2H),2.79–2.62(m,3H),2.07–1.93(m,1H).

[0657] Example 13 6-(6-((1H-1,2,3-triazol-1-yl)methyl)pyridinamido)-4-(4-(1-(4-(2,6-dioxopiperidin-3-yl)-2-fluorophenyl)piperidin-4-yl)phenyl)-7-fluoro-N,N-dimethyl-1H-indole-2-carboxamide 13

[0658] Intermediate: 13-D Synthesis

[0659] Step 1: 13-g of 2,6-bis(benzyloxy)-3-(4-bromo-3-fluorophenyl)pyridine

[0660] The starting materials 1-bromo-2-fluoro-4-iodobenzene13-e (20 g, 66.5 mmol) and 2,6-bis(benzyloxy)-3-(4,4,5,5-tetramethyl-1,3,2-dioxoborocyclo-2-yl)pyridine13-f (26.6 g, 63.8 mmol) were dissolved in tetrahydrofuran (400 mL) under ultra-dry solvent until completely dissolved. Under nitrogen protection, 1,1'-bis(diphenylphosphine)ferrocene palladium chloride (4.7 g, 6.4 mmol), potassium carbonate (26.5 g, 191.4 mmol), and water (100 mL) were added. Under nitrogen protection, the mixture was stirred in an oil bath at 60 °C for 12 hours. After the reaction was complete, the mixture was diluted with water (200 mL), extracted three times with ethyl acetate (300 mL x 3), and all organic phases were combined and washed once with saturated brine (200 mL). The organic phase was then dried with an appropriate amount of anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the crude product was purified by column chromatography (ethyl acetate / petroleum ether, 1:19) to obtain 13-g (19g, yield 64%, pale yellow solid).

[0661] MS m / z(ESI): 466.2 [M+H+] + ; 1 H NMR(400MHz, CDCl3) δ7.57(d,J=8.0Hz,1H),7.53–7.49(m,1H),7.42(d,J=7.2Hz,2H),7.39 –7.29(m,9H),7.21(dd,J=8.4,2.0Hz,1H),6.47(d,J=8.0Hz,1H),5.42(s,2H),5.37(s,2H).

[0662] Step 2: 2,6-bis(benzyloxy)-3-[4-(4-(4-chlorophenyl)piperidin-1-yl)-3-fluorophenyl]pyridine 13-i

[0663] Under nitrogen protection, 13 g (16.9 g, 36.4 mmol) of 2,6-bis(benzyloxy)-3-(4-bromo-3-fluorophenyl)pyridine was dissolved in 170 mL of ultra-dry solvent dioxane. Then, 13 g (14.2 g, 72.8 mmol) of 4-(4-chlorophenyl)piperidine, 35.6 g (109.1 mmol) of cesium carbonate, 3.3 g (3.6 mmol) of Pd2(dba)3, and 3.4 g (7.3 mmol) of Ru-phos were added sequentially. The reaction mixture was stirred at 110 °C for 4 hours. After the reaction was complete, the reaction solution was diluted with 150 mL of water and extracted three times with ethyl acetate (75 mL x 3). The organic phases were combined and washed twice with 75 mL x 2 of water and twice with saturated brine (50 mL x 2). The organic phase was dried over an appropriate amount of anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by column chromatography (petroleum ether / ethyl acetate, 19:1) to give 13-I (4.4 g, yield 20.9%, yellow solid; 10 g crude product). MS m / z (ESI): 427.9 [M-Bu] + .

[0664] Step 3: 2,6-Di(benzyloxy)-3-(3-fluoro-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxacyclopentan-2-yl)phenyl)piperidin-1-yl)phenyl)pyridine 13-j

[0665] 2,6-bis(benzyloxy)-3-[4-(4-(4-chlorophenyl)piperidin-1-yl)-3-fluorophenyl]pyridine 13-i (2 g, 3.45 mmol) was dissolved in dioxane (20 mL), followed by the addition of 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bis(1,3,2-dioxoborane) (1.75 g, 6.91 mmol), X-phos-Pd-G3 (292 mg, 0.35 mmol), and potassium acetate (1.02 g, 10.36 mmol). The mixture was stirred in an oil bath at 80 °C for 2 hours under nitrogen protection. After the reaction was complete, the mixture was diluted with water (30 mL), extracted three times with ethyl acetate (20 mL × 3), and all organic phases were combined and washed once with saturated brine (20 mL). The organic phase was then dried with an appropriate amount of anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the crude product was purified by column chromatography (ethyl acetate / petroleum ether, 1:19) to give 13-j (1.1 g, yield 47.5%, yellow solid) MS m / z (ESI): 671.5 [M+H) + ; 1H NMR (400MHz, CDCl3) δ7.79(d,J=8.0Hz,2H),7.59(d,J=8.0Hz,1H),7.44–7.28(m,15H),6.47(d,J=8.0Hz, 1H),5.44(s,2H),5.36(s,2H),3.62(d,J=9.2Hz,2H),2.83–2.68(m,3H),1.99–1.96(m,4H),1.34(s,12H).

[0666] Step 4: 3-(3-fluoro-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxoborane-2-yl)phenyl)piperidin-1-yl)phenyl)piperidin-2,6-dione 13-d

[0667] 1,6-Di(benzyloxy)-3-(3-fluoro-4-(4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxacyclopentan-2-yl)phenyl)piperidin-1-yl)phenyl)pyridine 13-j (1.1 g, 1.64 mmol) was dissolved in tetrahydrofuran (20 mL), and palladium on carbon (1.2 g) was added. The mixture was stirred at room temperature for 12 hours under hydrogen protection. After the reaction was complete, the mixture was filtered and concentrated under reduced pressure to give 13-d (800 mg, 99% yield, pale yellow solid).

[0668] MS m / z(ESI): 493.3 [M+H] + ; 1 H NMR (400MHz, CDCl3) δ7.98(s,1H),7.78(d,J=8.0Hz,2H),7.29(d,J=8.0Hz,2H),6.99(t,J=8.4Hz,1H),6.91(dd,J=10.8,4.4Hz,2H),3.72(dd,J=9.6, 5.2Hz,1H),3.57(d,J=12.0Hz,2H),2.83–2.77(m,2H),2.73(t,J=5.2Hz,1 H),2.70–2.61(m,2H),2.28–2.26(m,2H),2.02–1.92(m,4H),1.34(s,12H).

[0669] Example 13 Synthesis:

[0670] Step 1: Methyl 6-((1H-1,2,3-triazol-1-yl)methyl)pyridinecarboxylate 13-b

[0671] 1,2,3-triazole (660 mg, 9.56 mmol) was dissolved in tetrahydrofuran (40 mL), and potassium tert-butoxide (1.46 g, 13.04 mmol) was added. The reaction was carried out for 0.5 h at room temperature under nitrogen protection. Then 13-a (2 g, 8.69 mmol) was added, and the reaction was carried out for 2 h at room temperature under nitrogen protection. The reaction solution was diluted with dichloromethane, filtered, and the filtrate was concentrated under reduced pressure. The product was purified by rapid column chromatography (100% ethyl acetate) to give 13-b (800 mg, yield 42.2%, yellow oily liquid). MS m / z (ESI): 219.2 [M+H] + .

[0672] 1 H NMR (400MHz, CDCl3) δ8.10(d,J=8.0Hz,1H),7.85(t,J=8.0Hz,1H),7.77(s,2H),7.30(d,J=8.0Hz,1H),5.83(s,2H),4.03(s,3H).

[0673] Step 2: 6-((1H-1,2,3-triazol-1-yl)methyl)pyridinecarboxylic acid 13-b

[0674] 13-b (800 mg, 3.67 mmol) was dissolved in tetrahydrofuran (20 mL) and methanol (20 mL), and lithium hydroxide (878 mg, 36.66 mmol) and water (5 mL) were added. The reaction mixture was reacted at room temperature for 1 hour. The pH of the reaction solution was adjusted to 2-3 with concentrated hydrochloric acid, and the solution was concentrated under reduced pressure to give 13-b (0.8 g, crude product, white solid). MS m / z (ESI): 205.0 [M+H] + .

[0675] Step 3: 6-(6-((1H-1,2,3-triazol-1-yl)methyl)pyridinamido)-4-chloro-7-fluoro-N,N-dimethyl-1H-indole-2-carboxamide 13-c

[0676] 12-c (200 mg, 0.78 mmol) was dissolved in N,N-dimethylformamide (10 mL), and 13-b (319 mg, 1.56 mmol), 2-(7-azobenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate (892 mg, 2.35 mmol), and N,N-diisopropylethylamine (505 mg, 3.91 mmol) were added. The mixture was reacted overnight at room temperature. The reaction solution was diluted with water, extracted with ethyl acetate, and the organic phase was concentrated under reduced pressure. The product was purified by rapid column chromatography (3% methanol / dichloromethane) to give 13-c (185 mg, yield 53.5%, yellow solid). MS m / z (ESI): 442.0 [M+H] + .

[0677] Step 4: 6-(6-((1H-1,2,3-triazol-1-yl)methyl)pyridinamido)-4-(4-(1-(4-(2,6-dioxopiperidin-3-yl)-2-fluorophenyl)piperidin-4-yl)phenyl)-7-fluoro-N,N-dimethyl-1H-indole-2-carboxamide 13

[0678] 13-d (80 mg, 0.18 mmol) was dissolved in 1,4-dioxane (1.8 mL), and 13-c (89 mg, 0.18 mmol), methanesulfonic acid (2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)(2'-amino-1,1'-biphenyl-2-yl)palladium(II) (31 mg, 0.04 mmol), potassium acetate (53 mg, 0.54 mmol), and water (0.6 mL) were added. The mixture was microwaved at 100°C under nitrogen protection for 30 minutes. The reaction solution was diluted with water, extracted with dichloromethane, and the organic phase was concentrated under reduced pressure. Compound 13 (14.56 mg, yield 10.4%, white solid) was purified by preparative HPLC (50%-62% acetonitrile / 0.1% formic acid aqueous solution).

[0679] MS m / z(ESI): 772.7 [M+H] + .

[0680] 1 H NMR (400MHz, DMSO-d6) δ12.27(s,1H),10.82(s,1H),10.31(s,1H),8.46(d,J=0.8Hz,1H),8.13(s,1H),8.12(d ,J=1.6Hz,1H),7.84(d,J=0.8Hz,1H),7.74(d,J=6.4Hz,1H),7.63(d,J=8.4Hz,2H),7.56–7.53(m,1H),7.47(d ,J=8.4Hz,2H),7.09–7.02(m,2H),7.00–6.97(m,1H),6.93–6.91(m,1H),5.94(s,2H),3.85–3.79(m,1H),3.54 –3.46(m,2H),3.24–3.03(m,6H),2.88–2.73(m,4H),2.65–2.61(m,1H),2.28–2.16(m,1H),2.06–1.86(m,5H).

[0681] Example 14 6-(1-((1H-1,2,3-triazol-1-yl)methyl)-2-oxo-1,2-dihydropyridine-3-carboxamido)-4-(4-(4-(2-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)ethyl)piperazin-1-yl)-2-methoxyphenyl)-7-fluoro-N,N-dimethyl-1H-indole-2-carboxamide 14

[0682] Step 1: 4-(4-(6-(1-((1H-1,2,3-triazol-1-yl)methyl)-2-oxo-1,2-dihydropyridine-3-carboxamido)-2-(dimethylcarbamoyl)-7-fluoro-1H-indol-4-yl)-3-methoxyphenyl)piperazine-1-carboxylic acid tert-butyl ester 14-a

[0683] 13-c (120 mg, 0.26 mmol) was dissolved in 1,4-dioxane (7.2 mL), and 1-f (219 mg, 0.52 mmol), methanesulfonic acid (2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)(2'-amino-1,1'-biphenyl-2-yl)palladium(II) (22 mg, 0.03 mmol), potassium phosphate (167 mg, 0.79 mmol), and water (2.2 mL) were added. The reaction mixture was reacted at 80°C under nitrogen protection for 2 hours. The reaction solution was diluted with water, extracted with dichloromethane / methanol (7:3), and the organic phase was concentrated under reduced pressure. The product was purified by rapid column chromatography (6% methanol / dichloromethane) to give 14-a (100 mg, yield 53.5%, yellow solid). MS m / z (ESI): 714.7 [M+H] + .

[0684] Step 2: 6-(1-((1H-1,2,3-triazol-1-yl)methyl)-2-oxo-1,2-dihydropyridine-3-carboxamido)-7-fluoro-4-(2-methoxy-4-(piperazin-1-yl)phenyl)-N,N-dimethyl-1H-indole-2-carboxamide 14-b

[0685] 14-a (90 mg, 0.13 mmol) was dissolved in dichloromethane (2 mL), and trifluoroacetic acid (2 mL) was added. The reaction mixture was reacted at room temperature for 0.5 hours. The reaction solution was concentrated to give product 14-b (90 mg, crude product, yellow solid). MS m / z (ESI): 614.6 [M+H] + .

[0686] Step 3: 6-(1-((1H-1,2,3-triazol-1-yl)methyl)-2-oxo-1,2-dihydropyridine-3-carboxamido)-4-(4-(4-(2-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)ethyl)piperazin-1-yl)-2-methoxyphenyl)-7-fluoro-N,N-dimethyl-1H-indole-2-carboxamide 14

[0687] 14-b (90 mg, 0.15 mmol) was dissolved in dichloromethane (10 mL), and 1-c (66 mg, 0.22 mmol) was added. The mixture was reacted at room temperature for 1 hour. Then, sodium triacetoxyborohydride (93 mg, 0.44 mmol) was added, and the mixture was reacted at room temperature overnight. The reaction solution was concentrated, and the formate salt of compound 14 was purified by preparative HPLC (19%–23% acetonitrile / 0.1% formic acid aqueous solution) to obtain 11.65 mg of compound 14 (yield 8.8%, yellow solid).

[0688] MS m / z (ESI): 899.7 [M+H] + .

[0689] 1 H NMR (400MHz, DMSO-d6) δ11.97(s,1H),11.95(s,1H),11.10(s,1H),8.53(dd,J=7.2,2.0Hz,1H),8.44–8 .38(m,3H),7.95(d,J=6.4Hz,1H),7.81(d,J=0.8Hz,1H),7.16(d,J=8.4Hz,1H),7.02–6.92(m,3H),6.7 7–6.70(m,3H),6.69–6.67(m,1H),6.62(dd,J=8.4,2.0Hz,1H),6.51–6.49(m,1H),5.41–5.34(m,1H),3 .72(s,3H),3.62(s,3H),3.18–3.10(m,6H),2.93–2.83(m,2H),2.72–2.62(m,12H),2.06–1.96(m,2H).

[0690] Example 15 6-(1-(3-(1H-1,2,3-triazol-1-yl)propionyl)-1,2,5,6-tetrahydropyridin-3-yl)-4-(4-(4-(4-(2,6-dioxopiperidin-3-yl)-2-fluorobenzyl)piperidin-1-yl)-2-methoxyphenyl)-7-fluoro-N,N-dimethyl-1H-indole-2-carboxamide 15

[0691] Synthesis of intermediate 15-i:

[0692] 6-(1-(3-(1H-1,2,3-triazol-1-yl)propionyl)-1,2,5,6-tetrahydropyridin-3-yl)-7-fluoro-N,N-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborhecyclopentan-2-yl)-1H-indole-2-carboxamide 15-i

[0693] 6-B (2.5 g, 5.63 mmol) was dissolved in 1,4-dioxane (30 mL), and pinacol diborate (2.1 g, 8.45 mmol), methanesulfonic acid (2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)(2'-amino-1,1'-biphenyl-2-yl)palladium(II) (474 ​​mg, 0.56 mmol), and potassium acetate (1.7 g, 16.89 mmol) were added. The reaction mixture was purged with nitrogen three times and stirred at 80 °C under nitrogen protection for 2 hours. After the reaction was completed, the reaction mixture was diluted with water (50 mL), extracted with ethyl acetate (3 x 50 mL), and the organic phases were combined and washed with saturated brine (50 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The product was purified by rapid column chromatography (5% methanol / dichloromethane) to give 15-I (1.6 g, yield 53.08%, pale yellow solid).

[0694] MS m / z (ESI): 537.1 [M+H] + .

[0695] Example 15 Synthesis:

[0696] Step 1: 4-(4-(2-ethoxy-2-oxoethyl)-2-fluorobenzyl)piperidine-1-carboxylic acid tert-butyl ester 15-c

[0697] 15-a (5.0 g, 19.16 mmol) was dissolved in anhydrous N,N-dimethylformamide (50 mL), and 15-b (7.4 g, 22.99 mmol), [1,1'-bis(diphenylphosphine)ferrocene]palladium dichloride (1.4 g, 1.92 mmol), and cesium fluoride (8.7 g, 57.48 mmol) were added. The reaction mixture was purged with nitrogen three times and stirred at 90 °C under nitrogen protection for 5 hours. After the reaction was complete, the reaction mixture was diluted with water (50 mL) and extracted with ethyl acetate (3 x 50 mL). The organic phases were combined and washed with saturated brine (3 x 50 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The product was purified by rapid column chromatography (20% ethyl acetate / petroleum ether) to give 15-c (5.0 g, yield 69.17%, pale yellow oil).

[0698] 1 H NMR(400MHz, DMSO-d6)δ7.28(t,J=8.0Hz,1H),7.21–7.10(m,2H),6.32(s,1H),4.21–4.10( m,2H),3.75(s,2H),3.51–3.46(m,2H),2.41–2.29(m,5H),1.47(s,9H),1.28–1.22(m,3H).

[0699] Step 2: Ethyl 2-(3-fluoro-4-(piperidin-4-methylene)phenyl)acetate 15-d

[0700] 15-c (4.0 g, 10.61 mmol) was dissolved in 1,4-dioxane-hydrochloride (40 mL, 4 M) solution and reacted at room temperature for 3 hours. After the reaction was complete, the reaction solution was concentrated under reduced pressure to give 15-d (3.5 g, crude product, white solid). MS m / z (ESI): 278.3 [M+H] + .

[0701] Step 3: Ethyl 2-(4-((1-(4-chloro-3-methoxyphenyl)piperidin-4-methylene)methyl)-3-fluorophenyl)ethyl acetate 15-f

[0702] 15-d (3.5 g, 12.64 mmol) was dissolved in anhydrous dimethyl sulfoxide (40 mL), and 1-chloro-4-iodo-2-methoxybenzene (4.1 g, 15.16 mmol), cuprous iodide (480 mg, 2.53 mmol), L-proline (291 mg, 2.53 mmol), and potassium carbonate (5.2 g, 37.92 mmol) were added. The reaction mixture was purged with nitrogen three times and reacted at 80 °C for 16 hours. After the reaction was complete, the reaction mixture was diluted with water (50 mL), extracted with ethyl acetate (3 x 50 mL), and the organic phases were combined and washed with saturated brine (3 x 50 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The product was purified by rapid column chromatography (20% ethyl acetate / petroleum ether) to give 15-f (1.0 g, two-step yield 22.58%, white solid).

[0703] MS m / z(ESI): 418.0 [M+H] + .

[0704] Step 4: 3-(4-((1-(4-chloro-3-methoxyphenyl)piperidine-4-methylene)methyl)-3-fluorophenyl)piperidine-2,6-dione 15-h

[0705] 15-f (1.0 g, 2.40 mmol) and acrylamide (681 mg, 9.59 mmol) were dissolved in anhydrous N,N-dimethylformamide (20 mL), purged three times with nitrogen, and then potassium tert-butoxide solution (2.4 mL, 2.40 mmol, 1 M) was slowly added dropwise to the reaction mixture. The reaction mixture was stirred at room temperature for 2 hours. After the reaction was completed, the reaction mixture was quenched with saturated ammonium chloride solution (30 mL), extracted with ethyl acetate (3 x 30 mL), and the organic phases were combined and washed with saturated brine (3 x 30 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The product was purified by rapid column chromatography (50% ethyl acetate / petroleum ether) to give 15-h (300 mg, yield 28.31%, white solid).

[0706] MS m / z (ESI): 443.3 [M+H] + .

[0707] 1 H NMR (400MHz, DMSO-d6) δ10.86(s,1H),7.26(t,J=8.0Hz,1H),7.18(d,J=8.8Hz,1H),7.08 (dd,J=23.2,9.6Hz,2H),6.67(d,J=2.4Hz,1H),6.52(dd,J=8.8,2.4Hz,1H),6.28(s,1H) ,3.90(dd,J=12.0,4.8Hz,1H),3.83(s,3H),3.40–3.34(m,2H),3.28–3.23(m,2H),2.75– 2.62(m,1H),2.57–2.52(m,1H),2.49–2.39(m,4H),2.31–2.17(m,1H),2.09–2.00(m,1H).

[0708] Step 5: 6-(1-(3-(1H-1,2,3-triazol-1-yl)propionyl)-1,2,5,6-tetrahydropyridin-3-yl)-4-(4-(4-(4-(2,6-dioxopiperidin-3-yl)-2-fluorobenzyl)piperidin-1-yl)-2-methoxyphenyl)-7-fluoro-N,N-dimethyl-1H-indole-2-carboxamide 15

[0709] 15-h (150 mg, 0.339 mmol) was dissolved in 1,4-dioxane (2 mL) and water (0.4 mL). 15-i (218 mg, 0.407 mmol), methanesulfonic acid (2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)(2'-amino-1,1'-biphenyl-2-yl)palladium(II) (29 mg, 0.0339 mmol), and potassium acetate (99 mg, 1.018 mmol) were added. The mixture was reacted in a microwave at 100 °C for 20 minutes under nitrogen protection. After the reaction was complete, the reaction solution was diluted with water (5 mL) and extracted with ethyl acetate (3 x 5 mL). The organic phases were combined and washed with saturated brine (5 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. Compound 15 (101.21 mg, yield 36.58%, white solid) was isolated and purified by preparative HPLC (prep-HPLC (Waters 2767, Column: Sunfire C18 19*150mm*5um; Mobile Phase A: 0.05% TFA / H2O, B: ACN; Gradient: 32-40%; Retention Time: 10.0-11.3 min of 16 min) method).

[0710] MS m / z (ESI): 817.6 [M+H] + .

[0711] 1H NMR (400MHz, DMSO-d6) δ11.95(d,J=8.8Hz,1H),10.87(s,1H),8.11(d,J=10.4Hz,1H),7.68(d,J=11.6Hz,1H),7.29(t,J=8.0Hz,1H),7.20(d,J=8. 4Hz,1H),7.12(d,J=11.2Hz,1H),7.07(d,J=8.0Hz,1H),6.87(dd,J=22.0,6.4Hz,1H),6.74(s,1H),6.67(d,J=8.0Hz,1H),6.49(d,J=2.4Hz,1H),6 .32(s,1H),6.11(d,J=11.6Hz,1H),4.70–4.55(m,2H),4.33(d,J=23.2Hz ,2H),3.94–3.88(m,5H),3.72(d,J=4.0Hz,3H),3.67–3.63(m,1H),3.61– 3.58(m,1H),3.50–3.42(m,2H),3.40–3.31(m,2H),3.24–2.95(m,8H),2. 71–2.64(m,1H),2.56–2.54(m,1H),2.37–2.21(m,3H),2.10–1.98(m,1H).

[0712] Example 16 6-(6-(3-(1H-1,2,3-triazol-1-yl)propionyl)-6-azaspiro[3.5]non-7-en-8-yl)-4-(4-(1-(4-(2,6-dioxopiperidin-3-yl)-2-fluorophenyl)piperidin-4-yl)phenyl)-7-fluoro-N,N-dimethyl-1H-indole-2-carboxamide 16

[0713] Step 1: 8-(((trifluoromethyl)sulfonyl)oxy)-6-azaspiro[3.5]non-7-ene-6-carboxylic acid tert-butyl ester 16-a

[0714] tert-butyl 8-oxo-6-azaspiro[3.5]nonane-6-carboxylic acid ester 10-I (5.0 g, 21 mmol) was dissolved in ultra-dry solvent dichloromethane (50 mL), followed by the addition of triethylamine (17.4 mL, 125 mmol), N,N-dimethylpyridin-4-amine (255 mg, 2 mmol), and 1,1,1-trifluoro-N-phenyl-N-((trifluoromethyl)sulfonyl)methanesulfonamide (15 g, 42 mmol). The mixture was stirred at room temperature for 16 hours under nitrogen protection. After the reaction was complete, the reaction solution was diluted with dichloromethane (50 mL) and washed once with saturated sodium bicarbonate aqueous solution (50 mL) and then with water (50 mL). The solution was then dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (ethyl acetate / petroleum ether, 1:19) to give product 16-a (2.95 g, yield 38%, colorless liquid).

[0715] MS m / z(ESI): 357.2 [M-Bu+ACN] + .

[0716] Step 2: 8-(4,4,5,5-tetramethyl-1,3,2-dioxaborhecyclopentan-2-yl)-6-azaspiro[3.5]non-7-ene-6-carboxylic acid tert-butyl ester 16-b

[0717] 16-a (2.95 g, 7.94 mmol) was dissolved in dioxane (30 mL) in ultra-dry solvent. Then, 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bis(1,3,2-dioxoborane) (4.03 g, 15.89 mmol), 1,1'-bis(diphenylphosphine)ferrocene palladium chloride (581 mg, 0.79 mmol), and potassium acetate (2.34 g, 23.83 mmol) were added sequentially. The mixture was stirred at 80 °C for 16 hours under nitrogen protection. After the reaction was complete, the reaction solution was diluted with ethyl acetate (50 mL) and washed once each with water (30 mL) and saturated brine (30 mL). The product was then dried with anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (ethyl acetate / petroleum ether, 1:19) to give product 16-b (1.25 g, yield 45%, colorless liquid).

[0718] MS m / z(ESI): 294.3 [M-Bu] + ; 1H NMR (400MHz, CDCl3) δ6.81–6.60(m,1H),4.81–4.67(m,1H),3.43(d,J=23.2Hz,2H),2.05(s ,2H),1.99–1.91(m,2H),1.79–1.71(m,4H),1.50(d,J=4.8Hz,9H),1.27(d,J=2.0Hz,12H).

[0719] Step 3: 8-(4-chloro-2-(dimethylcarbamoyl)-7-fluoro-1H-indol-6-yl)-6-azaspiro[3.5]non-7-ene-6-carboxylic acid tert-butyl ester 16-c

[0720] 6-Bromo-4-chloro-7-fluoro-N,N-dimethyl-1H-indole-2-carboxamide 6-a (953 mg, 2.98 mmol) was dissolved in dioxane (19 mL), followed by the addition of tert-butyl 8-(4,4,5,5-tetramethyl-1,3,2-dioxaborhexacyclopentan-2-yl)-6-azaspiro[3.5]non-7-ene-6-carboxylic acid tert-butyl ester 16-b (1.25 g, 3.58 mmol), 1,1'-bis(diphenylphosphino)ferrocene palladium chloride (218 mg, 0.30 mmol), potassium carbonate (1.24 g, 8.95 mmol), and water (3.8 mL). The mixture was stirred in an oil bath at 100 °C for 16 hours under nitrogen protection. After the reaction was complete, the mixture was diluted with water (30 mL), extracted three times with ethyl acetate (20 mL * 3), and all organic phases were combined and washed once with saturated brine (20 mL). The organic phase was then dried with an appropriate amount of anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the crude product was purified by column chromatography (ethyl acetate / petroleum ether, 1:4) to give 16-c (1.14 g, yield 82.7%, yellow solid).

[0721] MS m / z(ESI): 462.2 [M+H+] + ; 1 H NMR (400MHz, DMSO-d6) δ12.12(s,1H),7.15(s,1H),7.01(d,J=5.6Hz,1H),6.78–6.71(m,1H),3.49 (s,2H),3.17–3.14(m,6H),2.50–2.47(m,2H),2.00–1.95(m,2H),1.85–1.81(m,4H),1.48(s,9H).

[0722] Step 4: 4-Chloro-7-fluoro-N,N-dimethyl-6-(6-azaspiro[3.5]non-7-en-8-yl)-1H-indole-2-carboxamide 16-d

[0723] 8-(4-chloro-2-(dimethylcarbamoyl)-7-fluoro-1H-indol-6-yl)-6-azaspiro[3.5]non-7-en-6-carboxylic acid tert-butyl ester 16-c (560 mg, 1.23 mmol) was dissolved in ultradry solvent dichloromethane (12 mL), and trifluoroacetic acid (3 mL) was added. The mixture was stirred at room temperature for 1 hour under nitrogen protection. After the reaction was complete, the solution was concentrated under reduced pressure to obtain crude product 16-d (500 mg, crude product, colorless liquid). MS m / z (ESI): 362.2 [M+H+] + .

[0724] Step 5: 6-(6-(3-(1H-1,2,3-triazol-1-yl)propionyl)-6-azaspiro[3.5]non-7-en-8-yl)-4-chloro-7-fluoro-N,N-dimethyl-1H-indole-2-carboxamide 16-e

[0725] The crude raw material 4-chloro-7-fluoro-N,N-dimethyl-6-(6-azaspiro[3.5]non-7-en-8-yl)-1H-indole-2-carboxamide 16-d (500 mg, 1.23 mmol) was dissolved in ultra-dry solvent dichloromethane (10 mL), and N,N-diisopropylethylamine (0.6 mL, 3.68 mmol), 3-(1H-1,2,3-triazol-1-yl)propionic acid 2-a (260 mg, 1.84 mmol), and 2-(7-azabenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphonate (700 mg, 1.84 mmol) were added sequentially. The mixture was stirred at room temperature for 2 hours under nitrogen protection. After the reaction was complete, the mixture was diluted with water (10 mL), extracted three times with ethyl acetate (10 mL * 3), and all organic phases were combined and washed once with saturated brine (10 mL). The organic phase was then dried with an appropriate amount of anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the crude product was purified by column chromatography (methanol / dichloromethane, 1:9) to obtain 16-e (240 mg, two-step yield 40.8%, yellow solid).

[0726] MS m / z (ESI): 485.4 [M+H+] + ; 1H NMR (400MHz, DMSO-d6) δ12.35(d,J=10.4Hz,1H),8.14(d,J=11.2Hz,1H),7.71(d,J=8.8Hz,1H),7.50(s,1H),7.17–7.04(m,2H),6.81(s,1H) ,4.66(t,J=6.4Hz,2H),3.59(d,J=6.0Hz,2H),3.27(dd,J=14.8,7.2Hz,4H),3.06(s,3H),2.53(s,3H),2.01–1.90(m,2H),1.88–1.74(m,4H).

[0727] Step 6: 6-(6-(3-(1H-1,2,3-triazol-1-yl)propionyl)-6-azaspiro[3.5]non-7-en-8-yl)-4-(4-(1-(4-(2,6-dioxopiperidin-3-yl)-2-fluorophenyl)piperidin-4-yl)phenyl)-7-fluoro-N,N-dimethyl-1H-indole-2-carboxamide 16

[0728] At room temperature, 6-(6-(3-(1H-1,2,3-triazol-1-yl)propionyl)-6-azaspiro[3.5]non-7-en-8-yl)-4-chloro-7-fluoro-N,N-dimethyl-1H-indole-2-carboxamide 16-e (240 mg, 0.495 mmol) and 3-(3-fluoro-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborhecyclopentan-2-yl) Phenyl)piperidin-1-yl)phenyl)piperidin-2,6-dione 13-d (293 mg, 0.594 mmol) was dissolved in dioxane (2.5 mL), and X-Phos-Pd-G3 (42 mg, 0.049 mmol), potassium acetate (146 mg, 1.485 mmol), and water (0.5 mL) were added sequentially. After purging with nitrogen three times, the mixture was sealed in a microwave tube and microwaved at 100 °C for 20 minutes. After the reaction was complete, the mixture was diluted with ethyl acetate and washed once with water. The crude solution was purified by preparative HPLC (prep-HPLC (Waters 2767 / Qda, Column: Pursuit XRs 10C18, 250*21.2mm, 10µm; Mobile Phase A: 0.1% FA / H2O, B: ACN; flow rate: 20ml / min; gradient: 21%–25%; retention time: 8.6–11 min of 16 min) to obtain compound 16 (white solid, 30 mg, yield 7.4%). Further separation by SFC yielded compounds 16-1 (white solid, 5.33 mg) and 16-2 (white solid, 5.43 mg).

[0729] 16-1:MS m / z(ESI):815.7[M+H] + 。

[0730] 1 H NMR(400MHz,DMSO-d6)δ12.10(d,J=12.4Hz,1H),10.82(s,1H),8.14(d,J=14.8Hz,1H),7.70(d,J=13.6Hz,1H),7.62(t,J=7.2Hz,2H),7.56(s,1H),7.44(d,J=7.6Hz,2H),7.11(s,1H),7.09–6.97(m,4H),6.85(s,1H),4.66(d,J=4.4Hz,2H),3.82(dd,J=12.0,4.8Hz,1H),3.61(d,J=8.4Hz,2H),3.49(d,J=10.8Hz,2H),3.25–3.03(m,8H),2.82(t,J=10.8Hz,2H),2.75(s,2H),2.59(s,2H),2.23–2.19(m,1H),1.96–1.80(m,12H)。

[0731] 16-2:MS m / z(ESI):815.7[M+H] + 。

[0732] 1 H NMR(400MHz,DMSO-d6)δ12.09(d,J=11.2Hz,1H),10.82(s,1H),8.14(d,J=14.8Hz,1H),7.70(d,J=13.6Hz,1H),7.62(t,J=7.2Hz,2H),7.56(s,1H),7.44(d,J=8.0Hz,2H),7.11(s,1H),7.09–6.97(m,4H),6.86(d,J=2.8Hz,1H),4.66(dd,J=11.2,6.4Hz,2H),3.82(dd,J=11.6,4.8Hz,1H),3.61(d,J=8.0Hz,2H),3.49(d,J=11.6Hz,2H),3.21–2.98(m,8H),2.83–2.79(m,2H),2.78–2.75(m,2H),2.60–2.59(m,2H),2.22–2.18(m,1H),1.96–1.80(m,12H)。

[0733] Example 17 6-(6-(3-(1H-1,2,3-triazol-1-yl)propionyl)-6-azaspiro[3.5]non-8-en-8-yl)-4-(4-(1-(4-(2,6-dioxopiperidin-3-yl)-2-fluorophenyl)piperidin-4-yl)phenyl)-7-fluoro-N,N-dimethyl-1H-indole-2-carboxamide 17

[0734] Step 1: tert-butyl 8-(((trifluoromethyl)sulfonyl)oxy)-6-azaspiro[3.5]non-8-ene-6-carboxylic acid ester 17-a

[0735] 10-i (5.0 g, 20.92 mmol) was dissolved in ultra-dry tetrahydrofuran (110 mL), purged three times with nitrogen, and the reaction solution was cooled to -78 °C. Then, bis(trimethylsilylaminolithium) (21.97 mL, 21.97 mmol, 1 M) was slowly added dropwise to the reaction solution. The mixture was stirred at -78 °C for 5 minutes and then the cryogenic bath was removed. The reaction solution was then heated to 0 °C and stirred for 1 hour. The reaction solution was then cooled to -78 °C, and 1,1,1-trifluoro-N-phenyl-N-((trifluoromethyl)sulfonyl)methanesulfonamide (9.7 g, 27.20 mmol, dissolved in 40 mL of tetrahydrofuran) was slowly added dropwise to the reaction solution. After the addition was complete, the reaction solution was heated to 0 °C and stirred for 45 minutes. Then, the mixture was slowly heated to room temperature and reacted for 16 hours. After the reaction was complete, the reaction solution was diluted with water (100 mL), extracted with ethyl acetate (3 × 100 mL), and the organic phases were combined and washed with saturated brine (100 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The product was purified by rapid column chromatography (10% ethyl acetate / petroleum ether) to give 17-a (1.1 g, yield 14.18%, pale yellow oil).

[0736] 1 H NMR (400MHz, CDCl3) δ5.96(s,1H),4.01(s,2H),3.53(s,2H),2.03–1.89(m,6H),1.48(s,9H).

[0737] Step 2: tert-butyl-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborane-2-yl)-6-azaspiro[3.5]non-8-ene-6-carboxylic acid ester 17-b

[0738] 17-a (1.1 g, 2.96 mmol) was dissolved in ultra-dry dioxane (20 mL), and then bis(diphenylphosphino)ferrocene palladium chloride (217 mg, 0.296 mmol) and potassium acetate (871 g, 8.89 mmol) were added sequentially. The mixture was purged with nitrogen three times, and the reaction solution was stirred at 100 °C for 16 hours. After the reaction was complete, the reaction solution was diluted with water (50 mL), extracted with ethyl acetate (3 x 50 mL), and the organic phases were combined and washed with saturated brine (50 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The product was purified by rapid column chromatography (5% ethyl acetate / petroleum ether) to give 17-b (1.0 g, yield 96.66%, pale yellow oil).

[0739] 1 H NMR (400MHz, CDCl3) δ6.63(s,1H),3.92(s,2H),3.49(s,2H),2.03–1.86(m,6H),1.48(s,9H),1.26(s,12H).

[0740] Step 3: tert-butyl 8-(4-chloro-2-(dimethylcarbamoyl)-7-fluoro-1H-indol-6-yl)-6-azaspiro[3.5]non-8-ene-6-carboxylic acid ester 17-c

[0741] 6-a (917 mg, 2.87 mmol), 17-b (1.0 g, 2.87 mmol), 1,1'-bis(diphenylphosphino)ferrocene palladium chloride (210 mg, 0.287 mmol), and potassium carbonate (1.2 g, 8.61 mmol) were dissolved in dioxane (15 mL) and water (1.5 mL), and the mixture was purged three times with nitrogen. The reaction solution was reacted at 100 °C for 16 hours. After the reaction was completed, the reaction solution was diluted with water (20 mL), extracted with ethyl acetate (3 x 30 mL), and the organic phases were combined and washed with saturated brine (20 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The product was purified by rapid column chromatography (50% ethyl acetate / petroleum ether) to give 17-c (260 mg, yield 19.66%, yellow oil).

[0742] MS m / z(ESI): 406.0 [M+H + -56] +

[0743] Step 4: 4-Chloro-7-fluoro-N,N-dimethyl-6-(6-azaspiro[3.5]non-8-en-8-yl)-1H-indole-2-carboxamide 17-d

[0744] 17-c (260 mg, 1.23 mmol) was dissolved in ultra-dry solvent dichloromethane (5 mL), and then trifluoroacetic acid (1 mL) was added. The reaction solution was reacted at room temperature for 2 hours. After the reaction was completed, the reaction solution was concentrated under reduced pressure to obtain 17-d (260 mg, crude product, brownish-brown oily substance), which was directly used for the next reaction.

[0745] MS m / z(ESI): 362.3 [M+H+] + Step 5: 6-(6-(3-(1H-1,2,3-triazol-1-yl)propionyl)-6-azaspiro[3.5]non-8-en-8-yl)-4-chloro-7-fluoro-N,N-dimethyl-1H-indole-2-carboxamide 17-e

[0746] 17-d (260 mg, 0.72 mmol), 3-(1H-1,2,3-triazol-1-yl)propionic acid (112 mg, 0.792 mmol), 2-(7-azabenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphonate (336 mg, 0.936 mmol), and N,N-diisopropylethylamine (0.4 mL, 2.16 mmol) were dissolved in ultra-dry solvent dichloromethane (5 mL). The reaction mixture was reacted at room temperature for 16 hours. After the reaction was complete, the mixture was diluted with water (10 mL) and extracted three times with dichloromethane (10 mL * 3). The organic phases were combined and washed with saturated brine (10 mL). The organic phase was dried with anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by high performance preparative chromatography (methanol / dichloromethane = 1 / 20) to give 17-e (170 mg, two-step yield 62.28%, white solid).

[0747] MS m / z (ESI): 485.3 [M+H] +

[0748] Step 6: 6-(6-(3-(1H-1,2,3-triazol-1-yl)propionyl)-6-azaspiro[3.5]non-8-en-8-yl)-4-(4-(1-(4-(2,6-dioxopiperidin-3-yl)-2-fluorophenyl)piperidin-4-yl)phenyl)-7-fluoro-N,N-dimethyl-1H-indole-2-carboxamide 17

[0749] 17-e (100 mg, 0.206 mmol) was dissolved in 1,4-dioxane (1.5 mL) and water (0.5 mL). 13-d (101 mg, 0.206 mmol), methanesulfonic acid (2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)(2'-amino-1,1'-biphenyl-2-yl)palladium(II) (17 mg, 0.0206 mmol), and potassium acetate (61 mg, 0.618 mmol) were added. The mixture was reacted in a microwave at 100 °C for 20 minutes under nitrogen protection. After the reaction was complete, the reaction solution was diluted with water (5 mL), extracted with ethyl acetate (3 x 5 mL), and the organic phases were combined and washed with saturated brine (5 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. Compound 17 (20.8 mg, yield 12.38%, white solid) was isolated and purified by preparative HPLC (prep-HPLC (Waters 2767 / QDA, Column: Boston 30*150mm*5um; Mobile Phase A: 0.05% TFA / H2O, B: ACN; flow rate: Gradient: 35-42%; Retention Time: 8.6-9.4 min of 18 min) method).

[0750] MS m / z (ESI): 815.7 [M+H] + ;1H NMR (400MHz, DMSO-d6) δ12.19(d,J=10.0Hz,1H),10.82(s,1H),8.11(d,J=14.0Hz,1H),7.68(d,J= 13.2Hz,1H),7.63(d,J=8.0Hz,2H),7.44(d,J=8.4Hz,2H),7.12–6.95(m,4H),6.87(s,1H),6.27(d, J=10.0Hz,1H),4.77–4.52(m,2H),4.31(d,J=14.8Hz,2H),3.89–3.77(m,1H),3.77–3.61(m,2H),3. 49(d,J=10.8Hz,2H),3.25–3.04(m,8H),2.89–2.65(m,4H),2.26–2.16(m,1H),2.10–1.82(m,12H).

[0751] Example 18 6-1-(3-(1,3,4-selenoimidazole-2-yl)propionyl)-1,2,5,6-tetrahydropyridin-3-yl)-4-(4-(4-(2,6-dioxopiperidin-3-yl)-2-fluorophenyl)piperidin-4-yl)phenyl)-7-fluoro-N,N-dimethyl-1H-indole-2-carboxamide

[0752] Step 1: At room temperature, 18-a (25.0 g, 107 mmol) was dissolved in ethanol (150 mL), and sodium hydrocarbonate (11.3 g, 107 mmol) was added. The mixture was stirred for 4 hours under nitrogen protection. Simultaneously, sodium borohydride (8.89 g, 235 mmol) was dissolved in ethanol (150 mL). Under nitrogen protection, selenium powder (16.9 g, 214 mmol) was added in portions at 0 °C until all the selenium powder was added. The system was slowly brought to room temperature, and a small amount of sodium borohydride was added to completely consume the selenium powder, resulting in a colorless solution. The supernatant of the 18-a system was collected using a syringe and added to the above mixture. The mixture was stirred at room temperature (28 °C) for 16 hours. After the reaction was complete, the mixture was filtered, and the filter cake was washed with ultra-dry ethanol and dried to obtain 18-b (4.00 g, crude product, pale purple solid). 1 H NMR (400MHz, DMSO-d6) δ9.06 (s, 1H), 7.79 (d, J = 131.3Hz, 2H), 4.51 (s, 2H).

[0753] Step 2: Methyl 3-(5-amino-1,3,4-selenozol-2-yl)propionate 18-c

[0754] The starting material 18-b (4.00 g, 29.0 mmol) and monomethyl succinate (3.83 g, 29.0 mmol) were dissolved in 1,4-dioxane (30 mL), and phosphorus oxychloride (24 mL) was slowly added. Under nitrogen protection, the reaction mixture was stirred at 75 °C for 1 hour. After concentration, the crude product was obtained. Under ice bath conditions, sodium bicarbonate aqueous solution was slowly added dropwise to adjust the pH to 7. The mixture was extracted multiple times with ethyl acetate (20 mL x 3), and the organic phases were combined, washed with saturated brine, and dried over anhydrous sodium sulfate. The solvent was evaporated to dryness, and the crude product was purified by column chromatography (silica gel, methanol / dichloromethane = 1 / 20) to obtain 18-c (1.30 g, yield 19.1%, yellow solid). MS m / z (ESI): 236.0 [M+H] + .

[0755] Step 3: Methyl 3-(5-bromo-1,3,4-selenosulfuron-2-yl)propionate 18-d

[0756] At room temperature, starting material 18-c (1.30 g, 5.55 mmol) and cuprous bromide (7.96 g, 55.5 mmol) were dissolved in acetonitrile (30 mL) under nitrogen protection. Amyl nitrite (1.96 g, 16.7 mmol) was added to the system at 80 °C. The reaction mixture was stirred at 80 °C for 1.5 h. The reaction solution was filtered to remove insoluble matter, the filtrate was concentrated under reduced pressure, water (10 mL) was added, and the mixture was extracted with ethyl acetate (20 mL x 3), washed with saturated brine, and dried over anhydrous sodium sulfate. The solvent was evaporated to dryness, and the crude product was purified by column chromatography (petroleum ether / ethyl acetate = 1 / 1) to give 18-d (1.10 g, yield 66.5%, yellow solid). MS m / z (ESI): 298.7 [M+H] + .

[0757] Step 4: Methyl 3-(1,3,4-selenodiazole-2-yl)propionate 18-e

[0758] The starting material 18-d (500 mg, 1.68 mmol) was dissolved in acetic acid (10 mL), and zinc powder (220 mg, 3.36 mmol) was added. The reaction mixture was stirred at 90 °C for 3 hours. The solvent was evaporated to dryness, tetrahydrofuran was added, and the mixture was sonicated and filtered. The filtrate was concentrated to obtain the crude product, which was purified by column chromatography (petroleum ether / ethyl acetate = 1 / 1) to obtain 18-e (300 mg, yield 81.5%, colorless oil). MS m / z (ESI): 221.1 [M+H] + .

[0759] Step 5: 18-f of 3-(1,3,4-selenodiazole-2-yl)propionic acid

[0760] The starting material 18-e (300 mg, 1.37 mmol) was dissolved in concentrated hydrochloric acid (3 mL). The reaction mixture was stirred at 90 °C for 1 hour. LC-MS showed that the reaction was complete. The solvent was evaporated to dryness to obtain 18-f (250 mg, crude product, pink oil), which proceeded directly to the next step without purification. MS m / z (ESI): 207.1 [M+H] + .

[0761] Step 6: 3-(4-chloro-2-(dimethylcarbamoyl)-7-fluoro-1H-indol-6-yl)-5,6-dihydropyridine-1(2H)-carboxylic acid tert-butyl ester 18-h

[0762] The starting materials 1-g (1.00 g, 3.13 mmol), 6-a (1.45 g, 4.70 mmol), 1,1-bis(diphenylphosphine)dipyridylferric palladium dichloride (229 mg, 0.313 mmol), and potassium carbonate (1.30 g, 9.39 mmol) were dissolved in a mixed solution of 1,4-dioxane (10 mL) and water (1 mL). Under nitrogen protection, the reaction mixture was stirred at 90 °C for 16 hours. The solvent was evaporated to dryness, and the crude product was purified by column chromatography (silica gel, ethyl acetate / petroleum ether = 1 / 1) to give 18-h (1.30 g, 98.6% yield, yellow solid). MS m / z (ESI): 463.1 [M+ACN] + .

[0763] Step 7: 3-(2-(dimethylcarbamoyl)-4-(4-(1-(4-(2,6-dioxopiperidin-3-yl)-2-fluorophenyl)piperidin-4-yl)phenyl)-7-fluoro-1H-indole-6-yl)-5,6-dihydropyridine-1(2H)-carboxylic acid tert-butyl ester 18-i

[0764] The starting materials 18-h (150 mg, 0.356 mmol), 13-d (176 mg, 0.356 mmol), (2-dicyclohexylphosphine-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl) (60.3 mg, 0.0712 mmol), and potassium acetate (105 mg, 1.07 mmol) were dissolved in a mixed solution of 1,4-dioxane (3 mL) and water (1 mL). Under nitrogen protection, the reaction mixture was stirred in a microwave oven at 100 °C for 0.33 h. After the reaction was complete, the mixture was extracted multiple times with ethyl acetate (10 mL x 3), and the organic phases were combined. The solvent was evaporated to dryness, and the crude product was purified by column chromatography (silica gel, ethyl acetate / petroleum ether = 2 / 1) to give 18-i (150 mg, yield 56.0%, colorless oil). MS m / z (ESI): 752.6 [M+H] + .

[0765] Step 8: 4-(4-(1-(4-(2,6-dioxopiperidin-3-yl)-2-fluorophenyl)piperidin-4-yl)phenyl)-7-fluoro-N,N-dimethyl-6-(1,2,5,6-tetrahydropyridin-3-yl)-1H-indole-2-carboxamide 18-j

[0766] Add 1,4-dioxane hydrochloride solution (4M, 1.0 mL) to 18-i (150 mg, 0.199 mmol). Stir the resulting mixture at room temperature for 1 hour, then concentrate under reduced pressure to give 18-j (140 mg, crude, yellow oil), which can be used directly without purification. MS m / z (ESI): 652.3 [M+H)+ .

[0767] Step 9: 6-1-(3-(1,3,4-selenoimidazole-2-yl)propionyl)-1,2,5,6-tetrahydropyridin-3-yl)-4-(4-(4-(2,6-dioxopiperidin-3-yl)-2-fluorophenyl)piperidin-4-yl)phenyl)-7-fluoro-N,N-dimethyl-1H-indole-2-carboxamide 18

[0768] At room temperature, 18-j (140 mg, 0.215 mmol), 18-f (250 mg, 1.22 mmol), and N,N,N′,N′-tetramethyl-O-(7-azabenzotriazol-1-yl)hexafluorophosphate urea (328 mg, 0.86 mmol) were dissolved in N,N-dimethylformamide (5 mL), mixed thoroughly, and then N,N-diisopropylethylamine (167 mg, 1.29 mmol) was added in portions. The mixture was stirred at room temperature for 1 hour. After the reaction was complete, water (10 mL) was added, and the mixture was extracted with ethyl acetate (5 mL x 3), washed with saturated brine, and dried over anhydrous sodium sulfate. The solvent was evaporated to dryness, and the crude product was purified by preparative HPLC (prep-HPLC (Waters 2767 / Qda, Column: Boston 30×150mm, 5µm; Mobile Phase A: 0.1% FA / H2O, B: ACN; flow rate: 20ml / min; gradient: 52%–52%; retention time: 9.15–10.0min of 18min) to obtain compound 18 (56.08mg, yield 31.2%, white solid).

[0769] MS m / z (ESI): 840.7 [M+H] + ; 1H NMR (400MHz, DMSO-d6) δ12.19(d,J=6.4Hz,1H),10.82(s,1H),10.19(d,J=6.8Hz,1H),7.63(d,J=8.0Hz,2 H),7.44(d,J=8.0Hz,2H),7.11–6.94(m,4H),6.91–6.82(m,1H),6.18(s,1H),4.39(d,J=16.8Hz,2H),3.82 (dd,J=11.6,4.8Hz,1H),3.73–3.58(m,2H),3.49(d,J=11.1Hz,2H),3.40–3.33(m,3H),3.12(d,J=60.3Hz ,6H),2.99–2.93(m,2H),2.82(t,J=10.8Hz,2H),2.76–2.60(m,2H),2.42–2.17(m,3H),2.06–1.79(m,5H).

[0770] Example 19 6-(1-(3-(1H-1,2,3-triazol-1-yl)propionyl)-1,2,5,6-tetrahydropyridin-3-yl)-4-(2-(4-(4-(2,6-dioxopiperidin-3-yl)-2-fluorophenyl)piperazin-1-yl)benzo[d][1,3]selenozol-6-yl)-7-fluoro-N,N-dimethyl-1H-indole-2-carboxamide 19

[0771] Step 1: 3-(4-bromo-3-fluorophenyl)piperidine-2,6-dione 19-a

[0772] 15-a (10.0 g, 38.31 mmol) and acrylamide (3.26 g, 45.98 mmol) were dissolved in anhydrous N,N-dimethylformamide (150 mL). The mixture was purged with nitrogen three times, and the reaction solution was cooled to 0 °C. Then, potassium tert-butoxide solution (45.98 mL, 45.98 mmol, 1 M) was slowly added dropwise to the reaction mixture, and the reaction was carried out at 0 °C for 1 hour. After the reaction was completed, the reaction solution was quenched with saturated ammonium chloride solution (200 mL), extracted with ethyl acetate (3 x 200 mL), and the organic phases were combined and washed with saturated brine (3 x 100 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The product was purified by rapid column chromatography (50% ethyl acetate / petroleum ether) to give 19-a (5.0 g, yield 45.63%, white solid).

[0773] MS m / z(ESI): 286.0 [M+H] + .

[0774] 1H NMR (400MHz, DMSO-d6) δ10.89(s,1H),7.67(t,J=8.0Hz,1H),7.32(dd,J=10.4,2.0Hz,1H),7.06(dd,J=8.4,2.0Hz, 1H),3.93(dd,J=12.4,4.8Hz,1H),2.76–2.60(m,1H),2.55(t,J=3.6Hz,1H),2.35–2.18(m,1H),2.09–1.94(m,1H).

[0775] Step 2: 6-Chloro-2-(piperazin-1-yl)benzo[d][1,3]selenoazole 19-b

[0776] 9-d (1.0 g, 2.5 mmol) was dissolved in 10 mL, 4 M, 1,4-dioxane-1,4-hydrochloride solution and reacted at room temperature for 4 hours. After the reaction was complete, the reaction solution was concentrated under reduced pressure to give 19-b (500 mg, yield 66.65%, white solid).

[0777] MS m / z(ESI): 302.2 [M+H] + .

[0778] Step 3: 3-(4-(4-(6-chlorobenzo[d][1,3]selenozol-2-yl)piperazin-1-yl)-3-fluorophenyl)piperidine-2,6-dione 19-c

[0779] 19-a (400 mg, 1.33 mmol), 19-b (380 mg, 1.33 mmol), PEPPSI IHept-Cl (129 mg, 0.133 mmol), and cesium carbonate (1.3 g, 3.99 mmol) were dissolved in anhydrous dioxane (10 mL). The reaction mixture was purged with nitrogen three times and reacted at 100 °C for 1 hour. After the reaction was complete, the reaction mixture was diluted with water (10 mL) and extracted with ethyl acetate (3 x 20 mL). The organic phases were combined and washed with saturated brine (10 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by high performance thin-layer chromatography (5% methanol / dichloromethane) to give 19-c (70 mg, yield 10.40%, white solid).

[0780] MS m / z (ESI): 507.3 [M+H] + .

[0781] Step 4: 6-(1-(3-(1H-1,2,3-triazol-1-yl)propionyl)-1,2,5,6-tetrahydropyridin-3-yl)-4-(2-(4-(4-(2,6-dioxopiperidin-3-yl)-2-fluorophenyl)piperazin-1-yl)benzo[d][1,3]selenozol-6-yl)-7-fluoro-N,N-dimethyl-1H-indole-2-carboxamide 19

[0782] 19-C (85 mg, 0.168 mmol) was dissolved in 1,4-dioxane (2 mL) and water (0.4 mL). 15-I (90 mg, 0.168 mmol), methanesulfonic acid (2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)(2'-amino-1,1'-biphenyl-2-yl)palladium(II) (14 mg, 0.0168 mmol), and potassium acetate (49 mg, 0.504 mmol) were added. The mixture was reacted in a microwave at 100 °C for 20 minutes under nitrogen protection. After the reaction was complete, the reaction solution was diluted with water (5 mL), extracted with ethyl acetate (3 x 5 mL), and the organic phases were combined and washed with saturated brine (5 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. Compound 19 (29.55 mg, yield 19.99%, white solid) was isolated and purified by preparative HPLC (prep-HPLC (Waters 2767 / QDA, Column: Boston 30*150mm*5um; Mobile Phase A: 0.1% TFA / H2O, B: ACN; Gradient: 52-52%; Retention Time: 6.2-7.2 min of 18 min) method).

[0783] MS m / z (ESI): 881.4 [M+H] + ,1H NMR(400MHz,DMSO-d6)δ12.19(s,1H),10.83(s,1H),8.24–8.05(m,2H),7.69(d,J =12.0Hz,1H),7.62–7.51(m,2H),7.14–6.97(m,4H),6.91(s,1H),6.17(s,1H),4.7 2–4.54(m,2H),4.46–4.28(m,2H),3.87–3.80(m,1H),3.75(s,4H),3.70–3.58(m, 2H),3.24–2.92(m,13H),2.67–2.61(m,1H),2.36–2.16(m,3H),2.07–1.94(m,1H).

[0784] Example 20 6-(2-(3-(1H-1,2,3-triazol-1-yl)propionyl)-1,2-dihydroisoquinoline-4-yl)-4-(4-(4-(2-(1-(2,6-dioxopyridin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)ethyl)piperazin-1-yl)-2-methoxyphenyl)-7-fluoro-N,N-dimethyl-1H-indole-2-carboxamide 20

[0785] Step 1: 2-Benzyl-4-hydroxyisoquinoline-2-onthium 20-b

[0786] 2-Benzyl-4-hydroxyisoquinoline (40.0 g, 0.278 mol) was dissolved in isopropanol (250 mL), and benzyl bromide (47.1 g, 0.278 mol) was added. The reaction mixture was reacted overnight at 80°C. The reaction solution was evaporated to dryness, slurried with isopropanol (80 mL), and the filter cake was collected. After washing with isopropanol, 20-b (50 g, 76% yield, pale yellow solid) was obtained. MS m / z (ESI): 236.1 [M+H] + .

[0787] Step 2: 2-Benzyl-1,2,3,4-Tetrahydroisoquinoline-4-ol 20-c

[0788] 2-Benzyl-4-hydroxyisoquinoline-2-onium (40 g, 0.169 mol) was dissolved in ethanol (400 mL) and water (400 mL), followed by the addition of sodium borohydride (6.40 g, 1.69 mol) in portions. The reaction was carried out overnight at 25°C. The reaction mixture was quenched with water, concentrated under reduced pressure, and extracted with ethyl acetate (300 mL x 3). The organic phase was collected, washed with water, and concentrated under reduced pressure. The solution was then purified by silica gel column chromatography (10% ethyl acetate / petroleum ether) to give product 24-c (30 g, 74% yield, pale yellow oil). MS m / z (ESI): 240.1 [M+H] + .

[0789] Step 3: 1,2,3,4-Tetrahydroisoquinoline-4-ol 20-d

[0790] 2-Benzyl-1,2,3,4-Tetrahydroisoquinoline-4-ol (30 g, 125 mmol) was dissolved in methanol (300 mL), followed by the addition of palladium on carbon (14.7 g, 13.7 mmol). The reaction was stirred at room temperature under hydrogen atmosphere for 16 hours. After the reaction was complete, the mixture was filtered, and the filtrate was collected and concentrated under reduced pressure to give compound 20-d (17 g, yield: 91%, pale yellow oil). MS m / z (ESI): 150.1 [M+H] + .

[0791] Step 4: 4-Hydroxy-3,4-dihydroisoquinoline-2(1H)-tert-butyl formate 20-e

[0792] 1,2,3,4-Tetrahydroisoquinoline-4-ol (17 g, 114 mmol) and triethylamine (20.8 g, 205 mmol) were dissolved in dichloromethane (200 mL), and Boc₂O (29.8 g, 137 mmol) was slowly added dropwise. The reaction mixture was stirred at 25°C for 1 hour. After the reaction was complete, the reaction mixture was concentrated under reduced pressure, and the concentrate was purified by silica gel column chromatography (5% ethyl acetate / petroleum ether) to give compound 20-e (23 g, yield: 80%, pale yellow oil).

[0793] MS m / z (ESI): 272.1 [M+Na] + Step 5: 20-f tert-butyl 4-oxo-3,4-dihydroisoquinoline-2(1H)-formate

[0794] 23 g (92.3 mmol) of tert-butyl 4-hydroxy-3,4-dihydroisoquinoline-2(1H)-carboxylate was dissolved in dichloromethane (1500 mL), and Dysmartin oxidant (78 g, 185 mmol) was slowly added. The reaction mixture was stirred at 25°C for 8 hours. The reaction mixture was filtered, and the filtrate was washed with water. The organic phase was concentrated under reduced pressure, dissolved in ethyl acetate, filtered, and the filtrate was collected. The filtrate was concentrated under reduced pressure and then purified by silica gel column chromatography (10% ethyl acetate / petroleum ether) to give 20-f (19 g, yield: 83%, pale yellow oil).

[0795] MS m / z (ESI): 270.1 [M+Na] +

[0796] Step 6: 20-g of 4-(((trifluoromethyl)sulfonyl)oxy)isoquinoline-2(1H)-formate tert-butyl ester

[0797] 1.1 g (4.4 mmol) of tert-butyl 4-oxo-3,4-dihydroisoquinoline-2(1H)-carboxylate was dissolved in anhydrous tetrahydrofuran (20 mL). At -78°C, LDA (2 mol / L tetrahydrofuran solution, 4.4 mL, 8.8 mmol) and a THF solution of N-bis(trifluoromethanesulfonyl)aniline (1.73 g, 4.84 mmol) (7 mL) were slowly added. After stirring for 1 hour, the temperature was slowly increased from -78°C to 25°C and stirring continued for 16 hours. LC-MS showed that the starting material disappeared and the target peak was reached. The pH of the reaction mixture was adjusted to 6-8 by adding saturated ammonium chloride solution. After extraction with ethyl acetate, the organic phase was collected, concentrated under reduced pressure, and purified by silica gel column chromatography to obtain 20 g (1.1 g, yield: 65%, pale yellow oil).

[0798] MS m / z(ESI): 324.0 [M+H-56] +

[0799] Step 7: 4-Chloro-7-fluoro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborane-2-yl)-N,N-dimethyl-1H-indole-2-carboxamide 20-i

[0800] 6-Bromo-4-chloro-7-fluoro-N,N-dimethyl-1H-indole-2-carboxamide (900 mg, 2.82 mmol) and diboronpinacol ester (858 mg, 3.38 mmol) were dissolved in 1,4-dioxane solution (15 mL). Potassium acetate (553 mg, 5.63 mmol) and Pd(dppf)Cl2 (206 mg, 0.282 mmol) were added. The reaction solution was stirred at 90°C under nitrogen protection for 2 h. LC-MS showed that the starting material disappeared and the main peak was the target peak. The reaction solution was quenched with water and extracted with ethyl acetate (10 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain crude 20-i (1.5 g, 70% purity), which was used directly in the next step.

[0801] MS m / z (ESI): 367.1 [M+H] +

[0802] Step 8: 4-(4-chloro-2-(dicarbamoyl)-7-fluoro-1H-indol-6-yl)isoquinoline-2(1H)-carboxylic acid tert-butyl ester 20-j

[0803] 4-Chloro-7-fluoro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborane-2-yl)-N,N-dimethyl-1H-indole-2-carboxamide (1.5 g, 2.76 mmol) and tert-butyl 4-(((trifluoromethyl)sulfonyl)oxy)isoquinoline-2(1H)-carboxylate (1.01 g, 2.76 mmol) were dissolved in 1,4-dioxane (15 mL) and water (3 mL). Potassium carbonate (765 mg, 5.53 mmol) and Pd(dppf)Cl2 (203 mg, 0.276 mmol) were added, and the reaction was carried out at 80°C under nitrogen protection for 1 hour. The reaction solution was extracted with ethyl acetate, and the organic phase was collected. The filtrate was concentrated under reduced pressure. The product was purified by silica gel column chromatography (15% ethyl acetate / petroleum ether) to give 20-j (950 mg, 73% yield, yellow solid). MS m / z (ESI): 470.1 [M+H] + ;

[0804] Step 9: 4-(4-chloro-2-(dicarbamoyl)-7-fluoro-1H-indol-6-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylic acid tert-butyl ester 20-k

[0805] 4-(4-chloro-2-(dicarbamoyl)-7-fluoro-1H-indol-6-yl)isoquinoline-2(1H)-carboxylic acid tert-butyl ester (950 mg, 2.02 mmol) was dissolved in tetrahydrofuran (10 mL), and a platinum-carbon catalyst (2.76 g, 1.42 mmol) was added. The reaction was carried out at 25°C and 45 psi under hydrogen atmosphere for 18 hours. The reaction solution was filtered, and the filtrate was concentrated under reduced pressure. The product was purified by silica gel column chromatography (20% ethyl acetate / petroleum ether) to give 20-K (400 mg, yield 41%, yellow solid). MS m / z (ESI): 416.0 [M+H-56] + .

[0806] Step 10: 4-Chloro-7-fluoro-N,N-dimethyl-6-(1,2,3,4-tetrahydroisoquinoline-4-yl)-1H-indole-2-carboxamide 20-l

[0807] 4-(4-chloro-2-(dicarbamoyl)-7-fluoro-1H-indol-6-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylic acid tert-butyl ester (400 mg, 0.848 mmol) was dissolved in a 1,4-dioxane solution of hydrogen chloride (10 mL). The reaction solution was reacted at 25°C for 1 hour. The reaction solution was concentrated under reduced pressure to give 20-l (300 mg, 95% yield, white solid). MS m / z (ESI): 372.1 [M+H] + .

[0808] Step 11: 6-(2-(3-(1H-1,2,3-triazol-1-yl)propamido)-1,2,3,4-tetrahydroisoquinoline-4-yl)-4-chloro-7-fluoro-N,N-dimethyl-1H-indole-2-carboxamide 20-m

[0809] 4-Chloro-7-fluoro-N,N-dimethyl-6-(1,2,3,4-tetrahydroisoquinoline-4-yl)-1H-indole-2-carboxamide (300 mg, 0.807 mmol), 3-(1H-1,2,3-triazol-1-yl)propionic acid (114 mg, 0.807 mmol), and EDCl (186 mg, 0.968 mmol) were dissolved in pyridine (3 mL). The reaction was carried out at 25°C under nitrogen protection for 1 hour. After concentration under reduced pressure, the product was purified by silica gel column chromatography (6% methanol / dichloromethane) to give 20-m (350 mg, 87% yield, yellow solid). MS m / z (ESI): 495.2 [M+H] + .

[0810] Step 12: 4-(4-(6-(2-(3-(1H-1,2,3-triazol-1-yl)propamido)-1,2,3,4-tetrahydroisoquinoline-4-yl)-2-(dicarbamoyl)-7-fluoro-1H-indole-4-yl)-3-methoxyphenyl)piperazine-1-carboxylic acid tert-butyl ester 20-n

[0811] 6-(2-(3-(1H-1,2,3-triazol-1-yl)propamido)-1,2,3,4-tetrahydroisoquinoline-4-yl)-4-chloro-7-fluoro-N,N-dimethyl-1H-indole-2-carboxamide (350 mg, 0.707 mmol) and 4-(3-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborane-2-yl)phenyl)piperazine-1-carboxylic acid tert-butyl ester (296 mg, 0.707 mmol) were dissolved in 1,4-dioxane (3.5 mL) and water (0.7 mL). Potassium phosphate (300 mg, 1.41 mmol) and XPhos Pd G3 (60 mg, 0.0707 mmol) were added, and the reaction was carried out at 90°C under nitrogen protection for 3 hours. The reaction solution was extracted with ethyl acetate, and the organic phase was collected. The filtrate was concentrated under reduced pressure. The product was purified by silica gel column chromatography (7% methanol / dichloromethane) to give 20-n (400 mg, 74% yield, pale yellow solid). MS m / z (ESI): 751.3 [M+H] + ;

[0812] Step 13: 6-(2-(3-(1H-1,2,3-triazol-1-yl)propamido)-1,2,3,4-tetrahydroisoquinoline-4-yl)-7-fluoro-4-(2-methoxy-4-(piperazin-1-yl)phenyl)-N,N-dimethyl-1H-indole-2-carboxamide 20-o

[0813] 4-(4-(6-(2-(3-(1H-1,2,3-triazol-1-yl)propamido)-1,2,3,4-tetrahydroisoquinoline-4-yl)-2-(dicarbamoyl)-7-fluoro-1H-indol-4-yl)-3-methoxyphenyl)piperazine-1-carboxylic acid tert-butyl ester (160 mg, 0.213 mmol) was dissolved in a 1,4-dioxane solution of hydrogen chloride (3 mL). The reaction solution was reacted at 25°C for 1 hour. After concentration under reduced pressure, the reaction solution was used to obtain 20-O hydrochloride (150 mg, 97% yield, white solid). MS m / z (ESI): 651.3 [M+H) + .

[0814] Step 14: 6-(2-(3-(1H-1,2,3-triazol-1-yl)propamido)-1,2,3,4-tetrahydroisoquinoline-4-yl)-4-(4-(4-(2-(1-(2,6-dioxopyridin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzi[d]imidazol-4-yl)ethyl)piperazin-1-yl)-2-methoxyphenyl)-7-fluoro-N,N-dimethyl-1H-indole-2-carboxamide 20

[0815] 20-O (150 mg, 0.207 mmol) was dissolved in methanol (3 mL), and 1-C (125 mg, 0.415 mmol) was added. The reaction mixture was allowed to react at room temperature for 16 hours. Sodium cyanoborohydride (39.1 mg, 0.622 mmol) was then added, and the reaction was allowed to proceed at room temperature for 1 hour. The reaction mixture was quenched with water, extracted with dichloromethane (3 × 10 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The formate salt of compound 20 (13.45 mg, yield 5.8%, white solid) was purified by preparative HPLC (prep-HPLC (Column: Sunfire-C18, 19*150 mm, 5 μm; Mobile Phase A: 0.1% FA / H2O, B: ACN; flow rate: 20 mL / min; gradient: 5%-60%).

[0816] MS m / z (ESI): 936.3 [M+H] + .

[0817] 1H NMR(400MHz,DMSO-d6)δ11.97–11.93(m,1H),11.09(s,1H),8.03(s,0.5H),7.65 (s,0.5H),7.61(s,0.5H),7.56(s,0.5H),7.32–7.27(m,1H),7.26–7.21(m,1.5H) ,7.18–7.13(m,1H),7.01–6.96(m,3H),6.96–6.92(m,1H),6.60(s,1H),6.56–6. 52(m,1H),6.50–6.47(m,1H),6.43–6.40(m,0.5H),6.33–6.27(m,1H),5.41–5.34 (m,1.5H),5.01–4.94(m,1H),4.84–4.78(m,1H),4.73–4.67(m,1H),4.65(s,0.5 H),4.61–4.55(m,1.5H),4.52–4.42(m,1.5H),4.28–4.19(m,1.5H),4.07–4.01(m ,1H),3.98–3.83(m,3H),3.64–3.59(m,5H),3.24–3.19(m,4H),3.15–3.08(m,4H ),2.98–2.84(m,3H),2.68–2.62(m,6H),2.30–2.24(m,1H),2.04–1.97(m,1.5H).

[0818] The examples in the table were synthesized using synthetic routes similar to those in Examples 1 to 20, and with appropriate starting materials and catalysts.

[0819] Example 26 1'-(3-(1H-1,2,3-triazol-1-yl)propionyl)-8-(4-(1-(4-(2,6-dioxopiperidin-3-yl)-2-fluorophenyl)piperidin-4-yl)phenyl)-N,N-dimethyl-2H,5H-spiro[furano[2,3-f]indole-3,3'-piperidin]-6-carboxamide 26

[0820] Step 1: 6-Bromo-4-chloro-7-fluoro-1-(4-methoxybenzyl)-N,N-dimethyl-1H-indole-2-carboxamide 26-a

[0821] Potassium hydroxide (1.31 g, 23.4 mmol) was added to a solution of 6-a (5.0 g, 15.6 mmol) in dimethyl sulfoxide (50 mL), and the reaction mixture was stirred for half an hour. Then, 4-methoxybenzyl chloride (3.66 g, 23.4 mmol) was added, and the mixture was slowly heated to room temperature with stirring for 16 hours. After the reaction was complete, water (200 mL) was added, and the mixture was extracted with ethyl acetate (3 × 50 mL). The organic phase was washed with saturated brine (40 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 1) to give compound 26-a (6.7 g, yield: 87.82%, yellow solid). MS m / z (ESI): 463.0 [M + Na] + .

[0822] 1H NMR (400MHz, DMSO-d6) δ7.46 (d, J = 5.0 Hz, 1H), 7.00 (d, J = 8.6 Hz, 2H), 6.85 (m, 3H), 5.45 (s, 2H), 3.70 (s, 3H), 2.99 (s, 3H), 2.86 (s, 3H).

[0823] Step 2: 4-Chloro-7-fluoro-1-(4-methoxybenzyl)-N,N-dimethyl-6-((trimethylsilyl)ethynyl)-1H-indole-2-carboxamide 26-b

[0824] 26-a (3.0 g, 6.8 mmol) was dissolved in triethylamine (30 mL), and trimethylsilylacetylene (3.34 g, 34 mmol), cuprous iodide (260 mg, 1.36 mmol), and palladium dichloride bis(triphenylphosphine) (480 mg, 0.68 mmol) were added. The reaction was carried out under nitrogen protection at 75 °C with stirring for 6 hours. The crude product was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 4 / 1) to give compound 26-b (3.32 g, yield: 95.5%, yellow solid). MS m / z (ESI): 457.2 [M+H]+.

[0825] 1H NMR (400MHz, DMSO-d6) δ7.23(d,J=5.0Hz,1H),6.98(d,J=8.7Hz,2H),6.85(m,3H),5.46(s,2H),3.70(s,3H),2.99(s,3H),2.86(s,3H),0.24(s,9H).

[0826] Step 3: 4-Chloro-6-ethynyl-7-fluoro-1-(4-methoxybenzyl)-N,N-dimethyl-1H-indole-2-carboxamide 26-c

[0827] 26-b (3.32 g, 7.3 mmol) was dissolved in tetrahydrofuran (30 mL), and a tetrahydrofuran solution of tetrabutylammonium fluoride (11 mL, 1 mol / L) was added. The reaction was stirred at room temperature for 16 hours. The crude product was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 2 / 1) to give compound TM29-2 (2.67 g, yield: 84.9%, yellow solid). MS m / z (ESI): 385.2 [M+H] + .

[0828] 1 H NMR(400MHz,DMSO-d6)δ7.27(d,J=4.9Hz,1H),7.01(d,J=8.6Hz,2H),6.88–6 .83(m,3H),5.46(s,2H),4.54(s,1H),3.70(s,3H),3.00(s,3H),2.86(s,3H).

[0829] Step 4: (Z)-6-(2-bromo-1-fluorovinyl)-4-chloro-7-fluoro-1-(4-methoxybenzyl)-N,N-dimethyl-1H-indole-2-carboxamide 26-d

[0830] 26-c (700 mg, 1.82 mmol) was added to a microwave-safe tube, followed by acetonitrile (12 mL) and water (0.6 mL), then silver fluoride (1.6 g, 12.7 mmol) and N-bromosuccinimide (356 mg, 2.0 mmol). The tube was sealed under nitrogen protection, and the reaction was stirred at 80°C for 16 hours. After the reaction was complete, the mixture was filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 3 / 1) to give compound 26-d (400 mg, yield: 51.1%, yellow solid). MS m / z (ESI): 504.9 [M + Na] + .

[0831] 1 H NMR (400MHz, CDCl3) δ7.25(d,J=5.2Hz,1H),7.03(d,J=8.8Hz,2H),6.81-6.73(m,2H),6.67(d ,J=2.0Hz,1H),6.32(d,J=28.8Hz,1H),5.58(s,2H),3.76(s,3H),3.03(br,3H),2.79(br,3H).

[0832] Step 5: ((Z)-4-chloro-7-fluoro-6-(1-fluoro-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborane-2-yl)vinyl)-1-(4-methoxybenzyl)-N,N-dimethyl-1H-indole-2-carboxamide 26-e

[0833] 26-d (230 mg, 0.48 mmol), pinacol diborate (145 mg, 0.57 mmol), and potassium acetate (93 mg, 0.95 mmol) were added to 1,4-dioxane (6 mL), followed by 1,1-bis(diphenylphosphine)dimerferropalladium dichloride (35 mg, 0.05 mmol). The reaction mixture was stirred at 80 °C for 1.5 hours under nitrogen protection. After the reaction was complete, a crude 1,4-dioxane solution of compound 26-e was obtained, which could be used directly in the next reaction without purification. MS m / z (ESI): 531.2 [M+H] + .

[0834] Step 6: 26 g of 3-bromo-1-(hydroxymethyl)pyridin-2(1H)-one

[0835] 26-F (5 g, 28.7 mmol) was dissolved in 1,4-dioxane (50 mL), and paraformaldehyde (0.88 g, 29.3 mmol) was added. The mixture was stirred at 100°C for 30 minutes under nitrogen protection. After the reaction was complete, a solution of crude compound 26-g in 1,4-dioxane was obtained. This solution could be used directly in the next step without purification.

[0836] 1 H NMR (400MHz, CDCl3) δ7.80 (dd, J = 7.6Hz, 2.0Hz, 1H), 7.66 (dd, J = 6.8Hz, 1.6Hz, 1H), 6.18 (t, J = 7.2Hz, 1H), 5.43 (s, 2H).

[0837] Step 7: 3-Bromo-1-(chloromethyl)pyridin-2(1H)-one 26-h

[0838] A 26-g (crude, 28.7 mmol) solution of 1,4-dioxane (50 mL) was cooled to 0°C, and thionyl chloride (376 mg, 3.16 mmol) was slowly added under nitrogen protection. The reaction mixture was stirred at room temperature for 4 hours. After the reaction was complete, the solution was concentrated under reduced pressure to give crude compound 26-h (pale yellow solid). MS m / z (ESI): 222.0 [M+H] + .

[0839] 1H NMR (400MHz, CDCl3) δ7.93 (d, J=7.2Hz, 1H), 7.38 (dd, J=7.2Hz, 2.0Hz, 1H), 6.16 (t, J=7.2Hz, 1H), 5.71 (s, 2H).

[0840] Step 8: 1-((1H-1,2,3-triazol-1-yl)methyl)-3-bromopyridin-2(1H)-one 26-i

[0841] 26-h (3 g, 13.5 mmol) was dissolved in tetrahydrofuran (50 mL), and 18-crown-6 (3.6 g, 13.5 mmol) and 1,2,3-1H-triazole (0.93 g, 13.5 mmol) were added. A tetrahydrofuran solution of 1N potassium tert-butoxide (27 mL, 27.0 mmol) was slowly added, and the reaction was stirred at room temperature for 16 hours. After the reaction was complete, the mixture was washed with saturated brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the crude product was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 3) to give compound 26-i (0.7 g, yellow solid). MS m / z (ESI): 255.0 [M+H] + .

[0842] 1 H NMR (400MHz, CDCl3) δ8.11(d,J=0.8Hz,1H),7.77(dd,J=7.2Hz,2.0Hz,1H),7.73(d ,J=0.8Hz,1H),7.67(dd,J=6.8Hz,2.0Hz,1H),6.43(s,2H),6.17(t,J=7.2Hz,1H).

[0843] Step 9: 5-(benzyloxy)-4-chloro-6-iodo-N,N-dimethyl-1H-indole-2-carboxamide 26-j

[0844] 26-i (130 mg, 0.51 mmol) was added to a 1,4-dioxane solution (6 mL) of 26-e (crude, 0.48 mmol), followed by water (0.6 mL) and potassium carbonate (141 mg, 1.02 mmol), and then 1,1-bis(diphenylphosphine)dimerferropalladium dichloride (37 mg, 0.05 mmol). The mixture was stirred at 80°C for 2 hours. After the reaction was complete, the mixture was concentrated under reduced pressure, and the crude product was purified by silica gel column chromatography (to pure ethyl acetate) to give compound 26-j (100 mg, yield: 33.9%, yellow solid). MS m / z (ESI): 455.0 [M+H] + .

[0845] 1H NMR (400MHz, CDCl3) δ9.50 (br, 1H), 7.84 (d, J = 0.8Hz, 1H), 7.67 (d, J = 6.8Hz, 2 H),7.45-7.37(m,3H),6.89(d,J=1.2Hz,1H),5.04(s,2H),3.37-3.31(m,6H).

[0846] Step 10: (Z)-6-(2-(1-(1H-1,2,3-triazol-1-yl)methyl)-2-oxo-1,2-dihydropyridin-3-yl)-1-fluorovinyl)-4-chloro-7-fluoro-N,N-dimethyl-1H-indole-2-carboxamide 26-k

[0847] 26-J (280 mg, 0.48 mmol) was dissolved in trifluoroacetic acid (5 mL), and the reaction mixture was stirred at room temperature for 16 hours. LC-MS analysis showed that there was residual starting material. The reaction mixture was concentrated under reduced pressure and subjected to rapid reversed-phase column chromatography to obtain compound 26-K (70 mg, yield: 31.6%, yellow solid). MS m / z (ESI): 459.1 [M+H] + .

[0848] 1 H NMR (400MHz, CDCl3) δ10.19(br,1H),8.25(d,J=0.8Hz,1H),8.12(d,J=7.2Hz,1H),7.84(d,J=0.8Hz,1H),7.61(dd,J=6.8Hz,1.6Hz,1H) ,7.35(d,J=5.2Hz,1H),6.96(t,J=2.4Hz,1H).6.89(d,J=41.2Hz,1H),6.49(s,2H),6.45(t,J=7.2Hz,1H),3.52(br,3H),3.25(br,3H).

[0849] Step 11: 4-(4-(1-(4-(2,6-dioxopiperidin-3-yl)-2-fluorophenyl)piperidin-4-yl)phenyl)-7-fluoro-6-((Z)-1-fluoro-2-(2-oxo-1-((Z)-3-vinyltriazine-2-en-1-yl)methyl)-1,2-dihydropyridin-3-yl)vinyl)-N,N-dimethyl-1H-indole-2-carboxamide 26

[0850] 26-K (50 mg, 0.109 mmol) was added to a sealed tube containing 2 mL of 1,4-dioxane solution (64 mg, 0.131 mmol), followed by water (0.1 mL) and cesium fluoride (33 mg, 0.218 mmol), and then XPhos Pd G3 (18 mg, 0.022 mmol). The mixture was stirred at 90°C for 2 hours. After the reaction was complete, the mixture was concentrated under reduced pressure, and the crude product was purified by silica gel column chromatography (ethyl acetate / methanol = 100 / 1). The crude product was then purified by pre-HPLC to obtain 26 (10 mg, yield 11.7%, yellow solid). MS m / z (ESI): 789-.4 [M+H] + .

[0851] 1 H NMR (400MHz, DMSO-d6) δ12.52(s,1H),10.82(s,1H),8.31(s,1H),7.96(d,J=6.8Hz,1H),7 .78(s,1H),7.64(d,J=8.0Hz,2H),7.46(d,J=8.4Hz,2H),7.26(d,J=6.0Hz,1H),7.08-6.81 (m,5H),6.55(s,2H),6.47(t,J=6.8Hz,1H),3.82(dd,J=11.6Hz,5.2Hz,2H),3.51-3.48(m, 2H),3.21(br,3H),3.07(br,3H),2.85-2.51(m,5H),3.33-2.20(m,1H),2.03-1.87(m,5H).

[0852] Example 27 6-(1-(3-(1H-1,2,3-triazol-1-yl)propamido)-5-(difluoromethylene)-1,2,5,6-tetrahydropyridin-3-yl)-4-(4-(1-(4-(2,6-dioxopiperidin-3-yl)-2-fluorophenyl)piperidin-4-yl)phenyl)-7-fluoro-N,N-dimethyl-1H-indole-2-carboxamide 27

[0853] Step 1: Methyl 4-(4-(4-bromophenyl)piperidin-1-yl)-3-fluorobenzoate 27-c

[0854] 27-a (8.6 g, 5.0 mmol) was dissolved in DMF (100 mL), and 27-b (12.0 g, 5.0 mmol) and potassium carbonate (13.8 g, 10.0 mmol) were added. The reaction mixture was reacted at 80°C under nitrogen protection for 16 hours. The reaction solution was cooled to room temperature and poured into 500 mL of water, resulting in the precipitation of a yellow solid. The solid was filtered and dried under vacuum to give 27-c (18.0 g, 92% yield, yellow solid). MS m / z (ESI): 392.0 [M+H] + .

[0855] Step 2: (4-(4-(4-bromophenyl)piperidin-1-yl)-3-fluorophenyl)methanol 27-d

[0856] 27-c (18.0 g, 45.9 mmol) was dissolved in ethanol (300 mL), and calcium chloride (10.2 g, 91.8 mmol) and sodium borohydride (17.4 g, 459 mmol) were added. The reaction was carried out at room temperature for 16 hours. The reaction solution was quenched with water (400 mL). Extraction was performed with ethyl acetate (4 x 300 mL), the organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to give 27-d (12.0 g, 72% yield, white solid). MS m / z (ESI): 364.0 [M+H] + .

[0857] Step 3: 2-(4-(4-(4-bromophenyl)piperidin-1-yl)-3-fluorophenyl)acetonitrile 27-e

[0858] 27-d (2.0 g, 5.50 mmol) was dissolved in dichloromethane (60 mL), and boron trifluoride diethyl ether (3.0 g, 21.2 mmol) was added. TMSCN (4.0 g, 40.32 mmol) was added dropwise at 0°C, and the reaction was carried out under nitrogen protection for 1 hour. The reaction was quenched with aqueous sodium bicarbonate solution. Extraction was performed with ethyl acetate (2 x 100 mL), the organic phase was dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography (0–10% ethyl acetate / petroleum ether) to give 27-e (1.6 g, 78% yield, white solid). MS m / z (ESI): 375.0 [M+H] + .

[0859] Step 4: 4-(4-(4-bromophenyl)piperidin-1-yl)-3-fluorophenyl)-4-cyanobutyrate tert-butyl ester 27-f

[0860] 27-e (1.6 g, 4.290 mmol) was dissolved in toluene (40 mL), and tert-butyl acrylate (500 mg, 3.9 mmol), triethylbenzyl ammonium chloride (977 mg, 4.29 mmol), and cesium carbonate (1.39 g, 4.29 mmol) were added. The reaction was carried out at 80°C under nitrogen protection for 3 hours. The reaction solution was cooled to room temperature, concentrated to dryness, and purified by silica gel column chromatography (0–10% ethyl acetate / petroleum ether) to give 27-f (700 mg, yield 32.7%, yellow solid). MS m / z (ESI): 501.1 [M+H] + .

[0861] Step 5: 27 g of 3-(4-(4-(bromophenyl)piperidin-1-yl)-3-fluorophenyl)piperidin-2,6-dione

[0862] 27-f (700 mg, 1.40 mmol) was dissolved in acetic acid (7 mL), and concentrated sulfuric acid (0.3 mL) was added. The reaction mixture was reacted at 80 °C under nitrogen protection for 16 hours. The reaction solution was cooled to room temperature, and water (50 mL) was added, resulting in the precipitation of a white solid. The solid was filtered and dried under vacuum to obtain 27-g (200 mg, yield 32%, white solid). MS m / z (ESI): 445.1 [M+H] + .

[0863] Step 6: 3-O-5-(((trifluoromethyl)sulfonyl)oxy)-3,6-dihydropyridine-1(2H)formate tert-butyl ester 27-i

[0864] 3,5-Dioxopiperidin-1-carboxylic acid tert-butyl ester (2.00 g, 9.40 mmol) and 2,6-dimethylpyridine (2.01 g, 18.8 mmol) were dissolved in dichloromethane (40 mL). Trifluoromethanesulfonic anhydride (2.12 g, 7.52 mmol) was added at 0°C, followed by slow heating to 25°C and reaction for 2 hours. The reaction solution was washed with 1 M hydrochloric acid, and the aqueous phase was extracted with dichloromethane. The combined organic phases were washed with saturated brine and concentrated to dryness. Purification by silica gel column chromatography (7% ethyl acetate / petroleum ether) gave product 27-i (2.1 g, 64% yield, white solid). MS m / z (ESI): 290.0 [M+H-56] + .

[0865] Step 7: 3-Oxo-5-((3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methylenebenzo[d][1,3,2]dioxoboronyl-2-yl)-3,6-dihydropyridine-1(2H)formate tert-butyl ester 27-k

[0866] 27-i and bis[(-)pinenediol]diboron ester (5.19 g, 14.5 mmol) were dissolved in 1,4-dioxane solution (30 mL), and potassium acetate (1.42 g, 14.5 mmol) and Pd(dppf)Cl2 (420 mg, 0.580 mmol) were added. The reaction mixture was stirred at 90 °C under nitrogen protection for 1 h. LC-MS showed that the starting material disappeared and the main peak was the target peak. The reaction mixture was quenched with water, extracted with ethyl acetate (3 x 10 mL), and the organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and evaporated to dryness. Purification by silica gel column chromatography (7% ethyl acetate / petroleum ether) gave the product 27-k (1.3 g, 60% yield). MS m / z (ESI): 398.2 [M+Na] + .

[0867] Step 8: 5-(4-chloro-2-(dimethylcarbamoyl)-7-fluoro-1-(4-methoxybenzyl)-1H-indol-6-yl)-3-oxo-3,6-dihydropyridine-1(2H)-carboxylic acid tert-butyl ester 27-l

[0868] 27-K (1.3 g, 3.50 mmol) and 26-A (1.39 g, 3.15 mmol) were dissolved in 1,4-dioxane (10 mL) and water (2 mL). Potassium carbonate (970 mg, 7.00 mmol) and Pd(dppf)Cl2 (260 mg, 0.350 mmol) were added, and the reaction was carried out at 60°C under nitrogen protection for 1 hour. The reaction solution was extracted with ethyl acetate, and the organic phase was collected. The filtrate was concentrated under reduced pressure. The product was purified by silica gel column chromatography (15% ethyl acetate / petroleum ether) to give 27-L (1.2 g, 62% yield, orange-yellow solid). MS m / z (ESI): 578.2 [M+Na] + .

[0869] Step 9: 5-(4-chloro-2-(dimethylcarbamoyl)-7-fluoro-1-(4-methoxybenzyl)-1H-indol-6-yl)-3-(difluoromethylene)-3,6-dihydropyridine-1(2H)-formate tert-butyl ester 27-n

[0870] 27-l (600 mg, 1.08 mmol) and difluoromethyl (2-pyridyl) sulfone (250 mg, 1.29 mmol) were dissolved in DMF (6 mL). A solution of potassium tert-butoxide in tetrahydrofuran (1 mol / L, 2.16 mL, 2.16 mmol) was slowly added dropwise at -60°C. The reaction mixture was stirred at -60°C for 1 hour, then slowly heated to 25°C and stirred for another hour. After the reaction was complete, a saturated ammonium chloride solution was added to quench the reaction, followed by extraction with dichloromethane (3 x 50 mL). The combined organic phases were washed with saturated brine and concentrated under reduced pressure. The concentrate was purified by silica gel column chromatography (20% ethyl acetate / petroleum ether) to give compound 27-n (300 mg, yield: 47%, pale yellow oil).

[0871] MS m / z (ESI): 612.2 [M+Na] +

[0872] Step 10: 4-Chloro-6-(5-(difluoromethylene)-1,2,5,6-tetrahydropyridin-3-yl)-7-fluoro-N,N-dimethyl-1H-indole-2-carboxamide 27-o

[0873] 27-n (300 mg, 0.508 mmol) was dissolved in dichloromethane (3 mL), and trifluoroacetic acid (1.39 g, 12.2 mmol) and trifluoromethanesulfonic acid (458 mg, 3.05 mmol) were added. The reaction solution was stirred at 25°C under nitrogen protection for 1 hour. After purging with nitrogen, crude 27-o (300 mg) was obtained. MS m / z (ESI): 370.1 [M+H] + .

[0874] Step 11: 6-(1-(3-(1H-1,2,3-triazol-1-yl)propamido)-5-(difluoromethylene)-1,2,5,6-tetrahydropyridin-3-yl)-4-chloro-7-fluoro-N,N-dimethyl-1H-indole-2-carboxamide 27-p

[0875] 27-O and 2-A (89 mg, 0.633 mmol) and DIPEA (629 mg, 4.87 mmol) were dissolved in dichloromethane (3 mL), and HATU (370 mg, 0.974 mmol) was added. The reaction mixture was stirred at 25°C under nitrogen protection for 1 hour. After the reaction was complete, the pH was adjusted to 7 with citric acid, and the mixture was extracted with dichloromethane (3 x 15 mL). The organic phases were combined and washed with saturated brine. After concentration under reduced pressure, the product was purified by silica gel column chromatography (6% methanol / dichloromethane) to give 27-P (240 mg, 100% yield, yellow oil). MS m / z (ESI): 493.1 [M+H] + .

[0876] Step 12: 6-(1-(3-(1H-1,2,3-triazol-1-yl)propamido)-5-(difluoromethylene)-1,2,5,6-tetrahydropyridin-3-yl)-7-fluoro-N,N-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxoborhecyclopentan-2-yl)-1H-indole-2-carboxamide 27-r

[0877] 27-p (240 mg, 0.487 mmol) and dipinoxane diboronate (309 mg, 1.22 mmol) were dissolved in 3 mL of 1,4-dioxane solution. Potassium acetate (119 mg, 1.22 mmol) and XPhos Pd G3 (41 mg, 0.0487 mmol) were added. The reaction mixture was stirred at 90°C under nitrogen protection for 1 h. LC-MS showed that the starting material disappeared, and the main peak was the target peak. The reaction mixture was concentrated and evaporated to dryness, then purified by silica gel column chromatography (7% methanol / dichloromethane) to give 27-p (220 mg, yield 77%). MS m / z (ESI): 585.3 [M+H] + .

[0878] Step 13: 6-(1-(3-(1H-1,2,3-triazol-1-yl)propamido)-5-(difluoromethylene)-1,2,5,6-tetrahydropyridin-3-yl)-4-(4-(1-(4-(2,6-dioxopiperidin-3-yl)-2-fluorophenyl)piperidin-4-yl)phenyl)-7-fluoro-N,N-dimethyl-1H-indole-2-carboxamide 27

[0879] 27-p (80.0 mg, 0.137 mmol) and 27-g (61.0 mg, 0.137 mmol) were dissolved in 1,4-dioxane (1 mL) and water (0.05 mL). Cesium fluoride (62.4 mg, 0.411 mmol) and XPhos Pd G3 (11.6 mg, 0.0137 mmol) were added, and the reaction was carried out at 90 °C under nitrogen protection for 1 hour. The reaction solution was quenched with water, extracted with dichloromethane (3 × 10 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. Compound 27 (4.58 mg, yield 4.0%, yellow solid) was isolated and purified by preparative HPLC (prep-HPLC (Column: Welch-C18, 21.2*250 mm, 10 μm; Mobile Phase A: 0.1% FA / H2O, B: ACN; flow rate: 20 ml / min; gradient: 25%-80%).

[0880] MS m / z (ESI): 823.3 [M+H] +;

[0881] 1 H NMR (400MHz, DMSO-d6) δ12.31–12.24(m,1H),10.82(s,1H),8.10(d,J=9.6Hz,1H),7.72–7.62(m,3H),7.45(d, J=8.0Hz,2H),7.17–7.08(m,1H),7.08–7.05(m,1H),7.05–7.01(m,1H),7.00–6.96(m,1H),6.88(s,1H),6.64–6 .60(m,1H),4.65–4.59(m,2H),4.59–4.51(m,2H),4.37–4.28(m,2H),3.84–3.79(m,1H),3.52–3.46(m,2H),3.2 1–3.12(m,5H),3.10–3.02(m,3H),2.86–2.78(m,3H),2.25–2.17(m,2H),2.05–1.98(m,2H),1.95–1.86(m,4H).

[0882] Example 28 6-((R)-1-(3-(1H-1,2,3-triazol-1-yl)propionyl)-5-(difluoromethylene)piperidin-3-yl)-4-(4-(1-(2-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)ethyl)piperidin-4-yl)phenyl)-7-fluoro-N,N-dimethyl-1H-indole-2-carboxamide 28

[0883] Step 1: 6-Bromo-4-chloro-7-fluoro-N,N-dimethyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indole-2-carboxamide 28-a

[0884] 6-a (8 g, 25.03 mmol) was dissolved in tetrahydrofuran (160 mL), and sodium hydride (60% dispersed in mineral oil) (2.00 g, 50.07 mmol) was added at 0 °C. The reaction was carried out under nitrogen protection at 0 °C for 0.5 h. Then, 2-(trimethylsilyl)ethoxymethyl chloride (5.01 g, 30.04 mmol) was added, and the reaction was carried out under nitrogen protection at room temperature for 1 h. The reaction solution was quenched with saturated ammonium chloride aqueous solution, extracted with ethyl acetate, and the organic phase was concentrated. The product was purified by rapid column chromatography (15%-20% ethyl acetate / petroleum ether) to give 28-a (7.35 g, yield 65.3%, yellow solid). MS m / z (ESI): 421.1 [M-28+H] + .

[0885] Step 2: 4-Chloro-7-fluoro-N,N-dimethyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxoboran-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indole-2-carboxamide 28-b

[0886] 28-a (7.35 g, 16.34 mmol) was dissolved in 1,4-dioxane (100 mL), and pinacol diboronate (6.22 g, 24.51 mmol), [1,1'-bis(diphenylphosphine)ferrocene]palladium(II) dichloride (1.20 g, 1.63 mmol), and potassium acetate (4.81 g, 49.02 mmol) were added. The reaction mixture was reacted overnight under nitrogen protection at 100 °C. The reaction solution was filtered, and the filtrate was concentrated. The product was purified by rapid column chromatography (20% ethyl acetate / petroleum ether) to give 28-b (6.91 g, yield 85.1%, green oily liquid). MS m / z (ESI): 497.3 [M+H] + .

[0887] Step 3: 5-(4-chloro-2-(dimethylcarbamoyl)-7-fluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indol-6-yl)-3-oxo-3,6-dihydropyridine-1(2H)-carboxylic acid tert-butyl ester 28-c

[0888] 28-b (6.91 g, 13.91 mmol) was dissolved in tetrahydrofuran (70 mL), and 27-i (7.20 g, 20.86 mmol), bis(triphenylphosphine) palladium dichloride (976 mg, 1.39 mmol), potassium carbonate (5.77 g, 41.72 mmol), and water (7 mL) were added. The reaction mixture was reacted at 60°C under nitrogen protection for 1 hour. The reaction solution was diluted with water, extracted with ethyl acetate, and the organic phase was concentrated. The product was purified by rapid column chromatography (30% ethyl acetate / petroleum ether) to give 28-c (6.2 g, yield 78.8%, yellow oily liquid). MS m / z (ESI): 588.1 [M+Na] + .

[0889] Step 4: 5-(4-chloro-2-(dimethylcarbamoyl)-7-fluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indol-6-yl)-3-hydroxy-3,6-dihydropyridine-1(2H)-carboxylic acid tert-butyl ester 28-d

[0890] 28-c (6.2 g, 10.95 mmol) was dissolved in methanol (200 mL), and cerium(III) chloride heptahydrate (4.08 g, 10.95 mmol) and sodium borohydride (1.04 g, 27.38 mmol) were added at 0°C. The reaction mixture was reacted at 0°C for 2 hours. The reaction solution was diluted with water, extracted with ethyl acetate, and the organic phase was concentrated. The product was purified by rapid column chromatography (35% ethyl acetate / petroleum ether) to give 28-d (4.5 g, yield 72.3%, yellow solid). MS m / z (ESI): 590.1 [M+Na] + .

[0891] Step 5: 4-Chloro-7-fluoro-6-(5-hydroxy-1,2,5,6-tetrahydropyridin-3-yl)-N,N-dimethyl-1H-indole-2-carboxamide 28-e

[0892] 28-d (5 g, 8.80 mmol) was dissolved in dichloromethane (48 mL), and trifluoroacetic acid (12 mL) was added. The reaction mixture was reacted at room temperature for 0.5 h. The reaction solution was concentrated, and potassium carbonate (5 g) and methanol (50 mL) were added. The reaction mixture was reacted at room temperature for 0.5 h. The reaction solution was diluted with dichloromethane / methanol (15:1) (200 mL), filtered, and the filtrate was concentrated to give 28-e (3.0 g, crude product, yellow solid). MS m / z (ESI): 338.0 [M+H] + .

[0893] Step 6: 6-(1-(3-(1H-1,2,3-triazol-1-yl)propionyl)-5-hydroxy-1,2,5,6-tetrahydropyridin-3-yl)-4-chloro-7-fluoro-N,N-dimethyl-1H-indole-2-carboxamide 28-f

[0894] 28-e (2.95 g, 8.73 mmol) was dissolved in dichloromethane (60 mL) and N,N-dimethylformamide (60 mL), and 2-a (1.36 g, 9.61 mmol), 2-(7-azobenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate (4.98 g, 13.10 mmol), and N,N-diisopropylethylamine (3.39 g, 26.20 mmol) were added. The reaction mixture was reacted at room temperature for 2 hours. The reaction solution was diluted with water, extracted with ethyl acetate, and the organic phase was concentrated. The product was purified by rapid column chromatography (9% methanol / dichloromethane) to give 28-f (1.2 g, yield 29.8%, yellow solid). MS m / z (ESI): 461.0 [M+H] + .

[0895] Step 7: 4-(4-(6-(1-(3-(1H-1,2,3-triazol-1-yl)propionyl)-5-hydroxy-1,2,5,6-tetrahydropyridin-3-yl)-2-(dimethylcarbamoyl)-7-fluoro-1H-indole-4-yl)phenyl)piperidin-1-carboxylic acid tert-butyl ester 28-h

[0896] 28-f (1.2 g, 2.60 mmol) was dissolved in 1,4-dioxane (20 mL), and 28-f (3.03 g, 7.81 mmol), methanesulfonic acid (2-dicyclohexylphosphine-2',4',6'-triisopropyl-1,1'-biphenyl)(2'-amino-1,1'-biphenyl-2-yl)palladium(II) (441 mg, 0.52 mmol), potassium phosphate (1.66 g, 7.81 mmol), and water (6 mL) were added. The reaction mixture was reacted at 80°C under nitrogen protection for 3 hours. The reaction solution was diluted with water, extracted with ethyl acetate, and the organic phase was concentrated. The product was purified by rapid column chromatography (6% methanol / dichloromethane) to give 28-h (1.02 g, yield 57.1%, yellow solid). MS m / z (ESI): 686.3 [M+H] + .

[0897] Step 8: 4-(4-(6-(1-(3-(1H-1,2,3-triazol-1-yl)propionyl)-5-hydroxypiperidin-3-yl)-2-(dimethylcarbamoyl)-7-fluoro-1H-indole-4-yl)phenyl)piperidin-1-carboxylic acid tert-butyl ester 28-i

[0898] 28-h (500 mg, 0.73 mmol) was dissolved in methanol (25 mL), and dry palladium on carbon (10%) (500 mg) was added. The reaction mixture was reacted overnight at room temperature under hydrogen atmosphere. The reaction solution was filtered, the filtrate was concentrated, and the product was purified by rapid column chromatography (5% methanol / dichloromethane) to give 28-i (275 mg, yield 54.9%, white solid). MS m / z (ESI): 688.3 [M+H] + .

[0899] Step 9: 4-(4-(6-(1-(3-(1H-1,2,3-triazol-1-yl)propionyl)-5-oxopiperidin-3-yl)-2-(dimethylcarbamoyl)-7-fluoro-1H-indole-4-yl)phenyl)piperidin-1-carboxylic acid tert-butyl ester 28-j

[0900] 28-i (275 mg, 0.40 mmol) was dissolved in dichloromethane (5 mL), and Dysmartin oxidant (220 mg, 0.52 mmol) was added at 0 °C. The reaction mixture was reacted at room temperature for 1 hour. The reaction solution was quenched with saturated sodium thiosulfate aqueous solution, followed by saturated sodium bicarbonate aqueous solution. The mixture was extracted with dichloromethane, the organic phase was concentrated, and the product was purified by rapid column chromatography (5% methanol / dichloromethane) to give 28-j (260 mg, yield 94.9%, yellow solid). MS m / z (ESI): 686.3 [M+H] + .

[0901] Step 10: 4-(4-(6-(1-(3-(1H-1,2,3-triazol-1-yl)propionyl)-5-(difluoromethylene)piperidin-3-yl)-2-(dimethylcarbamoyl)-7-fluoro-1H-indole-4-yl)phenyl)piperidin-1-carboxylic acid tert-butyl ester 28-k

[0902] 28-J (230 mg, 0.34 mmol) and difluoromethyl (2-pyridyl) sulfone (130 mg, 0.67 mmol) were dissolved in N,N-dimethylformamide (2.3 mL), and potassium tert-butoxide (1 M tetrahydrofuran solution) (1.0 mL, 1.01 mmol) was added at -50 °C. The reaction mixture was reacted for 2 hours at room temperature under nitrogen protection. The reaction solution was diluted with water, extracted with ethyl acetate, and the organic phase was concentrated. The product was purified by rapid column chromatography (6% methanol / dichloromethane) to give 28-K (70 mg, yield 29.0%, yellow solid). MS m / z (ESI): 720.3 [M+H] + .

[0903] Step 11: (R)-6-(1-(3-(1H-1,2,3-triazol-1-yl)propionyl)-5-(difluoromethylene)piperidin-3-yl)-7-fluoro-N,N-dimethyl-4-(4-(piperidin-4-yl)phenyl)-1H-indole-2-carboxamide 28-m

[0904] 28-i (24 mg, 0.03 mmol) was dissolved in dichloromethane (1.2 mL), and trifluoroacetic acid (0.3 mL) was added. The reaction mixture was reacted at room temperature for 1 hour. The reaction solution was concentrated to give 28-m (21 mg, crude product, yellow solid). MS m / z (ESI): 620.3 [M+H] + .

[0905] Step 12: 6-((R)-1-(3-(1H-1,2,3-triazol-1-yl)propionyl)-5-(difluoromethylene)piperidin-3-yl)-4-(4-(1-(2-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzi[d]imidazol-4-yl)ethyl)piperidin-4-yl)phenyl)-7-fluoro-N,N-dimethyl-1H-indole-2-carboxamide 28-m

[0906] 28-m (21 mg, 0.03 mmol) was dissolved in dichloromethane (2.1 mL), and 1-c (15 mg, 0.05 mmol) was added. The reaction was carried out at room temperature for 1 hour. Then, sodium triacetoxyborohydride (22 mg, 0.10 mmol) was added, and the reaction was carried out at room temperature overnight. The reaction solution was concentrated. The formate salt of compound 28 (13.43 mg, yield 43.8%, white solid) was purified by preparative HPLC (28%-33% acetonitrile / 0.1% formic acid aqueous solution).

[0907] MS m / z (ESI): 905.7 [M+H] + ;

[0908] 1 H NMR(400MHz,DMSO-d6)δ12.14(s,1H),11.10(s,1H),8.12–8.04(m,1H),7.72–7.65(m,1H),7.60 (d,J=8.0Hz,2H),7.39(d,J=8.0Hz,2H),7.13(d,J=6.0Hz,1H),7.00–6.97(m,2H),6.95–6.91(m ,1H),6.87–6.84(m,1H),5.42–5.32(m,1H),5.10–4.98(m,1H),4.66–4.55(m,2H),4.07–3.92(m ,1H),3.61(s,3H),3.18–2.86(m,15H),2.65–2.57(m,5H),2.26–1.93(m,5H),1.90–1.62(m,5H).

[0909] Example 29 6-(1-(3-(1H-1,2,3-triazol-1-yl)propionyl)-1,2,5,6-tetrahydropyridin-3-yl)-4-(2-(1-(4-(2,6-dioxopiperidin-3-yl)-2-fluorophenyl)piperidin-4-yl)benzo[b]selenophen-6-yl)-7-fluoro-N,N-dimethyl-1H-indole-2-carboxamide 29

[0910] Step 1: 5-Chloro-2-iodobenzyldiazotetrafluoroborate 29-b

[0911] The starting material 29-a (10.0 g, 39.452 mmol) was dissolved in water (30 mL), and the reaction solution was cooled to 0 °C. Then, an aqueous solution of fluoroboric acid (20 mL, 48%) and sodium nitrite (5.0 g, 72.463 mmol, dissolved in 15 mL of water) was slowly added dropwise to the reaction solution. The reaction solution was stirred at 0 °C for 3 hours. After the reaction was complete, a solid precipitated. The reaction solution was filtered, and the filter cake was washed successively with ice water and a small amount of ethanol, and finally with methyl tert-butyl ether to obtain 29-b (9.6 g, yield: 69.08%, white solid).

[0912] 1 H NMR (400MHz, DMSO-d6) δ8.96 (d, J = 2.4Hz, 1H), 8.42 (d, J = 8.8Hz, 1H), 8.08 (dd, J = 8.8, 2.4Hz, 1H).

[0913] Step 2: (5-chloro-2-iodophenyl)(methyl)selenium 29-c

[0914] 29-b (11.2 g, 31.794 mmol), 18-crown ether-6 (4.2 g, 15.891 mmol), and dimethyl diselenyl ether (6.57 g, 34.948 mmol) were dissolved in chloroform (150 mL). The reaction solution was cooled to 0 °C, and potassium acetate (6.24 g, 63.582 mmol) was added in portions at 0 °C (over 20 min). The mixture was purged with nitrogen three times, and the reaction was carried out at room temperature for 12 hours. After the reaction was complete, the reaction solution was filtered, the filter cake was washed with chloroform, and the filtrate was collected. The filtrate was washed with water, and the organic phases were combined. The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The product was purified by rapid column chromatography (5% ethyl acetate / petroleum ether) to give 29-c (9.0 g, yield 85.41%, pale yellow solid).

[0915] 1H NMR (400MHz, DMSO-d6) δ7.74(d,J=8.4Hz,1H),7.20(d,J=1.6Hz,1H),7.04(dd,J=8.4,1.6Hz,1H),2.38(s,3H).

[0916] Step 3: 4-((4-chloro-2-(methylseleno)phenyl)ethynyl)piperidine-1-carboxylic acid tert-butyl ester 29-d

[0917] 29-c (5 g, 15.085 mmol) was dissolved in ultradry N,N-dimethylformamide (80 mL), and tert-butyl-4-ethynylpiperidine-1-carboxylic acid ester (3.78 g, 18.061 mmol) was added. Cuprous iodide (0.57 g, 2.992 mmol), bis(triphenylphosphine) palladium dichloride (1.05 g, 1.495 mmol), and triethylamine (7.63 g, 75.402 mmol) were added under nitrogen protection and stirred at 25 °C for 12 hours. After the reaction was completed, the reaction solution was diluted with ethyl acetate (100 mL), washed with saturated brine (200 mL * 3), and the organic phase was dried over anhydrous sodium sulfate. The solution was filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (ethyl acetate / petroleum ether = 0 / 1 to 1 / 10) to obtain 29-d (5.0 g, yield 80.29%, pale yellow oil).

[0918] MS m / z(ESI): 314.0 [M-boc+H] + .

[0919] Step 4: 4-(6-chloro-3-iodobenzo[b]selenophen-2-yl)piperidine-1-carboxylic acid tert-butyl ester 29-e

[0920] 29-d (1.0 g, 2.422 mmol) was dissolved in anhydrous dichloromethane (10 mL), and then iodine (737 mg, 2.903 mmol) was dissolved in anhydrous dichloromethane (10 mL). The iodine solution was then added dropwise to the reaction mixture under nitrogen protection, and the reaction mixture was stirred at room temperature for 1 hour. After the reaction was complete, the color of the iodine was washed away by adding saturated sodium thiosulfate aqueous solution to the reaction mixture. The mixture was extracted three times with methyl tert-butyl ether, and the organic phase was concentrated under reduced pressure. The crude product was purified by column chromatography (ethyl acetate / petroleum ether, 1:15) to give 29-e (960 mg, yield: 75.53%, white solid).

[0921] MS m / z(ESI): 511.0 [M-56+ACN+H] + .

[0922] Step 5: 4-(6-chlorobenzo[b]selenophen-2-yl)piperidine-1-carboxylic acid tert-butyl ester 29-f

[0923] 29-e (860 mg, 1.639 mmol) was dissolved in ultra-dry toluene (10 mL), and azobisisobutyronitrile (17.5 mg) was added. After stirring for 10 min, tributyltin hydride (955 mg, 3.28 mmol) was added. Under nitrogen protection, the mixture was stirred at 100 °C for 12 hours. After the reaction was complete, the reaction solution was concentrated under reduced pressure. Methyl tert-butyl ether (100 mL) was added, and the mixture was washed with saturated brine (50 mL × 3). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (ethyl acetate / petroleum ether = 0 / 1 to 1 / 10) to obtain 29-f (280 mg, yield: 42.84%, pale yellow solid).

[0924] MS m / z(ESI): 385.0 [M-56+ACN+H] + .

[0925] Step 6: 29 g of 4-(6-chlorobenzo[b]selenophen-2-yl)piperidine

[0926] 29-f (1.2 g, 3.01 mmol) was dissolved in anhydrous dioxane (5 mL), and dioxane hydrochloride solution (5 mL, 4 M) was added under ice bath. Under nitrogen protection, the mixture was stirred at room temperature for 1 hour. After the reaction was complete, the reaction solution was concentrated under reduced pressure. The crude product was then purified with ammonia to give 29-g (800 mg, yield: 89.01%, white solid).

[0927] MS m / z(ESI): 300.0 [M+H] + .

[0928] Step 7: 3-(4-(4-(6-chlorobenzo[b]selenophen-2-yl)piperidin-1-yl)-3-fluorophenyl)piperidin-2,6-dione 29-h

[0929] 29-g (100 mg, 0.334 mmol), 19-a (96 mg, 0.334 mmol), PEPPSI IHept-Cl (32 mg, 0.0334 mmol), and cesium carbonate (327 mg, 1.002 mmol) were dissolved in ultra-dry dioxane (2 mL). The reaction solution was purged with nitrogen three times, and the reaction was carried out at 100 °C for 1 hour. The reaction was repeated in parallel five times. After the reaction was completed, the reaction solutions were combined, diluted with water (10 mL), and extracted with ethyl acetate (3 x 10 mL). The organic phases were combined and washed with saturated brine (10 mL). The organic phase was dried with anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by high performance thin-layer chromatography (5% methanol / dichloromethane) to obtain the crude product. The crude product was then purified by reversed-phase column chromatography (0-100% acetonitrile / water, 0.1% FA) to obtain 29-h (25 mg, yield 2.96%, pale yellow solid).

[0930] MS m / z (ESI): 505.2 [M+H] + .

[0931] Step 8: 6-(1-(3-(1H-1,2,3-triazol-1-yl)propionyl)-1,2,5,6-tetrahydropyridin-3-yl)-4-(2-(1-(4-(2,6-dioxopiperidin-3-yl)-2-fluorophenyl)piperidin-4-yl)benzo[b]selenophen-6-yl)-7-fluoro-N,N-dimethyl-1H-indole-2-carboxamide 29

[0932] 29-h (25 mg, 0.0496 mmol) was dissolved in 1,4-dioxane (2 mL) and water (0.4 mL). 15-i (27 mg, 0.0496 mmol), methanesulfonic acid (2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)(2'-amino-1,1'-biphenyl-2-yl)palladium(II) (44 mg, 0.00496 mmol), and potassium acetate (15 mg, 0.149...

Claims

1. A compound of formula (I), or a pharmaceutically acceptable salt thereof, a stereoisomer thereof, or an isotopic compound thereof, SBM-L-DIM(I) in, DIM (DIM is a degradation inducing moiety) is selected from the group consisting of: Wherein, W1 is a bond or NH; Ring G is selected from C6-C10 aromatic rings, 5-10 membered heteroaromatic rings containing 1-3 heteroatoms selected from N, O, S, and Se, 5-6 membered heterocycles containing 1-3 heteroatoms selected from N, O, and S, 5-6 membered heteroaromatic rings containing 1-3 heteroatoms selected from N, O, S, and Se, saturated or partially saturated C5-C6 carbon rings, and saturated or partially saturated 5-10 membered heterocycles containing 1-3 heteroatoms selected from N, O, and S; n1 is 0, 1, 2 or 3; Each R A Independently selected from the group consisting of: H, O=, S=, C1-C6 alkoxy, C1-C6 alkyl, C1-C6 haloalkyl, halogen, C1-C6 alkyl=, C3-C6 cycloalkyl=, C2-C6 alkenyl, C2-C6 alkynyl, haloC1-C6 alkyl=, haloC3-C6 cycloalkyl=, haloC2-C6 alkenyl, haloC2-C6 alkynyl; L (L is a divalent linking group) is: Y1 is selected from the following group: -L1-, =NO-L1-, =N-NH-L1-, =N-L1-; wherein L1 is independently selected from the following group: bond, C1-C6 alkylene, C1-C6 alkylene=, C2-C6 alkenylene, C1-C6 haloalkylene, C2-C6 alkyneylene, C1-C3 alkylene-O-C1-C3 alkylene-O-C1-C3 alkylene-O-, C1-C3 alkylene-O-; Y2 is selected from the following group: bond, C1-C6 alkylene, C1-C6 alkylene=, C2-C6 alkenylene, C1-C6 haloalkylene, C2-C6 alkynylene, C1-C3 alkylene-O-C1-C3 alkylalkylene, C1-C3 alkylene-O-C1-C3 alkylene-O-, C1-C3 alkylene-O-; Ring F is selected from saturated or partially saturated C4 to C12 carbon rings and saturated or partially saturated 4 to 12-membered heterocycles containing 1 to 3 heteroatoms selected from N, O, S, P and Se; the carbon ring and heterocycle are independently monocyclic or bicyclic fused rings, spirocyclic or bridged rings; The ring H is selected from non-existent, C6-C10 aromatic rings, 5-10 membered aromatic heterocycles containing 1-3 heteroatoms selected from N, O, S, P and Se, saturated or partially saturated C3-C10 membered carbon rings, and saturated or partially saturated 3-10 membered heterocycles containing 1-3 heteroatoms selected from N, O, S, P and Se; the carbon ring and heterocycle are independently monocyclic or bicyclic fused rings, spirocyclic rings, or bridged rings; Each R 11 and R 12 Independently selected from hydrogen, deuterium, cyano, carbonyl, C1-C6 haloalkoxy, C1-C6 alkoxy, C1-C6 alkyl, C1-C6 haloalkyl, halogen, C3-C6 cycloalkyl, C1-C6 alkyl, C2-C6 ynyl, C2-C6 alkenyl, haloC1-C6 alkyl, haloC3-C6 cycloalkyl, haloC2-C6 alkenyl, haloC2-C6 ynyl; or two R atoms on the same or different carbon atoms. 11 They connect together to form C1-C2 alkylene groups; SBM (SBM is a STAT6 binding moiety capable of binding to STAT6 protein) is selected from Formula IA or Formula IB: L3 is selected from vinylene, ethynylene, -COC1-C6 alkylene, -COC3-C6 cycloalkyl, -CO- 3-6 membered heterocyclic group containing 1-3 heteroatoms selected from O, N and S, -CH2COC1-C6 alkylene, C1-C6 alkylene, C1-C6 haloalkylene, 5-10 membered heteroaryl group containing 1-3 heteroatoms selected from O, N and S, -C(O)NR8-, -NR8CO, -NR8-, -O-, -S-, -S(O)-, -S(O)2-; L4 is selected from single bond, O, NR8, carbonyl, -NR8CO-, -SO2-, vinylidene, ethynylidene, halovinylidene, C1-C6 alkylidene, -COC1-C6 alkylidene; Ring A1 is selected from: C6-C10 aromatic rings, 5-6 membered aromatic heterocycles containing 1-3 heteroatoms selected from N, O, S, P and Se, benzo[a] 5-6 membered aromatic heterocycles containing 1-3 heteroatoms selected from N, O, S, P and Se, 5-6 membered aromatic heterocycles containing 1-3 heteroatoms selected from N, O, S, P and Se, and 5-6 membered aromatic heterocycles containing 1-3 heteroatoms selected from N, O, S, P and Se; Ring B is selected from C3-C20 membered carbon rings that are absent, saturated, or partially saturated; 3-20 membered heterocycles that are saturated or partially saturated and contain 1-3 heteroatoms selected from N, O, S, P, and Se; C6-C20 membered aromatic rings; or 5-20 membered aromatic heterocycles that contain 1-3 heteroatoms selected from N, O, S, P, and Se; wherein the carbon ring and heterocycle are independently monocyclic, bicyclic, or tricyclic fused rings, spirocyclic, or bridged rings. The ring C is selected from non-existent, C6-C10 aromatic rings, 5-10 membered aromatic heterocycles containing 1-3 heteroatoms selected from N, O, S, P and Se, saturated or partially saturated C3-C10 membered carbon rings, and saturated or partially saturated 3-10 membered heterocycles containing 1-3 heteroatoms selected from N, O, S, P and Se. X2, X3, and X4 are independently selected from C, N(H), O, S, and Se; and X2, X3, and X4 together with the two C atoms on the benzene ring they are attached to form a 5-membered heteroaromatic ring with 1 or 2 heteroatoms; Each m can be 0, 1, 2, 3 or 4 independently; Each n is independently 0, 1, or 2; Each of R3, R4, R5, R6, R7 and R 10 Independently selected from the group consisting of: hydrogen, deuterium, halogen, cyano, carbonyl, C1-C6 alkyl, C1-C6 haloalkyl, =C1-C6 alkyl, =C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C3-C6 cycloalkyl, -CONR8R9, -NR8COR9, -NR8R9, -OR8, -SR8, -S(O)R8, -P(O)(OH)2, -S(O)2NR8R9, -S(O)2R8; Each R8 and R9 is independently selected from the group consisting of: hydrogen, deuterium, halogen, cyano, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C3-C6 cycloalkyl; or the N atom to which R8 and R9 are attached may form a substituted or unsubstituted 5- to 10-membered aromatic heterocycle containing 1-3 heteroatoms selected from N, O and S, or a substituted or unsubstituted 5- to 10-membered heterocycle containing 1-3 heteroatoms selected from N, O and S, wherein any substituent on the aromatic heterocycle or heterocycle may be attached to any R3 to form a C1-C6 alkylene, C2-C6 alkenylene, C2-C6 alkyneylene, C1-C3 alkylene-O-C1-C3 alkylene-O-C1-C3 alkylene-O-, C1-C6 alkylene-O-; Any two adjacent R4 and X2, X3, X4 can be connected to form a saturated or partially saturated C3 to C20 membered carbon ring, or a saturated or partially saturated 3 to 20 membered heterocycle containing 1 to 3 heteroatoms selected from N, O, S, P and Se. The carbon ring and heterocycle are independently monocyclic, bicyclic or tricyclic fused rings, spirocyclic or bridged rings. R7 and L4 and / or R5 can be connected to form saturated or partially saturated C3 to C20 membered carbon rings, or saturated or partially saturated 3 to 20 membered heterocycles containing 1 to 3 heteroatoms selected from N, O, S, P and Se, wherein the carbon ring and heterocycle are independently monocyclic, bicyclic or tricyclic fused rings, spirocyclic or bridged rings. Each of R3 and R4, R7, R 11 Any one of them can be connected to form a saturated or partially saturated C3 to C20 membered carbon ring, or a saturated or partially saturated 3 to 20 membered heterocycle containing 1 to 4 heteroatoms selected from N, O, S, P and Se, wherein the carbon ring and heterocycle are independently fused rings, spiro rings or bridged rings of monocyclic, bicyclic or tricyclic nature. R 10 It can be connected with any one of X2, R8, and R5 to form a saturated or partially saturated C3-C7 membered carbon ring, or a saturated or partially saturated 3-7 membered heterocycle containing 1-3 heteroatoms selected from N, O, S, P, and Se; ring E is a saturated or partially saturated C3-C6 membered carbon ring, or a saturated or partially saturated 3-6 membered heterocycle containing 1-3 heteroatoms selected from N, O, S, P, and Se, or a phenyl or a 5-6 membered aromatic heterocycle containing 1-3 heteroatoms selected from N, O, S, P, and Se; Among them, ring D is a saturated or partially saturated C3-C6 membered carbon ring, a saturated or partially saturated 3-6 membered heterocycle containing 1-3 heteroatoms selected from N, O, S, P and Se, a phenyl ring, a 5-6 membered aromatic heterocycle containing 1-3 heteroatoms selected from N, O, S, P and Se, or a 5-6 membered aromatic heterocycle containing 1-3 heteroatoms selected from N, O, S, P and Se and a benzo[a]benzene ring; Furthermore, rings E and D together form a spiral ring or a parallel ring structure; n, m, X2, L3, L4, R4, R5, R6, B, and C are defined as above; Each of the above groups may optionally be further substituted by one or more groups selected from the group consisting of: D, oxo, halogen, -CO-, thio, -NO2, -CN, -N3, OH, COOH, SF5, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkyl-ON=, substituted or unsubstituted C3-C6 cycloalkyl=, substituted or unsubstituted C1-C6 alkyl=, substituted or unsubstituted C1-C6 alkyl-S-, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C2-C6 alkynyl, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted C1-C6 alkoxy, amino, substituted or unsubstituted C1-C6 alkyl NH-, substituted or unsubstituted (C1-C6 alkyl)2N-, substituted or unsubstituted C1-C6 alkyl CO-, substituted or unsubstituted C1-C6 alkyl COO-, substituted or unsubstituted C1-C6 alkyl OCO-, substituted or unsubstituted C1-C6 alkylCONH-, substituted or unsubstituted C1-C6 alkylNHCO-, substituted or unsubstituted substituted or unsubstituted C6-C10 aryl, substituted or unsubstituted 5-10-membered heteroaryl containing 1-3 heteroatoms selected from N, O, S, substituted or unsubstituted 3-8-membered heterocyclic group containing 1-3 heteroatoms selected from N, O, S, or the two adjacent substituents on the cycloalkyl, heterocyclic, aryl, or heteroaryl group optionally form a substituted or unsubstituted C3-8 cycloalkyl or a substituted or unsubstituted 3-8-membered heterocyclic group containing 1-3 heteroatoms selected from N, O, S together with the atoms attached thereto; wherein "substituted" means that one or more H on the group are independently substituted by a group selected from the group consisting of: D, halogen, -CN, OH, amino, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy.

2. The compound of formula (I) as claimed in claim 1, or a pharmaceutically acceptable salt thereof, stereoisomer thereof, or isotopic compound thereof, characterized in that, Ring F is selected from the group consisting of:

3. The compound of formula (I) as claimed in claim 1, or a pharmaceutically acceptable salt thereof, stereoisomer thereof, or isotopic compound thereof. in, DIM is selected from the group consisting of: Wherein, R1 is a C1-C4 alkyl group; X is selected from O, NH, and S; Each R2 is independently selected from H, C1-C6 alkoxy, C1-C6 alkyl, C1-C6 haloalkyl, and halogen; Each n is independently 0, 1, or 2.

4. The compound of claim 1 of formula (I), or a pharmaceutically acceptable salt, stereoisomer or isotopologue thereof, wherein, L is: Wherein, X1 is independently selected from CH or N; X1' is selected from N, CH, O, S or P=O; L1 is independently selected from the group consisting of: bond, C1-C6 alkylene, C1-C6 alkylene, C2-C6 alkenyl, C1-C6 haloalkylene and ethynylene; each R 11 and R 12 is independently selected from H, C1-C6alkoxy, C1-C6alkyl, C1-C6haloalkyl, and halogen; or two R 11 are jointly connected to form a C1-C2alkylene; Each n is independently 0, 1, or 2.

5. The compound of claim 1 of formula (I), or a pharmaceutically acceptable salt, stereoisomer or isotopologue thereof, wherein, SBM is: in, X2 is selected from N or Se; R8 and R9 are independently selected from hydrogen, deuterium, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C3-C6 cycloalkyl; or R8 and R9 together with their attached N atom form a substituted or unsubstituted 5-6 membered heteroaromatic ring with 1, 2 or 3 nitrogen atoms, or a substituted or unsubstituted 5-6 membered heterocyclic ring with 1, 2 or 3 nitrogen atoms; wherein, substitution means that the group is independently substituted by one or more groups selected from the group consisting of: D, halogen, OH, NH2, N (C1-C3 alkyl). 1-2 =CF2; R'4 and R”4 are independently selected from hydrogen, deuterium, halogen, C1-C6 alkyl, and C3-C6 cycloalkyl; R3 is independently selected from hydrogen, deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, and C3-C6 cycloalkyl; Alternatively, R8 can be connected to R'4 or R”4 to form a 5-8 membered heterocyclic group containing at least one N heteroatom; Alternatively, one of R8 and R3 may be linked to form a substituted or unsubstituted 9-16 membered heterocyclic group containing at least one N heteroatom; wherein the substitution refers to the group being independently and optionally substituted by one or more groups selected from the group consisting of: D, halogen, halogen or unsubstituted C1-C6 alkyl, halogen or unsubstituted C1-C6 alkoxy, halogen-substituted or unsubstituted C3-C6 cycloalkyl, halogen-substituted or unsubstituted C1-C6 alkyl; or substituents on the same atom, adjacent atoms or alternating atoms may be linked to form a C3-C6 cycloalkyl, or a 3-6 membered heterocyclic group containing 1-3 heteroatoms selected from O, N and S; wherein each m, X2, L3, L4, R3, R5, R6, R 10 A1, B and C are as defined in claim 1.

6. The compound of claim 5, or a pharmaceutically acceptable salt, stereoisomer, or isotopologue thereof, wherein Ring A1is selected from the group consisting of:

7. The compound of claim 1 of formula (I), or a pharmaceutically acceptable salt, stereoisomer or isotopologue thereof, wherein, SBM is: in, X2 is selected from N or Se; R8 and R9 are independently selected from hydrogen, deuterium, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C3-C6 cycloalkyl; or R8 and R9 together with their attached N atom form a substituted or unsubstituted 5-6 membered heteroaromatic ring with 1, 2 or 3 nitrogen atoms, or a substituted or unsubstituted 5-6 membered heterocyclic ring with 1, 2 or 3 nitrogen atoms; wherein, substitution means that the group is independently substituted by one or more groups selected from the group consisting of: D, halogen, OH, NH2, N (C1-C3 alkyl). 1-2 =CF2; R'4 and R”4 are independently selected from hydrogen, deuterium, halogen, C1-C6 alkyl, and C3-C6 cycloalkyl; R'3 and R”3 are independently selected from hydrogen, deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, and C3-C6 cycloalkyl; Alternatively, R8 can be connected to R'4 or R”4 to form a 5-8 membered heterocyclic group containing at least one N heteroatom; Alternatively, R8 and R'3 may be linked to form a substituted or unsubstituted 9-16 membered heterocyclic group containing at least one N heteroatom; wherein the substitution refers to the group being independently and optionally substituted by one or more groups selected from the group consisting of: D, halogen, halogen or unsubstituted C1-C6 alkyl, halogen or unsubstituted C1-C6 alkoxy, halogen-substituted or unsubstituted C3-C6 cycloalkyl, halogen-substituted or unsubstituted C1-C6 alkyl; or substituents on the same atom, adjacent atoms or alternating atoms may be linked to form a C3-C6 cycloalkyl, or a 3-6 membered heterocyclic group containing 1-3 heteroatoms selected from O, N and S; wherein each m, X2, L3, L4, R3, R5, R6, R 10 B and C are as defined in the present application.

8. The compound of claim 5, or a pharmaceutically acceptable salt, stereoisomer, or isotopologue thereof. DIM is selected from the group consisting of: Wherein, R1 is a C1-C4 alkyl group; X is selected from O, NH, and S; Each R2 is independently selected from H, C1-C6 alkoxy, C1-C6 alkyl, C1-C6 haloalkyl, and halogen; Each n is independently 0, 1, or 2; L is: Y1 is selected from: bond, C1-C3 alkylene, =NO-, =N-NH-, =N-; Ring F is selected from the following group: Y2 is the bond; and the ring H does not exist, and all n values ​​are 0; Having a structure Wherein, R'5 is independently selected from H, =C1-C6 alkyl, =C1-C6 haloalkyl, C1-C6 alkyl, C1-C6 haloalkyl, or two R'5 on any carbon atom are connected together and together with the carbon atom to form a C3-C6 carbon ring, a halogenated C3-C6 carbon ring, a 3-6 membered heterocyclic group containing 1-3 heteroatoms selected from O, N and S, or a halogenated 3-6 membered heterocyclic group containing 1-3 heteroatoms selected from O, N and S; L4 is selected from: -CF=CH-, -CH=CH-, ethynyl group, -NHCO-; selected from the group consisting of: Each R5 is independently selected from: H, halogen, CN, C1-C3 alkyl, C1-C3 haloalkyl, C3-C4 cycloalkyl.

9. The compound of claim 1, or a pharmaceutically acceptable salt, stereoisomer, or isotopologue thereof, wherein Ring B or selected from the group consisting of 10. The compound of claim 1, or a pharmaceutically acceptable salt, stereoisomer, or isotopologue thereof, wherein SBM is selected from the group consisting of:

11. The compound of claim 1, or a pharmaceutically acceptable salt, stereoisomer, or isotopologue thereof, wherein The compounds are selected from the group consisting of:

12. A pharmaceutical composition, characterized by, This includes the compounds as described in any one of claims 1-11, or their pharmaceutically acceptable salts, stereoisomers, or isotopic compounds, and pharmaceutically acceptable carriers.

13. Use of the compound of any one of claims 1-11 or a pharmaceutically acceptable salt, stereoisomer or isotopic compound thereof, and the pharmaceutical composition of claim 12 in the preparation of a STAT6 protein degrader.

14. Use of the compound of any one of claims 1-11 or a pharmaceutically acceptable salt, stereoisomer or isotope thereof, and the pharmaceutical composition of claim 7 in the preparation of a medicament for the prevention or treatment of STAT6 protein-mediated diseases.

15. The use according to claim 14, characterized in that, The diseases mentioned are selected from the following groups: cancer, neurodegenerative diseases, viral diseases, autoimmune diseases, inflammatory diseases, hereditary diseases, hormone-related diseases, metabolic diseases, organ transplant-related diseases, immunodeficiency diseases, skeletal dysfunction or hypermobility disorders, infectious diseases, thrombosis-induced platelet aggregation, liver diseases, pathological immune diseases involving T cell activation, cardiovascular diseases, or CNS diseases.